<!--
Latest-updates detailed page

Instruction:

1. The homepage version's three hashtags (###) title should be linked to the two hashtags (##) title here.

2. Dated updates should be listed in descending order.

3. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

4. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

5. Please do not delete this instruction.

-->

## Publications

- Editorial (September 21)
    - Shafer R. “A SARS-CoV-2 antiviral therapy score card” _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).
- Paper (September 4)
    - Tzou PL, Tao KM, et int., and Shafer R. “Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds” _Viruses_, 2020. [doi.org/10.3390/v12091006](https://doi.org/10.3390/v12091006). \[[PubMed32916958](https://www.ncbi.nlm.nih.gov/pubmed/32916958/)\].

## Webinars

- August 10
    - SARS-CoV-2 Antivirals: Remdesivir and other Polymerase Inhibitors. August 10, 2020. Robert Shafer, MD, Professor of Medicine, Division of Infectious Diseases, Stanford University. ([video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044))

## Educational Materials

- [Spike structures. Figures of SARS-CoV-2](/page/spike-structures/)
    - Figure 1. SARS-CoV-2 Trimeric Spike.
    - Figure 2. Trimeric spike structures illustrating receptor binding domain (RBD) up (open; ACE2 accessible) and down (closed) configurations.
    - Figure 3. Spike RBD bound to ACE-2.
    - Figure 4. Spike S1 and S2 subunits.
    - Figure 5. S1 domains.
    - Figure 6. RBD core mAb epitopes.
    - Figure 7. RBD RBM antibody sites.
    - Figure 8. RBD RBM antibody sites.
    - Figure 9. Regeneron ACE2-competing mAbs.
    - Figure 10. Naturally occurring spike RBD variants and mAb escape mutations.
- [Spike mutation annotation viewer](/mut-annot-viewer/SARS2S/)
    - [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/)
- [Monoclonal antibodies](/page/mab-tables/)
    - [Clinical Trials](/page/mab-tables/#clinical.trials)
    - [Animal Model Studies](/page/mab-tables/#animal.model.studies)
    - [Inhibitory potency, sequence data, and structural data](/page/mab-tables/#identification.in.vitro.potency.sequence.data.and.structural.data)

## Press Release

- October 7
    - [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly202010071.pdf)
    - [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly202010072.pdf)
- October 2
    - [Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Synairgen20200930.pdf)
    - [Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly20200930.pdf)
    - [Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Regeneron20200930.pdf)

## Database Entries
### October 2020
- October 05
    - Wahl A, Gralinski L, et int., and Garcia JV. [“Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.”](/search/?article=Wahl20) _Research square_, [2020. doi.org/10.21203/rs.3.rs-80404/v1](https://doi.org/10.21203/rs.3.rs-80404/v1). \[[PubMed32995766](https://www.ncbi.nlm.nih.gov/pubmed/32995766/)\] \[[PMC7523135](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523135/)\]
    - Ansarin K, Tolouian R, et int., and Chapman KR. [“Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.”](/search/?article=Ansarin20) _BioImpacts_, 2020. [doi.org/10.34172/bi.2020.27](https://doi.org/10.34172/bi.2020.27). \[[PubMed32983936](https://www.ncbi.nlm.nih.gov/pubmed/32983936/)\] \[[PMC7502909]\](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502909/)
- October 03
    - Jones BE, Brown-Augsburger PL, et int., and Falconer E. [“LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.”](/search/?article=Jones20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.30.318972](https://doi.org/10.1101/2020.09.30.318972).
    - Sagar S, Rathinavel AK, et int., and Radhakrishnan P. [“Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells.”](/search/?article=Sagar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.16.297366](https://doi.org/10.1101/2020.09.16.297366). \[[PubMed32995771](https://www.ncbi.nlm.nih.gov/pubmed/32995771/)\] \[[PMC7523097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523097/)\]
    - Watson A, Ferreira L, et int., and Stroud R. [“Peptide Antidotes to SARS-CoV-2 (COVID-19).”](/search/?article=Watson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.06.238915](https://doi.org/10.1101/2020.08.06.238915).
- October 01
    - Proud PC, Tsitoura D, et int., and Carroll MW. [“Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.”](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
    - Son J, Huang S, et int., and Ding S. [“Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.”](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
    - Fagre AC, Manhard J, et int., and Schountz T. [“A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.”](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
    - Lin C, Li Y, et int., and Chen J. [“Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.”](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
    - Xiao T, Lu J, et int., and Chen B. [“A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.”](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
    - Zhang L, Cao L, et int., and Zhu F. [“A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.”](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### September 2020
- September 29
    - Brunaugh AD, Seo H, et int., and Smyth HD. [“Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.”](/search/?article=Brunaugh20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
    - Curreli F, Victor SMB, et int., and Debnath AK. [“Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.”](/search/?article=Curreli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
- September 28
    - Updated: Cao L, Goreshnik I, et int., and Baker D. [“De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.”](/search/?article=Cao20e) _Science_, 2020. [doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909). \[[PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]
    - Updated: Lang J, Yang N, et int., and Jiang C. [“Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans.”](/search/?article=Lang11) _PLoS ONE_, 2011. [doi.org/10.1371/journal.pone.0023710](https://doi.org/10.1371/journal.pone.0023710). \[[PubMed21887302](https://www.ncbi.nlm.nih.gov/pubmed/21887302/)\] \[[PMC3161750](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161750/)\]
    - Updated: Salazar E, Perez KK, et int., and Musser JM. [“Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.”](/search/?article=Salazar20) _The American Journal of Pathology_, 2020. [doi.org/10.1016/j.ajpath.2020.05.014](https://doi.org/10.1016/j.ajpath.2020.05.014). \[[PubMed32473109](https://www.ncbi.nlm.nih.gov/pubmed/32473109/)\] \[[PMC7251400](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251400/)\]
- September 25
    - Ellen ter B, Dinesh Kumar N, et int., and Smit J. [“Resveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.”](/search/?article=Ellen%20ter20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).
- September 24
    - Pereda R, González D, et int., and Domínguez RE. [“Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.”](/search/?article=Pereda20) _Journal of Interferon & Cytokine Research_, 2020. [doi.org/10.1089/jir.2020.0124](https://doi.org/10.1089/jir.2020.0124). \[[PubMed32960147](https://www.ncbi.nlm.nih.gov/pubmed/32960147/)\]
- September 23
    - Cao L, Goreshnik I, et int., and Baker D. [“De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.”](/search/?article=Cao20e) _Science_, 2020. [doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909). \[[PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]
- September 15
    - Li T, Han X, et int., and Jin A. [“A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.”](/search/?article=Li20e) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.11.292631](https://doi.org/10.1101/2020.09.11.292631).
- September 14
    - Cohen-Dvashi H, Weinstein J, et int., and Diskin R. [“Coronacept – a potent immunoadhesin against SARS-CoV-2.”](/search/?article=Cohen-Dvashi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.12.247940](https://doi.org/10.1101/2020.08.12.247940).
    - Glasgow A, Glasgow J, et int., and Wells JA. [“Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.”](/search/?article=Glasgow20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.31.231746](https://doi.org/10.1101/2020.07.31.231746). \[[PubMed32766586](https://www.ncbi.nlm.nih.gov/pubmed/32766586/)\] \[[PMC7402043](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402043/)\]
    - Hassan AO, Case JB, et int., and Diamond MS. [“A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.”](/search/?article=Hassan20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011). \[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\] \[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
    - Olaleye OA, Kaur M, et int., and Adebusuyi T. [“Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro.”](/search/?article=Olaleye20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.14.250480](https://doi.org/10.1101/2020.08.14.250480). \[[PubMed32817951](https://www.ncbi.nlm.nih.gov/pubmed/32817951/)\] \[[PMC7430586](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430586/)\]
    - de Vries M, Mohamed AS, et int., and Dittmann M. [“Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.”](/search/?article=Vries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.28.272880](https://doi.org/10.1101/2020.08.28.272880). \[[PubMed32869028](https://www.ncbi.nlm.nih.gov/pubmed/32869028/)\] \[[PMC7457613](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/)\]
    - Zhang Q, Chen CZ, et int., and Ye Y. [“Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro.”](/search/?article=Zhang20e) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.14.202549](https://doi.org/10.1101/2020.07.14.202549). \[[PubMed32699847](https://www.ncbi.nlm.nih.gov/pubmed/32699847/)\] \[[PMC7373127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373127/)\]
- September 09
    - Updated: Li Y, Xie Z, et int., and Li L. [“Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.”](/search/?article=Li20) _Med_, 2020. [doi.org/10.1016/j.medj.2020.04.001](https://doi.org/10.1016/j.medj.2020.04.001). \[[PubMed32838353](https://www.ncbi.nlm.nih.gov/pubmed/32838353/)\] \[[PMC7235585](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235585/)\]
    - Updated: Magagnoli J, Narendran S, et int., and Ambati J. [“Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.”](/search/?article=Magagnoli20) _Med_, 2020. [doi.org/10.1016/j.medj.2020.06.001](https://doi.org/10.1016/j.medj.2020.06.001). \[[PubMed32838355](https://www.ncbi.nlm.nih.gov/pubmed/32838355/)\] \[[PMC7274588](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274588/)\]
    - Updated: Pizzorno A, Padey B, et int., and Rosa-Calatrava M. [“Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.”](/search/?article=Pizzorno20) _Cell Reports Medicine_, 2020. [doi.org/10.1016/j.xcrm.2020.100059](https://doi.org/10.1016/j.xcrm.2020.100059). \[[PubMed32835306](https://www.ncbi.nlm.nih.gov/pubmed/32835306/)\] \[[PMC7373044](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373044/)\]
    - Updated: Ren Z, Luo H, et int., and Chang J. [“A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study.”](/search/?article=Ren20) _Advanced Science_, 2020. [doi.org/10.1002/advs.202001435](https://doi.org/10.1002/advs.202001435). \[[PubMed32837847](https://www.ncbi.nlm.nih.gov/pubmed/32837847/)\] \[[PMC7404576](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404576/)\]
- September 08
    - Agarwal A, Mukherjee A, et int., and Abraham P. [“Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial).”](/search/?article=Agarwal20) _medRxiv_, 2020. [doi.org/10.1101/2020.09.03.20187252](https://doi.org/10.1101/2020.09.03.20187252).
    - Bansal S, Jonsson CB, et int., and César Vega J. [“Iota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture.”](/search/?article=Bansal20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.19.225854](https://doi.org/10.1101/2020.08.19.225854).
    - Chan KK, Dorosky D, et int., and Procko E. [“Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.”](/search/?article=Chan20) _Science_, 2020. [doi.org/10.1126/science.abc0870](https://doi.org/10.1126/science.abc0870). \[[PubMed32753553](https://www.ncbi.nlm.nih.gov/pubmed/32753553/)\]
    - Zhu H, Chen CZ, et int., and Huang R. [“Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.”](/search/?article=Zhu20e) __, 2020.
- September 07
    - Drayman N, Jones KA, et int., and Tay S. [“Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.”](/search/?article=Drayman20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.31.274639](https://doi.org/10.1101/2020.08.31.274639). \[[PubMed32908976](https://www.ncbi.nlm.nih.gov/pubmed/32908976/)\] \[[PMC7480023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480023/)\]
    - Zhao H, To KKW, et int., and Yuen K. [“A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.”](/search/?article=Zhao20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-17986-9](https://doi.org/10.1038/s41467-020-17986-9). \[[PubMed32843628](https://www.ncbi.nlm.nih.gov/pubmed/32843628/)\] \[[PMC7447754](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447754/)\]
    - Zmudzinski M, Rut W, et int., and Drag M. [“Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies.”](/search/?article=Zmudzinski20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.30.273979](https://doi.org/10.1101/2020.08.30.273979).
- September 04
    - Avendano-Sola C, Ramos-Martinez A, et int., and Duarte RF. [“Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial.”](/search/?article=Avendano-Sola20) _medRxiv_, 2020. [doi.org/10.1101/2020.08.26.20182444](https://doi.org/10.1101/2020.08.26.20182444).
- September 03
    - Du S, Cao Y, et int., and Xiao J. [“Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency.”](/search/?article=Du20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.09.195263](https://doi.org/10.1101/2020.07.09.195263).
    - Ghahremanpour MM, Tirado-Rives J, et int., and Jorgensen WL. [“Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.”](/search/?article=Ghahremanpour20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.28.271957](https://doi.org/10.1101/2020.08.28.271957). \[[PubMed32869018](https://www.ncbi.nlm.nih.gov/pubmed/32869018/)\] \[[PMC7457600](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457600/)\]
    - Gorshkov K, Chen CZ, et int., and Zheng W. [“The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators.”](/search/?article=Gorshkov20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.16.091520](https://doi.org/10.1101/2020.05.16.091520). \[[PubMed32511355](https://www.ncbi.nlm.nih.gov/pubmed/32511355/)\] \[[PMC7259466](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259466/)\]
    - Lang J, Yang N, et int., and Jiang C. [“Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans.”](/search/?article=Lang11) _PLoS ONE_, 2011. [doi.org/10.1371/journal.pone.0023710](https://doi.org/10.1371/journal.pone.0023710). \[[PubMed21887302](https://www.ncbi.nlm.nih.gov/pubmed/21887302/)\] \[[PMC3161750](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161750/)\]
    - Resnick SJ, Iketani S, et int., and Chavez A. [“A simplified cell-based assay to identify coronavirus 3CL protease inhibitors.”](/search/?article=Resnick20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.29.272864](https://doi.org/10.1101/2020.08.29.272864). \[[PubMed32869020](https://www.ncbi.nlm.nih.gov/pubmed/32869020/)\] \[[PMC7457602](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457602/)\]
- September 02
    - Li T, Cai H, et int., and Li D. [“A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.”](/search/?article=Li20d) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.09.143438](https://doi.org/10.1101/2020.06.09.143438).
- September 01
    - Bermejo-Jambrina M, Eder J, et int., and Geijtenbeek TBH. [“SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins.”](/search/?article=Bermejo-Jambrina20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.18.255810](https://doi.org/10.1101/2020.08.18.255810).
    - Chen Y, Lear T, et int., and Chen B. [“A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry.”](/search/?article=Chen20k) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-48659/v1](https://doi.org/10.21203/rs.3.rs-48659/v1). \[[PubMed32818215](https://www.ncbi.nlm.nih.gov/pubmed/32818215/)\] \[[PMC7430593](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430593/)\]
    - Ejemel M, Li Q, et int., and Wang Y. [“A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.”](/search/?article=Ejemel20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18058-8](https://doi.org/10.1038/s41467-020-18058-8). \[[PubMed32826914](https://www.ncbi.nlm.nih.gov/pubmed/32826914/)\] \[[PMC7442812](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442812/)\]
    - Kreye J, Reincke SM, et int., and Prüss H. [“A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.”](/search/?article=Kreye20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.15.252320](https://doi.org/10.1101/2020.08.15.252320). \[[PubMed32817952](https://www.ncbi.nlm.nih.gov/pubmed/32817952/)\] \[[PMC7430590](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430590/)\]
    - Noy-Porat T, Makdasi E, et int., and Rosenfeld R. [“A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.”](/search/?article=Noy-Porat20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18159-4](https://doi.org/10.1038/s41467-020-18159-4). \[[PubMed32855401](https://www.ncbi.nlm.nih.gov/pubmed/32855401/)\] \[[PMC7452893](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452893/)\]
    - Olagnier D, Farahani E, et int., and Holm CK. [“Identification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.”](/search/?article=Olagnier20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.16.206458](https://doi.org/10.1101/2020.07.16.206458).
    - Schooley RT, Carlin AF, et int., and Hostetler KY. [“Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity.”](/search/?article=Schooley20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.26.269159](https://doi.org/10.1101/2020.08.26.269159). \[[PubMed32869033](https://www.ncbi.nlm.nih.gov/pubmed/32869033/)\] \[[PMC7457622](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457622/)\]
    - Updated: Weston S, Coleman CM, et int., and Frieman MB. [“Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo.”](/search/?article=Weston20) _Journal of Virology_, 2020. [doi.org/10.1128/jvi.01218-20](https://doi.org/10.1128/jvi.01218-20). \[[PubMed32817221](https://www.ncbi.nlm.nih.gov/pubmed/32817221/)\]
### August 2020
- August 26
    - Bradfute SB, Hurwitz I, et int., and Harkins MS. [“Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.”](/search/?article=Bradfute20) _The Journal of Infectious Diseases_, 2020. [doi.org/10.1093/infdis/jiaa505](https://doi.org/10.1093/infdis/jiaa505). \[[PubMed32779705](https://www.ncbi.nlm.nih.gov/pubmed/32779705/)\] \[[PMC7454720](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454720/)\]
    - Chen CZ, Shinn P, et int., and Zheng W. [“Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.”](/search/?article=Chen20j) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.18.255877](https://doi.org/10.1101/2020.08.18.255877). \[[PubMed32839771](https://www.ncbi.nlm.nih.gov/pubmed/32839771/)\] \[[PMC7444282](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444282/)\]
    - Fu W, Liu Y, et int., and Lu H. [“A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19.”](/search/?article=Fu20b) _EClinicalMedicine_, 2020. [doi.org/10.1016/j.eclinm.2020.100478](https://doi.org/10.1016/j.eclinm.2020.100478). \[[PubMed32838238](https://www.ncbi.nlm.nih.gov/pubmed/32838238/)\] \[[PMC7388798](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388798/)\]
    - Haagmans BL, Noack D, et int., and Rockx B. [“SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model.”](/search/?article=Haagmans20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.24.264630](https://doi.org/10.1101/2020.08.24.264630).
    - Hattori S, Higshi-Kuwata N, et int., and Mitsuya H. [“GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.”](/search/?article=Hattori20) _mBio_, 2020. [doi.org/10.1128/mbio.01833-20](https://doi.org/10.1128/mbio.01833-20). \[[PubMed32820005](https://www.ncbi.nlm.nih.gov/pubmed/32820005/)\] \[[PMC7441487](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441487/)\]
    - Karoyan P, Vieillard V, et int., and Lequin O. [“An hACE2 peptide mimic blocks SARS-CoV-2 Pulmonary Cell Infection.”](/search/?article=Karoyan20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.24.264077](https://doi.org/10.1101/2020.08.24.264077).
    - Si L, Bai H, et int., and Ingber DE. [“Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics.”](/search/?article=Si20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.13.039917](https://doi.org/10.1101/2020.04.13.039917).
    - Yang S, Chen S, et int., and Hsu M. [“Synthesis, Crystal Structure, Structure−Activity Relationships, and Antiviral Activity of a Potent SARS Coronavirus 3CL Protease Inhibitor.”](/search/?article=Yang06) _Journal of Medicinal Chemistry_, 2006. [doi.org/10.1021/jm0603926](https://doi.org/10.1021/jm0603926). \[[PubMed16884309](https://www.ncbi.nlm.nih.gov/pubmed/16884309/)\]
    - Updated: Matsuyama S, Kawase M, et int., and Fukushi S. [“The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells.”](/search/?article=Matsuyama20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.22.258459](https://doi.org/10.1101/2020.08.22.258459).
- August 25
    - Updated: Matsuyama S, Kawase M, et int., and Fukushi S. [“The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells.”](/search/?article=Matsuyama20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.22.258459](https://doi.org/10.1101/2020.08.22.258459).
- August 24
    - Cao R, Hu H, et int., and Zhong W. [“Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.”](/search/?article=Cao20d) _ACS Infectious Diseases_, 2020. [doi.org/10.1021/acsinfecdis.0c00522](https://doi.org/10.1021/acsinfecdis.0c00522). \[[PubMed32786284](https://www.ncbi.nlm.nih.gov/pubmed/32786284/)\] \[[PMC7437450](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437450/)\]
    - Chen Y, Yang W, et int., and Hung M. [“Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro.”](/search/?article=Chen20i) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.14.250258](https://doi.org/10.1101/2020.08.14.250258).
    - Ivashchenko AA, Dmitriev KA, et int., and Ivachtchenko AV. [“AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.”](/search/?article=Ivashcenko20) _Clinical Infectious Diseases_, 2020. [doi.org/10.1093/cid/ciaa1176](https://doi.org/10.1093/cid/ciaa1176). \[[PubMed32770240](https://www.ncbi.nlm.nih.gov/pubmed/32770240/)\] \[[PMC7454388](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454388/)\]
    - Oguntuyo KY, Stevens CS, et int., and Lee B. [“In plain sight: the role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics.”](/search/?article=Oguntuyo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.14.248880](https://doi.org/10.1101/2020.08.14.248880). \[[PubMed32817940](https://www.ncbi.nlm.nih.gov/pubmed/32817940/)\] \[[PMC7430570](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430570/)\]
    - Spinner CD, Gottlieb RL, et int., and Marty FM. [“Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19.”](/search/?article=Spinner20) _JAMA_, 2020. [doi.org/10.1001/jama.2020.16349](https://doi.org/10.1001/jama.2020.16349). \[[PubMed32821939](https://www.ncbi.nlm.nih.gov/pubmed/32821939/)\] \[[PMC7442954](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442954/)\]
    - Vatansever EC, Yang K, et int., and Liu WR. [“Bepridil is potent against SARS-CoV-2 In Vitro.”](/search/?article=Vatansever20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.23.112235](https://doi.org/10.1101/2020.05.23.112235). \[[PubMed32511370](https://www.ncbi.nlm.nih.gov/pubmed/32511370/)\] \[[PMC7263498](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263498/)\]
    - Yang C, Peng T, et int., and Lee S. [“Repurposing old drugs as antiviral agents for coronaviruses.”](/search/?article=Yang20b) _Biomedical Journal_, 2020. [doi.org/10.1016/j.bj.2020.05.003](https://doi.org/10.1016/j.bj.2020.05.003). \[[PubMed32563698](https://www.ncbi.nlm.nih.gov/pubmed/32563698/)\] \[[PMC7245249](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245249/)\]
    - Updated: Kang Y, Chou Y, et int., and Kirchhausen T. [“Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.”](/search/?article=Kang20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.21.053058](https://doi.org/10.1101/2020.04.21.053058). \[[PubMed32511398](https://www.ncbi.nlm.nih.gov/pubmed/32511398/)\] \[[PMC7263545](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263545/)\]
- August 21
    - Barnes CO, West AP, et int., and Bjorkman PJ. [“Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.”](/search/?article=Barnes20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.025](https://doi.org/10.1016/j.cell.2020.06.025). \[[PubMed32645326](https://www.ncbi.nlm.nih.gov/pubmed/32645326/)\] \[[PMC7311918](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311918/)\]
    - Liu H, Wu NC, et int., and Wilson IA. [“Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.”](/search/?article=Liu20g) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.02.233536](https://doi.org/10.1101/2020.08.02.233536). \[[PubMed32793906](https://www.ncbi.nlm.nih.gov/pubmed/32793906/)\] \[[PMC7418720](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418720/)\]
    - Sadeghi A, Ali Asgari A, et int., and Merat S. [“Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.”](/search/?article=Sadeghi20) _Journal of Antimicrobial Chemotherapy_, 2020. [doi.org/10.1093/jac/dkaa334](https://doi.org/10.1093/jac/dkaa334). \[[PubMed32812039](https://www.ncbi.nlm.nih.gov/pubmed/32812039/)\] \[[PMC7454592](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454592/)\]
    - Wu NC, Yuan M, et int., and Wilson IA. [“An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.”](/search/?article=Wu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.26.222232](https://doi.org/10.1101/2020.07.26.222232). \[[PubMed32743580](https://www.ncbi.nlm.nih.gov/pubmed/32743580/)\] \[[PMC7386498](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386498/)\]
    - Yuan M, Wu NC, et int., and Wilson IA. [“A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.”](/search/?article=Yuan20b) _Science_, 2020. [doi.org/10.1126/science.abb7269](https://doi.org/10.1126/science.abb7269). \[[PubMed32245784](https://www.ncbi.nlm.nih.gov/pubmed/32245784/)\] \[[PMC7164391](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164391/)\]
    - Yuan M, Liu H, et int., and Wilson IA. [“Structural basis of a shared antibody response to SARS-CoV-2.”](/search/?article=Yuan20c) _Science_, 2020. [doi.org/10.1126/science.abd2321](https://doi.org/10.1126/science.abd2321). \[[PubMed32661058](https://www.ncbi.nlm.nih.gov/pubmed/32661058/)\] \[[PMC7402627](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402627/)\]
    - Zost SJ, Gilchuk P, et int., and Crowe JE. [“Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.”](/search/?article=Zost20) _Nature Medicine_, 2020. [doi.org/10.1038/s41591-020-0998-x](https://doi.org/10.1038/s41591-020-0998-x). \[[PubMed32651581](https://www.ncbi.nlm.nih.gov/pubmed/32651581/)\]
- August 17
    - Beasley MD, Aracic S, et int., and Kiefel BR. [“Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries.”](/search/?article=Beasley20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.27.224089](https://doi.org/10.1101/2020.07.27.224089).
    - Custódio TF, Das H, et int., and Löw C. [“Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.”](/search/?article=Custodio20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.23.165415](https://doi.org/10.1101/2020.06.23.165415).
    - Hanke L, Perez LV, et int., and McInerney GM. [“An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.”](/search/?article=Hanke20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.02.130161](https://doi.org/10.1101/2020.06.02.130161).
    - Huo J, Le Bas A, et int., and Naismith JH. [“Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.”](/search/?article=Huo20c) _Nature Structural & Molecular Biology_, 2020. [doi.org/10.1038/s41594-020-0469-6](https://doi.org/10.1038/s41594-020-0469-6). \[[PubMed32661423](https://www.ncbi.nlm.nih.gov/pubmed/32661423/)\]
    - Hurlburt NK, Wan Y, et int., and Pancera M. [“Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.”](/search/?article=Hurlburt20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.12.148692](https://doi.org/10.1101/2020.06.12.148692). \[[PubMed32577631](https://www.ncbi.nlm.nih.gov/pubmed/32577631/)\] \[[PMC7301900](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301900/)\]
    - Sun Z, Chen C, et int., and Dimitrov DS. [“Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.”](/search/?article=Sun20) _mAbs_, 2020. [doi.org/10.1080/19420862.2020.1778435](https://doi.org/10.1080/19420862.2020.1778435). \[[PubMed32544372](https://www.ncbi.nlm.nih.gov/pubmed/32544372/)\]
    - Wang B, Asarnow D, et int., and Wang C. [“Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization.”](/search/?article=Wang20h) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.14.203414](https://doi.org/10.1101/2020.07.14.203414). \[[PubMed32699850](https://www.ncbi.nlm.nih.gov/pubmed/32699850/)\] \[[PMC7373131](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373131/)\]
    - Zhou D, Duyvesteyn HME, et int., and Huang KA. [“Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.”](/search/?article=Zhou20b) _Nature Structural & Molecular Biology_, 2020. [doi.org/10.1038/s41594-020-0480-y](https://doi.org/10.1038/s41594-020-0480-y). \[[PubMed32737466](https://www.ncbi.nlm.nih.gov/pubmed/32737466/)\]
- August 15
    - Gai J, Ma L, et int., and Wan Y. [“A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.”](/search/?article=Gai20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.09.242867](https://doi.org/10.1101/2020.08.09.242867).
    - Schoof M, Faust B, et int., and Manglik A. [“An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation.”](/search/?article=Schoof20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.08.238469](https://doi.org/10.1101/2020.08.08.238469). \[[PubMed32817938](https://www.ncbi.nlm.nih.gov/pubmed/32817938/)\] \[[PMC7430568](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430568/)\]
- August 14
    - Good SS, Westover J, et int., and Sommadossi J. [“AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic.”](/search/?article=Good20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.11.242834](https://doi.org/10.1101/2020.08.11.242834).
    - Joyner MJ, Senefeld JW, et int., and Casadevall A. [“Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience.”](/search/?article=Joyner20b) _medRxiv_, 2020. [doi.org/10.1101/2020.08.12.20169359](https://doi.org/10.1101/2020.08.12.20169359). \[[PubMed32817978](https://www.ncbi.nlm.nih.gov/pubmed/32817978/)\] \[[PMC7430623](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430623/)\]
    - Lv Z, Deng Y, et int., and Wang X. [“Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.”](/search/?article=Lv20) _Science_, 2020. [doi.org/10.1126/science.abc5881](https://doi.org/10.1126/science.abc5881). \[[PubMed32703908](https://www.ncbi.nlm.nih.gov/pubmed/32703908/)\] \[[PMC7402622](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402622/)\]
    - Pan X, Zhou P, et int., and Xiao G. [“Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro.”](/search/?article=Pan20) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104868](https://doi.org/10.1016/j.antiviral.2020.104868). \[[PubMed32659292](https://www.ncbi.nlm.nih.gov/pubmed/32659292/)\] \[[PMC7351055](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351055/)\]
    - Updated: Xu X, Han M, et int., and Wei H. [“Effective treatment of severe COVID-19 patients with tocilizumab.”](/search/?article=Xu20b) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2005615117](https://doi.org/10.1073/pnas.2005615117). \[[PubMed32350134](https://www.ncbi.nlm.nih.gov/pubmed/32350134/)\] \[[PMC7245089](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245089/)\]
- August 10
    - Wang Q, Guo H, et int., and Hu Z. [“Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study.”](/search/?article=Wang20g) _medRxiv_, 2020. [doi.org/10.1101/2020.05.29.20114223](https://doi.org/10.1101/2020.05.29.20114223).
- August 09
    - Hoffmann M, Hofmann-Winkler H, et int., and Pöhlmann S. [“Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.”](/search/?article=Hoffmann20d) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.05.237651](https://doi.org/10.1101/2020.08.05.237651). \[[PubMed32793911](https://www.ncbi.nlm.nih.gov/pubmed/32793911/)\] \[[PMC7418737](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418737/)\]
    - Luban J, Sattler R, et int., and Peltz S. [“The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.”](/search/?article=Luban20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.05.238394](https://doi.org/10.1101/2020.08.05.238394). \[[PubMed32793904](https://www.ncbi.nlm.nih.gov/pubmed/32793904/)\] \[[PMC7418718](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418718/)\]
- August 08
    - Iketani S, Forouhar F, et int., and Ho DD. [“Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.”](/search/?article=Iketani20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.03.235291](https://doi.org/10.1101/2020.08.03.235291). \[[PubMed32793898](https://www.ncbi.nlm.nih.gov/pubmed/32793898/)\] \[[PMC7418712](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418712/)\]
- August 07
    - Baum A, Copin R, et int., and Kyratsous CA. [“REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters.”](/search/?article=Baum20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.02.233320](https://doi.org/10.1101/2020.08.02.233320).
    - Gorial FI, Mashhadani S, et int., and Rasheed JI. [“Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial).”](/search/?article=Gorial20) _medRxiv_, 2020. [doi.org/10.1101/2020.07.07.20145979](https://doi.org/10.1101/2020.07.07.20145979).
    - Kang Y, Chou Y, et int., and Kirchhausen T. [“Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.”](/search/?article=Kang20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.21.053058](https://doi.org/10.1101/2020.04.21.053058). \[[PubMed32511398](https://www.ncbi.nlm.nih.gov/pubmed/32511398/)\] \[[PMC7263545](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263545/)\]
- August 06
    - Chen S, Lu C, et int., and Zhang G. [“Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients.”](/search/?article=Chen20h) _medRxiv_, 2020. [doi.org/10.1101/2020.08.02.20166710](https://doi.org/10.1101/2020.08.02.20166710).
    - Hoagland DA, Clarke DJ, et int., and tenOever BR. [“Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds.”](/search/?article=Hoagland20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.12.199687](https://doi.org/10.1101/2020.07.12.199687).
    - Klemm T, Ebert G, et int., and Komander D. [“Mechanism and inhibition of SARS-CoV-2 PLpro.”](/search/?article=Klemm20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.18.160614](https://doi.org/10.1101/2020.06.18.160614).
    - Linsky TW, Vergara R, et int., and Silva D. [“De novo design of ACE2 protein decoys to neutralize SARS-CoV-2.”](/search/?article=Linsky20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.03.231340](https://doi.org/10.1101/2020.08.03.231340). \[[PubMed32793910](https://www.ncbi.nlm.nih.gov/pubmed/32793910/)\] \[[PMC7418730](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418730/)\]
    - Morokutti-Kurz M, Graf P, et int., and Prieschl-Grassauer E. [“SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan.”](/search/?article=Morokutti-Kurz20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.28.224733](https://doi.org/10.1101/2020.07.28.224733).
    - Sacco MD, Ma C, et int., and Wang J. [“Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L.”](/search/?article=Sacco20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.27.223727](https://doi.org/10.1101/2020.07.27.223727). \[[PubMed32766590](https://www.ncbi.nlm.nih.gov/pubmed/32766590/)\] \[[PMC7402059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402059/)\]
    - Vanderheiden A, Ralfs P, et int., and Suthar MS. [“Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.”](/search/?article=Vanderheiden20) _Journal of Virology_, 2020. [doi.org/10.1128/jvi.00985-20](https://doi.org/10.1128/jvi.00985-20). \[[PubMed32699094](https://www.ncbi.nlm.nih.gov/pubmed/32699094/)\]
- August 05
    - Meng Z, Wang T, et int., and Luo J. [“An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area.”](/search/?article=Meng20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.11.20061473](https://doi.org/10.1101/2020.04.11.20061473).
    - Ou X, Liu Y, et int., and Qian Z. [“Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.”](/search/?article=Ou20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-15562-9](https://doi.org/10.1038/s41467-020-15562-9). \[[PubMed32221306](https://www.ncbi.nlm.nih.gov/pubmed/32221306/)\] \[[PMC7100515](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100515/)\]
    - Wang N, Zhan Y, et int., and Hong P. [“Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.”](/search/?article=Wang20f) _Cell Host & Microbe_, 2020. [doi.org/10.1016/j.chom.2020.07.005](https://doi.org/10.1016/j.chom.2020.07.005). \[[PubMed32707096](https://www.ncbi.nlm.nih.gov/pubmed/32707096/)\] \[[PMC7368656](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368656/)\]
    - Updated: Hung IF, Lung K, et int., and Yuen K. [“Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.”](/search/?article=Hung20) _The Lancet_, 2020. [doi.org/10.1016/s0140-6736(20)31042-4](https://doi.org/10.1016/s0140-6736(20)31042-4). \[[PubMed32401715](https://www.ncbi.nlm.nih.gov/pubmed/32401715/)\] \[[PMC7211500](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211500/)\]
    - Updated: Wan J, Xing S, et int., and Lan F. [“Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.”](/search/?article=Wan20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.107918](https://doi.org/10.1016/j.celrep.2020.107918). \[[PubMed32668215](https://www.ncbi.nlm.nih.gov/pubmed/32668215/)\] \[[PMC7332464](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332464/)\]
- August 04
    - Alsoussi WB, Turner JS, et int., and Ellebedy AH. [“A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.”](/search/?article=Alsoussi20) _The Journal of Immunology_, 2020. [doi.org/10.4049/jimmunol.2000583](https://doi.org/10.4049/jimmunol.2000583). \[[PubMed32591393](https://www.ncbi.nlm.nih.gov/pubmed/32591393/)\]
    - Beddingfield B, Iwanaga N, et int., and Bix G. [“The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.”](/search/?article=Beddingfield20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.15.153387](https://doi.org/10.1101/2020.06.15.153387). \[[PubMed32587959](https://www.ncbi.nlm.nih.gov/pubmed/32587959/)\] \[[PMC7310614](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310614/)\]
    - Yang KS, Ma XR, et int., and Liu WR. [“A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors.”](/search/?article=Liu20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.28.223784](https://doi.org/10.1101/2020.07.28.223784). \[[PubMed32766582](https://www.ncbi.nlm.nih.gov/pubmed/32766582/)\] \[[PMC7402039](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402039/)\]
    - Xiao X, Wang C, et int., and Wang J. [“Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2.”](/search/?article=Xiao20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.06.188953](https://doi.org/10.1101/2020.07.06.188953).
- August 03
    - Doi K, Ikeda M, et int., and Morimura N. [“Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.”](/search/?article=Doi20) _Critical Care_, 2020. [doi.org/10.1186/s13054-020-03078-z](https://doi.org/10.1186/s13054-020-03078-z). \[[PubMed32620147](https://www.ncbi.nlm.nih.gov/pubmed/32620147/)\] \[[PMC7332736](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332736/)\]
    - Lou Y, Liu L, and Qiu Y. [“Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial.”](/search/?article=Lou20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.29.20085761](https://doi.org/10.1101/2020.04.29.20085761).
    - Mitjà O, Corbacho-Monné M, et int., and Vall-Mayans M. [“OUP accepted manuscript.”](/search/?article=Mitja20b) _Clinical Infectious Diseases_, 2020. [doi.org/10.1093/cid/ciaa1009](https://doi.org/10.1093/cid/ciaa1009). \[[PubMed32674126](https://www.ncbi.nlm.nih.gov/pubmed/32674126/)\] \[[PMC7454406](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454406/)\]
    - Updated: Sales-Medina DF, Ferreira LRP, et int., and Freitas-Junior LH. [“Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19.”](/search/?article=Sales-Medina20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.09.196337](https://doi.org/10.1101/2020.07.09.196337).
- August 02
    - Ren Z, Luo H, et int., and Chang J. [“A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study.”](/search/?article=Ren20) _Advanced Science_, 2020. [doi.org/10.1002/advs.202001435](https://doi.org/10.1002/advs.202001435). \[[PubMed32837847](https://www.ncbi.nlm.nih.gov/pubmed/32837847/)\] \[[PMC7404576](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404576/)\]
    - Vanhove B, Duvaux O, et int., and Soulillou J. [“High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.”](/search/?article=Vanhove20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.25.217158](https://doi.org/10.1101/2020.07.25.217158).
### July 2020
- July 31
    - Bae J, Lee GE, et int., and Park M. [“Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza.”](/search/?article=Bae20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.28.225102](https://doi.org/10.1101/2020.07.28.225102).
    - Kreer C, Zehner M, et int., and Klein F. [“Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.”](/search/?article=Kreer20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.044](https://doi.org/10.1016/j.cell.2020.06.044). \[[PubMed32673567](https://www.ncbi.nlm.nih.gov/pubmed/32673567/)\] \[[PMC7355337](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355337/)\]
    - Straus MR, Bidon M, et int., and Daniel S. [“FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells.”](/search/?article=Straus20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214577](https://doi.org/10.1101/2020.07.21.214577).
- July 29
    - Hempel T, Raich L, et int., and Noé F. [“Molecular mechanism of SARS-CoV-2 cell entry inhibition via TMPRSS2 by Camostat and Nafamostat mesylate.”](/search/?article=Hempel20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214098](https://doi.org/10.1101/2020.07.21.214098).
    - Sakoulas G, Geriak M, et int., and Haddad F. [“Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial.”](/search/?article=Sakoulas20) _medRxiv_, 2020. [doi.org/10.1101/2020.07.20.20157891](https://doi.org/10.1101/2020.07.20.20157891).
    - Yao JS, Paguio JA, et int., and Celi LA. [“The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19.”](/search/?article=Yao20b) _Chest_, 2020. [doi.org/10.1016/j.chest.2020.06.082](https://doi.org/10.1016/j.chest.2020.06.082). \[[PubMed32710890](https://www.ncbi.nlm.nih.gov/pubmed/32710890/)\] \[[PMC7375307](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375307/)\]
- July 28
    - Mitja O, Ubals M, et int., and Clotet B. [“A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease.”](/search/?article=Mitja20) _medRxiv_, 2020. [doi.org/10.1101/2020.07.20.20157651](https://doi.org/10.1101/2020.07.20.20157651).
- July 27
    - Hoffmann M, Mösbauer K, et int., and Pöhlmann S. [“Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.”](/search/?article=Hoffmann20c) _Nature_, 2020. [doi.org/10.1038/s41586-020-2575-3](https://doi.org/10.1038/s41586-020-2575-3). \[[PubMed32698190](https://www.ncbi.nlm.nih.gov/pubmed/32698190/)\]
    - Ou T, Mou H, et int., and Farzan M. [“Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.”](/search/?article=Ou20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.22.216150](https://doi.org/10.1101/2020.07.22.216150).
    - Xiong R, Zhang L, et int., and Xu K. [“Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2.”](/search/?article=Xiong20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.11.983056](https://doi.org/10.1101/2020.03.11.983056).
- July 25
    - Cavalcanti AB, Zampieri FG, et int., and Berwanger O. [“Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.”](/search/?article=Calvacanti20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2019014](https://doi.org/10.1056/nejmoa2019014). \[[PubMed32706953](https://www.ncbi.nlm.nih.gov/pubmed/32706953/)\] \[[PMC7397242](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397242/)\]
    - Chen J, Xia L, et int., and Lu H. [“Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.”](/search/?article=Chen20g) _Open Forum Infectious Diseases_, 2020. [doi.org/10.1093/ofid/ofaa241](https://doi.org/10.1093/ofid/ofaa241). \[[PubMed32671131](https://www.ncbi.nlm.nih.gov/pubmed/32671131/)\] \[[PMC7337805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337805/)\]
- July 23
    - Fu Z, Huang B, et int., and Huang H. [“Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules.”](/search/?article=Fu20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.17.208959](https://doi.org/10.1101/2020.07.17.208959).
    - Huo J, Le Bas A, et int., and Naismith JH. [“Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.”](/search/?article=Huo20b) _Nature Structural & Molecular Biology_, 2020. [doi.org/10.1038/s41594-020-0469-6](https://doi.org/10.1038/s41594-020-0469-6). \[[PubMed32661423](https://www.ncbi.nlm.nih.gov/pubmed/32661423/)\]
    - Wu Y, Li C, et int., and Ying T. [“Identification of Human Single-Domain Antibodies against SARS-CoV-2.”](/search/?article=Wu20b) _Cell Host & Microbe_, 2020. [doi.org/10.1016/j.chom.2020.04.023](https://doi.org/10.1016/j.chom.2020.04.023). \[[PubMed32413276](https://www.ncbi.nlm.nih.gov/pubmed/32413276/)\] \[[PMC7224157](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224157/)\]
    - Zhu W, Xu M, et int., and Zheng W. [“Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.”](/search/?article=Zhu20d) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.17.207019](https://doi.org/10.1101/2020.07.17.207019). \[[PubMed32803196](https://www.ncbi.nlm.nih.gov/pubmed/32803196/)\] \[[PMC7427131](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427131/)\]
    - Cai Q, Yang M, et int., and Liu L. [“Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.”](/search/?article=Cai20) _Engineering_, 2020. [doi.org/10.1016/j.eng.2020.03.007](https://doi.org/10.1016/j.eng.2020.03.007). \[[PubMed32346491](https://www.ncbi.nlm.nih.gov/pubmed/32346491/)\] \[[PMC7185795](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185795/)\]
    - Updated: Rosenke K, Jarvis MA, et int., and Feldmann H. [“Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2.”](/search/?article=Rosenke20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.10.145144](https://doi.org/10.1101/2020.06.10.145144). \[[PubMed32577633](https://www.ncbi.nlm.nih.gov/pubmed/32577633/)\] \[[PMC7301902](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301902/)\]
- July 22
    - Updated: Gautret P, Lagier J, et int., and Raoult D. [“Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.”](/search/?article=Gautret20) _International Journal of Antimicrobial Agents_, 2020. [doi.org/10.1016/j.ijantimicag.2020.105949](https://doi.org/10.1016/j.ijantimicag.2020.105949). \[[PubMed32205204](https://www.ncbi.nlm.nih.gov/pubmed/32205204/)\] \[[PMC7102549](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/)\]
    - Updated: Liu J, Cao R, et int., and Wang M. [“Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.”](/search/?article=Liu20) _Cell Discovery_, 2020. [doi.org/10.1038/s41421-020-0156-0](https://doi.org/10.1038/s41421-020-0156-0). \[[PubMed32194981](https://www.ncbi.nlm.nih.gov/pubmed/32194981/)\] \[[PMC7078228](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078228/)\]
    - Updated: Wang Y, Zhang D, et int., and Wang C. [“Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.”](/search/?article=Wang20c) _The Lancet_, 2020. [doi.org/10.1016/s0140-6736(20)31022-9](https://doi.org/10.1016/s0140-6736(20)31022-9). \[[PubMed32423584](https://www.ncbi.nlm.nih.gov/pubmed/32423584/)\] \[[PMC7190303](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190303/)\]
- July 19
    - Seydoux E, Homad LJ, et int., and Stamatatos L. [“Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.”](/search/?article=Seydoux20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.12.091298](https://doi.org/10.1101/2020.05.12.091298). \[[PubMed32511342](https://www.ncbi.nlm.nih.gov/pubmed/32511342/)\] \[[PMC7241105](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241105/)\]
    - Skipper CP, Pastick KA, et int., and Boulware DR. [“Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.”](/search/?article=Skipper20) _Annals of Internal Medicine_, 2020. [doi.org/10.7326/m20-4207](https://doi.org/10.7326/m20-4207). \[[PubMed32673060](https://www.ncbi.nlm.nih.gov/pubmed/32673060/)\] \[[PMC7384270](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384270/)\]
- July 18
    - Baker JD, Uhrich RL, et int., and Kraemer BC. [“A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.”](/search/?article=Baker20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.10.197889](https://doi.org/10.1101/2020.07.10.197889).
    - Chen CZ, Xu M, et int., and Whittaker GR. [“Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles.”](/search/?article=Chen20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.10.197988](https://doi.org/10.1101/2020.07.10.197988). \[[PubMed32839777](https://www.ncbi.nlm.nih.gov/pubmed/32839777/)\] \[[PMC7444289](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444289/)\]
    - Dow GS, Luttick A, et int., and Rayner C. [“Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro.”](/search/?article=Dow20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.12.199059](https://doi.org/10.1101/2020.07.12.199059).
- July 17
    - Horby P, Mafham M, et int., and Landray MJ. [“Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.”](/search/?article=Horby20) _medRxiv_, 2020. [doi.org/10.1101/2020.07.15.20151852](https://doi.org/10.1101/2020.07.15.20151852).
- July 13
    - Bouhaddou M, Memon D, et int., and Krogan NJ. [“The Global Phosphorylation Landscape of SARS-CoV-2 Infection.”](/search/?article=Bouhaddou20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.034](https://doi.org/10.1016/j.cell.2020.06.034). \[[PubMed32645325](https://www.ncbi.nlm.nih.gov/pubmed/32645325/)\] \[[PMC7321036](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321036/)\]
    - Updated: Caly L, Druce JD, et int., and Wagstaff KM. [“The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.”](/search/?article=Caly20) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104787](https://doi.org/10.1016/j.antiviral.2020.104787). \[[PubMed32251768](https://www.ncbi.nlm.nih.gov/pubmed/32251768/)\] \[[PMC7129059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/)\]
    - Updated: Chen J, Liu D, et int., and Lu H. [“[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].”](/search/?article=Chen20d) _Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences_, 2020. [doi.org/10.3785/j.issn.1008-9292.2020.03.03](https://doi.org/10.3785/j.issn.1008-9292.2020.03.03). \[[PubMed32391667](https://www.ncbi.nlm.nih.gov/pubmed/32391667/)\]
    - Updated: Dahl H, Linde A, and Strannegård Ö. [“In vitro inhibition of SARS virus replication by human interferons.”](/search/?article=Dahl04) _Scandinavian Journal of Infectious Diseases_, 2004. [doi.org/10.1080/00365540410021144](https://doi.org/10.1080/00365540410021144). \[[PubMed15764169](https://www.ncbi.nlm.nih.gov/pubmed/15764169/)\]
    - Updated: Geleris J, Sun Y, et int., and Schluger NW. [“Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.”](/search/?article=Geleris20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2012410](https://doi.org/10.1056/nejmoa2012410). \[[PubMed32379955](https://www.ncbi.nlm.nih.gov/pubmed/32379955/)\] \[[PMC7224609](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224609/)\]
    - Updated: Grein J, Ohmagari N, et int., and Flanigan T. [“Compassionate Use of Remdesivir for Patients with Severe Covid-19.”](/search/?article=Grein20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2007016](https://doi.org/10.1056/nejmoa2007016). \[[PubMed32275812](https://www.ncbi.nlm.nih.gov/pubmed/32275812/)\] \[[PMC7169476](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169476/)\]
    - Updated: Li L, Zhang W, et int., and Liu Z. [“Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19.”](/search/?article=Li20c) _JAMA_, 2020. [doi.org/10.1001/jama.2020.10044](https://doi.org/10.1001/jama.2020.10044). \[[PubMed32492084](https://www.ncbi.nlm.nih.gov/pubmed/32492084/)\] \[[PMC7270883](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270883/)\]
    - Updated: Molina J, Delaugerre C, et int., and de Castro N. [“No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.”](/search/?article=Molina20) _Médecine et Maladies Infectieuses_, 2020. [doi.org/10.1016/j.medmal.2020.03.006](https://doi.org/10.1016/j.medmal.2020.03.006). \[[PubMed32240719](https://www.ncbi.nlm.nih.gov/pubmed/32240719/)\] \[[PMC7195369](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195369/)\]
- July 11
    - Driouich J, Cochin M, et int., and Nougairède A. [“Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.”](/search/?article=Driouich20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.07.191775](https://doi.org/10.1101/2020.07.07.191775).
    - Garcia G, Sharma A, et int., and Arumugaswami V. [“Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication.”](/search/?article=Garcia20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.24.150326](https://doi.org/10.1101/2020.06.24.150326).
    - Jeon YJ, Gil CH, et int., and Kim HJ. [“The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium.”](/search/?article=Jeon20b) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104860](https://doi.org/10.1016/j.antiviral.2020.104860). \[[PubMed32565134](https://www.ncbi.nlm.nih.gov/pubmed/32565134/)\] \[[PMC7303047](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303047/)\]
    - Sauerhering L, Kupke A, et int., and Peteranderl C. [“Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon λ In Vitro And In Mice.”](/search/?article=Sauerhering20) _European Respiratory Journal_, 2020. [doi.org/10.1183/13993003.01826-2019](https://doi.org/10.1183/13993003.01826-2019). \[[PubMed32616594](https://www.ncbi.nlm.nih.gov/pubmed/32616594/)\] \[[PMC7331652](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331652/)\]
- July 09
    - Cao Y, Su B, et int., and Xie XS. [“Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells.”](/search/?article=Cao20c) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.05.025](https://doi.org/10.1016/j.cell.2020.05.025). \[[PubMed32425270](https://www.ncbi.nlm.nih.gov/pubmed/32425270/)\] \[[PMC7231725](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231725/)\]
    - Liu L, Wang P, et int., and Ho DD. [“Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike.”](/search/?article=Liu20e) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.17.153486](https://doi.org/10.1101/2020.06.17.153486). \[[PubMed32587975](https://www.ncbi.nlm.nih.gov/pubmed/32587975/)\] \[[PMC7310634](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310634/)\]
    - Robbiani DF, Gaebler C, et int., and Nussenzweig MC. [“Convergent antibody responses to SARS-CoV-2 in convalescent individuals.”](/search/?article=Robbiani20) _Nature_, 2020. [doi.org/10.1038/s41586-020-2456-9](https://doi.org/10.1038/s41586-020-2456-9). \[[PubMed32555388](https://www.ncbi.nlm.nih.gov/pubmed/32555388/)\] \[[PMC7442695](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442695/)\]
    - Wec AZ, Wrapp D, et int., and Walker LM. [“Broad neutralization of SARS-related viruses by human monoclonal antibodies.”](/search/?article=Wec20) _Science_, 2020. [doi.org/10.1126/science.abc7424](https://doi.org/10.1126/science.abc7424). \[[PubMed32540900](https://www.ncbi.nlm.nih.gov/pubmed/32540900/)\] \[[PMC7299279](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299279/)\]
    - Chi X, Yan R, et int., and Chen W. [“A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.”](/search/?article=Chi20) _Science_, 2020. [doi.org/10.1126/science.abc6952](https://doi.org/10.1126/science.abc6952). \[[PubMed32571838](https://www.ncbi.nlm.nih.gov/pubmed/32571838/)\] \[[PMC7319273](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319273/)\]
    - Huo J, Zhao Y, et int., and Stuart DI. [“Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.”](/search/?article=Huo20) _Cell Host & Microbe_, 2020. [doi.org/10.1016/j.chom.2020.06.010](https://doi.org/10.1016/j.chom.2020.06.010). \[[PubMed32585135](https://www.ncbi.nlm.nih.gov/pubmed/32585135/)\] \[[PMC7303615](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303615/)\]
    - Wan J, Xing S, et int., and Lan F. [“Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.”](/search/?article=Wan20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.107918](https://doi.org/10.1016/j.celrep.2020.107918). \[[PubMed32668215](https://www.ncbi.nlm.nih.gov/pubmed/32668215/)\] \[[PMC7332464](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332464/)\]
- July 07
    - Gharbharan A, Jordans CCE, et int., and Rijnders B. [“Convalescent Plasma for COVID-19. A randomized clinical trial.”](/search/?article=Gharbharan20) __, 2020. [doi.org/10.1101/2020.07.01.20139857](https://doi.org/10.1101/2020.07.01.20139857).
    - Swaim CD, Perng Y, et int., and Huibregtse JM. [“6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities.”](/search/?article=Swaim20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.01.183020](https://doi.org/10.1101/2020.07.01.183020). \[[PubMed32637945](https://www.ncbi.nlm.nih.gov/pubmed/32637945/)\] \[[PMC7337375](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337375/)\]
    - Wettstein L, Conzelmann C, et int., and Münch J. [“Alpha-1 antitrypsin inhibits SARS-CoV-2 infection.”](/search/?article=Wettstein20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.02.183764](https://doi.org/10.1101/2020.07.02.183764).
- July 05
    - Hansen J, Baum A, et int., and Kyratsous CA. [“Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.”](/search/?article=Hansen20) _Science_, 2020. [doi.org/10.1126/science.abd0827](https://doi.org/10.1126/science.abd0827). \[[PubMed32540901](https://www.ncbi.nlm.nih.gov/pubmed/32540901/)\] \[[PMC7299284](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299284/)\]
    - Kaptein SJ, Jacobs S, et int., and Delang L. [“Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine.”](/search/?article=Kaptein20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.19.159053](https://doi.org/10.1101/2020.06.19.159053).
    - Kato F, Matsuyama S, et int., and Takeda M. [“Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2.”](/search/?article=Kato20) _Microbiology and Immunology_, 2020. [doi.org/10.1111/1348-0421.12828](https://doi.org/10.1111/1348-0421.12828). \[[PubMed32579258](https://www.ncbi.nlm.nih.gov/pubmed/32579258/)\] \[[PMC7362101](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362101/)\]
    - Kawase M, Shirato K, et int., and Matsuyama S. [“Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry.”](/search/?article=Kawase12) _Journal of Virology_, 2012. [doi.org/10.1128/jvi.00094-12](https://doi.org/10.1128/jvi.00094-12). \[[PubMed22496216](https://www.ncbi.nlm.nih.gov/pubmed/22496216/)\] \[[PMC3393535](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393535/)\]
### June 2020
- June 30
    - Bakowski MA, Beutler N, et int., and Rogers TF. [“Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19.”](/search/?article=Bakowski20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.16.153403](https://doi.org/10.1101/2020.06.16.153403).
    - Faico-Filho KS, Conte DD, et int., and Bellei N. [“Effect of hydroxychloroquine on SARS-CoV-2 viral load in patients with COVID-19.”](/search/?article=Faico-Filho20) _medRxiv_, 2020. [doi.org/10.1101/2020.06.16.20133066](https://doi.org/10.1101/2020.06.16.20133066).
- June 29
    - Felgenhauer U, Schoen A, et int., and Weber F. [“Inhibition of SARS-CoV-2 by type I and type III interferons.”](/search/?article=Felgenhauer20) _Journal of Biological Chemistry_, 2020. [doi.org/10.1074/jbc.ac120.013788](https://doi.org/10.1074/jbc.ac120.013788). \[[PubMed32587093](https://www.ncbi.nlm.nih.gov/pubmed/32587093/)\]
    - Guimond SE, Mycroft-West CJ, et int., and Turnbull JE. [“Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus.”](/search/?article=Guimond20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.24.169334](https://doi.org/10.1101/2020.06.24.169334).
    - Mycroft-West CJ, Su D, et int., and Skidmore MA. [“Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin.”](/search/?article=Mycroft-West20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.28.066761](https://doi.org/10.1101/2020.04.28.066761).
    - Shrimp JH, Kales SC, et int., and Hall MD. [“An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.”](/search/?article=Shrimp20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.23.167544](https://doi.org/10.1101/2020.06.23.167544). \[[PubMed32596694](https://www.ncbi.nlm.nih.gov/pubmed/32596694/)\] \[[PMC7315994](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315994/)\]
- June 26
    - Sacramento CQ, Fintelman-Rodrigues N, et int., and Souza TML. [“The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2.”](/search/?article=Sacramento20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.15.153411](https://doi.org/10.1101/2020.06.15.153411).
    - Tandon R, Sharp JS, et int., and Linhardt RJ. [“Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.”](/search/?article=Tandon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.08.140236](https://doi.org/10.1101/2020.06.08.140236). \[[PubMed32577638](https://www.ncbi.nlm.nih.gov/pubmed/32577638/)\] \[[PMC7302190](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302190/)\]
- June 23
    - Baum A, Fulton BO, et int., and Kyratsous CA. [“Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.”](/search/?article=Baum20) _Science_, 2020. [doi.org/10.1126/science.abd0831](https://doi.org/10.1126/science.abd0831). \[[PubMed32540904](https://www.ncbi.nlm.nih.gov/pubmed/32540904/)\] \[[PMC7299283](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299283/)\]
    - Hansen J, Baum A, et int., and Kyratsous CA. [“Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.”](/search/?article=Hansen20) _Science_, 2020. [doi.org/10.1126/science.abd0827](https://doi.org/10.1126/science.abd0827). \[[PubMed32540901](https://www.ncbi.nlm.nih.gov/pubmed/32540901/)\] \[[PMC7299284](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299284/)\]
    - Rosenke K, Jarvis MA, et int., and Feldmann H. [“Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2.”](/search/?article=Rosenke20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.10.145144](https://doi.org/10.1101/2020.06.10.145144). \[[PubMed32577633](https://www.ncbi.nlm.nih.gov/pubmed/32577633/)\] \[[PMC7301902](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301902/)\]
- June 22
    - Dittmar M, Lee JS, et int., and Cherry S. [“Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2.”](/search/?article=Dittmar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.19.161042](https://doi.org/10.1101/2020.06.19.161042).
    - Krüger J, Groß R, et int., and Münch J. [“Remdesivir but not famotidine inhibits SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids.”](/search/?article=Krueger20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.10.144816](https://doi.org/10.1101/2020.06.10.144816).
- June 21
    - Barnard DL, Day CW, et int., and Sidwell RW. [“Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections?.”](/search/?article=Barnard08) _Antiviral Research_, 2008. [doi.org/10.1016/j.antiviral.2007.12.005](https://doi.org/10.1016/j.antiviral.2007.12.005). \[[PubMed18423639](https://www.ncbi.nlm.nih.gov/pubmed/18423639/)\] \[[PMC2582943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582943/)\]
    - Sbidian E, Josse J, et int., and Audureau E. [“Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France.”](/search/?article=Sbidian20) _medRxiv_, 2020. [doi.org/10.1101/2020.06.16.20132597](https://doi.org/10.1101/2020.06.16.20132597).
- June 19
    - Svenningsen EB, Thyrsted J, et int., and Poulsen TB. [“Ionophore antibiotic X-206 is a potent and selective inhibitor of SARS-CoV-2 infection in vitro.”](/search/?article=Svenningsen20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.14.149153](https://doi.org/10.1101/2020.06.14.149153).
- June 16
    - Luan X, Shang W, et int., and Zhang S. [“Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376.”](/search/?article=Luan20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.07.138677](https://doi.org/10.1101/2020.06.07.138677).
    - Rajter JC, Sherman M, et int., and Rajter J. [“ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19.”](/search/?article=Rajter20) _medRxiv_, 2020. [doi.org/10.1101/2020.06.06.20124461](https://doi.org/10.1101/2020.06.06.20124461).
- June 15
    - Salgado-Benvindo C, Thaler M, et int., and van Hemert MJ. [“Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.”](/search/?article=Silva20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.00900-20](https://doi.org/10.1128/aac.00900-20). \[[PubMed32513797](https://www.ncbi.nlm.nih.gov/pubmed/32513797/)\]
    - Xiong H, Cao J, et int., and Xia N. [“Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro.”](/search/?article=Xiong20) _bioRxiv_, 2020. [doi.org/10.1101/2020.06.05.135996](https://doi.org/10.1101/2020.06.05.135996).
- June 08
    - He Z, Zhao W, et int., and Gao X. [“Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies.”](/search/?article=He20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.28.120642](https://doi.org/10.1101/2020.05.28.120642).
    - Mirabelli C, Wotring JW, et int., and Sexton JZ. [“Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19.”](/search/?article=Mirabelli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.27.117184](https://doi.org/10.1101/2020.05.27.117184). \[[PubMed32577649](https://www.ncbi.nlm.nih.gov/pubmed/32577649/)\] \[[PMC7302203](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302203/)\]
    - Park S, Yu K, et int., and Choi YK. [“Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.”](/search/?article=Park20) _mBio_, 2020. [doi.org/10.1128/mbio.01114-20](https://doi.org/10.1128/mbio.01114-20). \[[PubMed32444382](https://www.ncbi.nlm.nih.gov/pubmed/32444382/)\] \[[PMC7244896](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244896/)\]
    - Pedersen NC, Kim Y, et int., and Chang K. [“Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis.”](/search/?article=Pedersen18) _Journal of Feline Medicine and Surgery_, 2017. [doi.org/10.1177/1098612x17729626](https://doi.org/10.1177/1098612x17729626). \[[PubMed28901812](https://www.ncbi.nlm.nih.gov/pubmed/28901812/)\] \[[PMC5871025](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871025/)\]
    - Pedersen NC, Perron M, et int., and Liu H. [“Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis.”](/search/?article=Pedersen19) _Journal of Feline Medicine and Surgery_, 2019. [doi.org/10.1177/1098612x19825701](https://doi.org/10.1177/1098612x19825701). \[[PubMed30755068](https://www.ncbi.nlm.nih.gov/pubmed/30755068/)\] \[[PMC6435921](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435921/)\]
    - Perera KD, Galasiti Kankanamalage AC, et int., and Kim Y. [“Protease inhibitors broadly effective against feline, ferret and mink coronaviruses.”](/search/?article=Perera18) _Antiviral Research_, 2018. [doi.org/10.1016/j.antiviral.2018.10.015](https://doi.org/10.1016/j.antiviral.2018.10.015). \[[PubMed30342822](https://www.ncbi.nlm.nih.gov/pubmed/30342822/)\] \[[PMC6240502](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240502/)\]
    - Yuan S, Chan JF, et int., and Yuen K. [“Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.”](/search/?article=Yuan20) _Pharmacological Research_, 2020. [doi.org/10.1016/j.phrs.2020.104960](https://doi.org/10.1016/j.phrs.2020.104960). \[[PubMed32473310](https://www.ncbi.nlm.nih.gov/pubmed/32473310/)\] \[[PMC7254006](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254006/)\]
- June 04
    - Boulware DR, Pullen MF, et int., and Hullsiek KH. [“A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.”](/search/?article=Boulware20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2016638](https://doi.org/10.1056/nejmoa2016638). \[[PubMed32492293](https://www.ncbi.nlm.nih.gov/pubmed/32492293/)\] \[[PMC7289276](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289276/)\]
    - Li L, Zhang W, et int., and Liu Z. [“Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19.”](/search/?article=Li20c) _JAMA_, 2020. [doi.org/10.1001/jama.2020.10044](https://doi.org/10.1001/jama.2020.10044). \[[PubMed32492084](https://www.ncbi.nlm.nih.gov/pubmed/32492084/)\] \[[PMC7270883](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270883/)\]
- June 01
    - Davoudi-Monfared E, Rahmani H, et int., and Yekaninejad MS. [“Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.”](/search/?article=Davoudi-Monfared20) _medRxiv_, 2020. [doi.org/10.1101/2020.05.28.20116467](https://doi.org/10.1101/2020.05.28.20116467).
### May 2020
- May 29
    - Goldman JD, Lye DC, et int., and Subramanian A. [“Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.”](/search/?article=Goldman20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2015301](https://doi.org/10.1056/nejmoa2015301). \[[PubMed32459919](https://www.ncbi.nlm.nih.gov/pubmed/32459919/)\] \[[PMC7377062](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/)\]
- May 28
    - Wan J, Xing S, et int., and Lan F. [“Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection.”](/search/?article=Lan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.19.104117](https://doi.org/10.1101/2020.05.19.104117).
    - Shi R, Shan C, et int., and Yan J. [“A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.”](/search/?article=Shi20) _Nature_, 2020. [doi.org/10.1038/s41586-020-2381-y](https://doi.org/10.1038/s41586-020-2381-y). \[[PubMed32454512](https://www.ncbi.nlm.nih.gov/pubmed/32454512/)\]
- May 26
    - Mehra MR, Desai SS, et int., and Patel AN. [“RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.”](/search/?article=Mehra20) _The Lancet_, 2020. [doi.org/10.1016/s0140-6736(20)31180-6](https://doi.org/10.1016/s0140-6736(20)31180-6). \[[PubMed32450107](https://www.ncbi.nlm.nih.gov/pubmed/32450107/)\] \[[PMC7255293](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255293/)\]
- May 25
    - Beigel JH, Tomashek KM, et int., and Lane HC. [“Remdesivir for the Treatment of Covid-19 — Preliminary Report.”](/search/?article=Beigel20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2007764](https://doi.org/10.1056/nejmoa2007764). \[[PubMed32445440](https://www.ncbi.nlm.nih.gov/pubmed/32445440/)\] \[[PMC7262788](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/)\]
    - Estebanez M, Ramirez-Olivencia G, et int., and Membrillo de Novales FJ. [“Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study.”](/search/?article=Estebanez20) _medRxiv_, 2020. [doi.org/10.1101/2020.05.15.20084293](https://doi.org/10.1101/2020.05.15.20084293).
    - Liu STH, Lin H, et int., and Bouvier NM. [“Convalescent plasma treatment of severe COVID-19: A matched control study.”](/search/?article=Liu20d) _medRxiv_, 2020. [doi.org/10.1101/2020.05.20.20102236](https://doi.org/10.1101/2020.05.20.20102236).
    - Vuong W, Khan MB, et int., and Lemieux MJ. [“Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.”](/search/?article=Vuong20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.03.073080](https://doi.org/10.1101/2020.05.03.073080).
    - Zost SJ, Gilchuk P, et int., and Crowe JE. [“Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.”](/search/?article=Zost20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.22.111005](https://doi.org/10.1101/2020.05.22.111005). \[[PubMed32511409](https://www.ncbi.nlm.nih.gov/pubmed/32511409/)\] \[[PMC7263556](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263556/)\]
- May 24
    - Konno S, Thanigaimalai P, et int., and Hayashi Y. [“Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.”](/search/?article=Konno13) _Bioorganic & Medicinal Chemistry_, 2012. [doi.org/10.1016/j.bmc.2012.11.017](https://doi.org/10.1016/j.bmc.2012.11.017). \[[PubMed23245752](https://www.ncbi.nlm.nih.gov/pubmed/23245752/)\] \[[PMC7127713](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127713/)\]
    - Roberts A, Thomas W, et int., and Ambrosino D. [“Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters.”](/search/?article=Roberts06) _The Journal of Infectious Diseases_, 2006. [doi.org/10.1086/500143](https://doi.org/10.1086/500143). \[[PubMed16453264](https://www.ncbi.nlm.nih.gov/pubmed/16453264/)\] \[[PMC7109703](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109703/)\]
    - Wu Y, Wang F, et int., and Liu L. [“A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.”](/search/?article=Wu20) _medRxiv_, 2020. [doi.org/10.1101/2020.05.01.20077743](https://doi.org/10.1101/2020.05.01.20077743).
    - Zhao J, Perera RAPM, et int., and Peiris M. [“Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection.”](/search/?article=Zhao15) _Journal of Virology_, 2015. [doi.org/10.1128/jvi.00446-15](https://doi.org/10.1128/jvi.00446-15). \[[PubMed25787284](https://www.ncbi.nlm.nih.gov/pubmed/25787284/)\] \[[PMC4442417](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442417/)\]
- May 23
    - Mehra MR, Desai SS, et int., and Patel AN. [“RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.”](/search/?article=Mandeep20) _The Lancet_, 2020. [doi.org/10.1016/S0140-6736(20)31180-6](https://doi.org/10.1016/S0140-6736(20)31180-6). \[[PubMed32450107](https://www.ncbi.nlm.nih.gov/pubmed/32450107/)\] \[[PMC7255293](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255293/)\]
    - Rajasekharan S, Bonotto RM, et int., and Marcello A. [“Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2.”](/search/?article=Rajasekharan20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.18.101691](https://doi.org/10.1101/2020.05.18.101691).
    - Węglarz-Tomczak E, Tomczak JM, et int., and Brul S. [“Discovery of potent inhibitors of PLproCoV2 by screening a library of selenium-containing compounds.”](/search/?article=Weglarz-Tomczak20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.20.107052](https://doi.org/10.1101/2020.05.20.107052).
    - Zhang Y, Zhang Q, et int., and Zhang B. [“Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.”](/search/?article=Zhang20d) _Emerging Microbes & Infections_, 2020. [doi.org/10.1080/22221751.2020.1772676](https://doi.org/10.1080/22221751.2020.1772676). \[[PubMed32432977](https://www.ncbi.nlm.nih.gov/pubmed/32432977/)\] \[[PMC7448857](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448857/)\]
- May 21
    - Pizzorno A, Padey B, et int., and Rosa-Calatrava M. [“Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia.”](/search/?article=Pizzorno20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.31.017889](https://doi.org/10.1101/2020.03.31.017889).
    - Holwerda M, V’kovski P, et int., and Dijkman R. [“Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2.”](/search/?article=Holwerda20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.17.100404](https://doi.org/10.1101/2020.05.17.100404).
    - Ju B, Zhang Q, et int., and Zhang L. [“Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.”](/search/?article=Ju20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.21.990770](https://doi.org/10.1101/2020.03.21.990770).
- May 19
    - Jacobs J, Grum-Tokars V, et int., and Stauffer SR. [“Discovery, Synthesis, And Structure-Based Optimization of a Series ofN-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease.”](/search/?article=Jacobs13) _Journal of Medicinal Chemistry_, 2012. [doi.org/10.1021/jm301580n](https://doi.org/10.1021/jm301580n). \[[PubMed23231439](https://www.ncbi.nlm.nih.gov/pubmed/23231439/)\] \[[PMC3569073](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569073/)\]
    - Riva L, Yuan S, et int., and Chanda SK. [“A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals.”](/search/?article=Riva20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.16.044016](https://doi.org/10.1101/2020.04.16.044016). \[[PubMed32511357](https://www.ncbi.nlm.nih.gov/pubmed/32511357/)\] \[[PMC7263415](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263415/)\]
    - Shirato K, Kawase M, and Matsuyama S. [“Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2.”](/search/?article=Shirato13) _Journal of Virology_, 2013. [doi.org/10.1128/jvi.01890-13](https://doi.org/10.1128/jvi.01890-13). \[[PubMed24027332](https://www.ncbi.nlm.nih.gov/pubmed/24027332/)\] \[[PMC3838146](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838146/)\]
    - Zhu J, Deng Y, et int., and Xie Z. [“An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon.”](/search/?article=Zhu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.02.074021](https://doi.org/10.1101/2020.05.02.074021).
- May 18
    - Blanchard JE, Elowe NH, et int., and Brown ED. [“High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase.”](/search/?article=Blanchard04) _Chemistry & Biology_, 2004. [doi.org/10.1016/j.chembiol.2004.08.011](https://doi.org/10.1016/j.chembiol.2004.08.011). \[[PubMed15489171](https://www.ncbi.nlm.nih.gov/pubmed/15489171/)\] \[[PMC7134594](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134594/)\]
    - Duan X, Han Y, et int., and Chen S. [“Identification of Drugs Blocking SARS-CoV-2 Infection using Human Pluripotent Stem Cell-derived Colonic Organoids.”](/search/?article=Duan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.02.073320](https://doi.org/10.1101/2020.05.02.073320).
    - Han Y, Yang L, et int., and Chen S. [“Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids.”](/search/?article=Han20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.05.079095](https://doi.org/10.1101/2020.05.05.079095). \[[PubMed32511403](https://www.ncbi.nlm.nih.gov/pubmed/32511403/)\] \[[PMC7263550](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263550/)\]
    - Houser KV, Gretebeck L, et int., and Subbarao K. [“Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.”](/search/?article=Houser16) _The Journal of Infectious Diseases_, 2016. [doi.org/10.1093/infdis/jiw080](https://doi.org/10.1093/infdis/jiw080). \[[PubMed26941283](https://www.ncbi.nlm.nih.gov/pubmed/26941283/)\] \[[PMC4837915](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837915/)\]
    - Rogers TF, Zhao F, et int., and Burton DR. [“Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model.”](/search/?article=Rogers20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.11.088674](https://doi.org/10.1101/2020.05.11.088674). \[[PubMed32511387](https://www.ncbi.nlm.nih.gov/pubmed/32511387/)\] \[[PMC7263516](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263516/)\]
    - Shie J, Fang J, et int., and Wong C. [“Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters.”](/search/?article=Shie05b) _Bioorganic & Medicinal Chemistry_, 2005. [doi.org/10.1016/j.bmc.2005.05.065](https://doi.org/10.1016/j.bmc.2005.05.065). \[[PubMed15994085](https://www.ncbi.nlm.nih.gov/pubmed/15994085/)\] \[[PMC7119063](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119063/)\]
    - Zhang H, Zhang H, et int., and Cai SX. [“Design and Synthesis of Dipeptidyl Glutaminyl Fluoromethyl Ketones as Potent Severe Acute Respiratory Syndrome Coronovirus (SARS-CoV) Inhibitors.”](/search/?article=Zhang06) _Journal of Medicinal Chemistry_, 2006. [doi.org/10.1021/jm0507678](https://doi.org/10.1021/jm0507678). \[[PubMed16451084](https://www.ncbi.nlm.nih.gov/pubmed/16451084/)\]
- May 17
    - Li W, Drelich A, et int., and Dimitrov DS. [“Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models.”](/search/?article=Li20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.13.093088](https://doi.org/10.1101/2020.05.13.093088). \[[PubMed32511413](https://www.ncbi.nlm.nih.gov/pubmed/32511413/)\] \[[PMC7263560](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263560/)\]
    - Shannon A, Selisko B, et int., and Canard B. [“Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase.”](/search/?article=Shannon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.15.098731](https://doi.org/10.1101/2020.05.15.098731). \[[PubMed32511380](https://www.ncbi.nlm.nih.gov/pubmed/32511380/)\] \[[PMC7263509](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263509/)\]
- May 16
    - Joyner M, Wright RS, et int., and Casadevall A. [“Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients.”](/search/?article=Joyner20) _medRxiv_, 2020. [doi.org/10.1101/2020.05.12.20099879](https://doi.org/10.1101/2020.05.12.20099879). \[[PubMed32511566](https://www.ncbi.nlm.nih.gov/pubmed/32511566/)\] \[[PMC7274247](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274247/)\]
    - Lan X, Shao C, et int., and Xu Y. [“Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study.”](/search/?article=Lan20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.25.20079079](https://doi.org/10.1101/2020.04.25.20079079).
- May 14
    - Brouwer PJ, Caniels TG, et int., and van Gils MJ. [“Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.”](/search/?article=Brouwer20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.12.088716](https://doi.org/10.1101/2020.05.12.088716).
    - Johnson RF, Bagci U, et int., and Marasco WA. [“3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.”](/search/?article=Johnson16) _Virology_, 2016. [doi.org/10.1016/j.virol.2016.01.004](https://doi.org/10.1016/j.virol.2016.01.004). \[[PubMed26828465](https://www.ncbi.nlm.nih.gov/pubmed/26828465/)\] \[[PMC4769911](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769911/)\]
    - Ko M, Jeon S, et int., and Kim S. [“Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate.”](/search/?article=Ko20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.12.090035](https://doi.org/10.1101/2020.05.12.090035).
    - Pinto D, Park Y, et int., and Corti D. [“Structural and functional analysis of a potent sarbecovirus neutralizing antibody.”](/search/?article=Pinto20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.07.023903](https://doi.org/10.1101/2020.04.07.023903). \[[PubMed32511354](https://www.ncbi.nlm.nih.gov/pubmed/32511354/)\] \[[PMC7255795](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255795/)\]
    - Salazar E, Perez KK, et int., and Musser JM. [“Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas.”](/search/?article=Salazar20) _medRxiv_, 2020. [doi.org/10.1101/2020.05.08.20095471](https://doi.org/10.1101/2020.05.08.20095471). \[[PubMed32511574](https://www.ncbi.nlm.nih.gov/pubmed/32511574/)\] \[[PMC7274255](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274255/)\]
    - Ye M, Fu D, et int., and Lv T. [“Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China.”](/search/?article=Ye20) _Journal of Medical Virology_, 2020. [doi.org/10.1002/jmv.25882](https://doi.org/10.1002/jmv.25882). \[[PubMed32293713](https://www.ncbi.nlm.nih.gov/pubmed/32293713/)\] \[[PMC7262027](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262027/)\]
    - Zeng Q, Yu Z, et int., and Liu Z. [“Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.”](/search/?article=Zeng20) _The Journal of Infectious Diseases_, 2020. [doi.org/10.1093/infdis/jiaa228](https://doi.org/10.1093/infdis/jiaa228). \[[PubMed32348485](https://www.ncbi.nlm.nih.gov/pubmed/32348485/)\] \[[PMC7197534](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197534/)\]
- May 12
    - Gautret P, Lagier J, et int., and Raoult D. [“Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.”](/search/?article=Gautret20b) _Travel Medicine and Infectious Disease_, 2020. [doi.org/10.1016/j.tmaid.2020.101663](https://doi.org/10.1016/j.tmaid.2020.101663). \[[PubMed32289548](https://www.ncbi.nlm.nih.gov/pubmed/32289548/)\] \[[PMC7151271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151271/)\]
    - Million M, Lagier J, et int., and Raoult D. [“Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.”](/search/?article=Million20) _Travel Medicine and Infectious Disease_, 2020. [doi.org/10.1016/j.tmaid.2020.101738](https://doi.org/10.1016/j.tmaid.2020.101738). \[[PubMed32387409](https://www.ncbi.nlm.nih.gov/pubmed/32387409/)\] \[[PMC7199729](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199729/)\]
    - Rosenberg ES, Dufort EM, et int., and Zucker HA. [“Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.”](/search/?article=Rosenberg20) _JAMA_, 2020. [doi.org/10.1001/jama.2020.8630](https://doi.org/10.1001/jama.2020.8630). \[[PubMed32392282](https://www.ncbi.nlm.nih.gov/pubmed/32392282/)\] \[[PMC7215635](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215635/)\]
- May 11
    - Geleris J, Sun Y, et int., and Schluger NW. [“Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.”](/search/?article=Geleris20) New England Journal of Medicine, 2020. [doi.org/10.1056/nejmoa2012410](https://doi.org/10.1056/nejmoa2012410). \[[PubMed32379955](https://www.ncbi.nlm.nih.gov/pubmed/32379955/)\] \[[PMC7224609](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224609/)\]
- May 09
    - Freedberg DE, Conigliaro J, et int., and Abrams JA. [“Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.”](/search/?article=Freedberg20) _medRxiv_, 2020. [doi.org/10.1101/2020.05.01.20086694](https://doi.org/10.1101/2020.05.01.20086694).
    - Huang M, Li M, et int., and Shan H. [“Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.”](/search/?article=Huang20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.26.20081059](https://doi.org/10.1101/2020.04.26.20081059).
    - Hung IF, Lung K, et int., and Yuen K. [“Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.”](/search/?article=Hung20) _The Lancet_, 2020. [doi.org/10.1016/S0140-6736(20)31042-4](https://doi.org/10.1016/S0140-6736(20)31042-4). \[[PubMed32401715](https://www.ncbi.nlm.nih.gov/pubmed/32401715/)\] \[[PMC7211500](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211500/)\]
- May 08
    - Monteil V, Kwon H, et int., and Penninger JM. [“Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.”](/search/?article=Monteil20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.04.004](https://doi.org/10.1016/j.cell.2020.04.004). \[[PubMed32333836](https://www.ncbi.nlm.nih.gov/pubmed/32333836/)\] \[[PMC7181998](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181998/)\]
    - Plaze M, Attali D, et int., and Gaillard R. [“Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.”](/search/?article=Plaze20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.05.079608](https://doi.org/10.1101/2020.05.05.079608).
    - Wang X, Cao R, et int., and Wang M. [“The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro.”](/search/?article=Wang20d) _Cell Discovery_, 2020. [doi.org/10.1038/s41421-020-0169-8](https://doi.org/10.1038/s41421-020-0169-8). \[[PubMed32373347](https://www.ncbi.nlm.nih.gov/pubmed/32373347/)\] \[[PMC7195821](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195821/)\]
- May 05
    - Day CW, Baric R, et int., and Barnard DL. [“A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.”](/search/?article=Day09) _Virology_, 2009. [doi.org/10.1016/j.virol.2009.09.023](https://doi.org/10.1016/j.virol.2009.09.023). \[[PubMed19853271](https://www.ncbi.nlm.nih.gov/pubmed/19853271/)\] \[[PMC2787736](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787736/)\]
    - Ellinger B, Bojkova D, et int., and Ciesek S. [“Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection.”](/search/?article=Ellinger20) __, 2020. [doi.org/10.21203/rs.3.rs-23951/v1](https://doi.org/10.21203/rs.3.rs-23951/v1).
    - Jiang L, Wang N, et int., and Zhang L. [“Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein.”](/search/?article=Jiang14) _Science Translational Medicine_, 2014. [doi.org/10.1126/scitranslmed.3008140](https://doi.org/10.1126/scitranslmed.3008140). \[[PubMed24778414](https://www.ncbi.nlm.nih.gov/pubmed/24778414/)\]
    - Liu S, Lien CZ, et int., and Wang TT. [“Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection.”](/search/?article=Liu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.29.067983](https://doi.org/10.1101/2020.04.29.067983).
    - Mercuro NJ, Yen CF, et int., and Gold HS. [“Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).”](/search/?article=Mercuro20) _JAMA Cardiol_, 2020. \[[PubMed32356863](https://www.ncbi.nlm.nih.gov/pubmed/32356863/)\]
    - Yu B, Wang DW, and Li C. [“Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19.”](/search/?article=Yu20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.27.20073379](https://doi.org/10.1101/2020.04.27.20073379).
    - Zheng F, Zhou Y, et int., and Gong G. [“A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19.”](/search/?article=Zheng20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.24.20077735](https://doi.org/10.1101/2020.04.24.20077735).
### April 2020
- April 30
    - Chen X, Li R, et int., and Ye L. [“Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.”](/search/?article=Chen20e) _Cellular & Molecular Immunology_, 2020. [doi.org/10.1038/s41423-020-0426-7](https://doi.org/10.1038/s41423-020-0426-7). \[[PubMed32313207](https://www.ncbi.nlm.nih.gov/pubmed/32313207/)\] \[[PMC7167496](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167496/)\]
    - Pruijssers AJ, George AS, et int., and Sheahan TP. [“Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.”](/search/?article=Pruijssers20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.27.064279](https://doi.org/10.1101/2020.04.27.064279). \[[PubMed32511392](https://www.ncbi.nlm.nih.gov/pubmed/32511392/)\] \[[PMC7263539](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263539/)\]
    - Cao J, Forrest JC, and Zhang X. [“A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.”](/search/?article=Cao15) _Antiviral Research_, 2014. [doi.org/10.1016/j.antiviral.2014.11.010](https://doi.org/10.1016/j.antiviral.2014.11.010). \[[PubMed25451075](https://www.ncbi.nlm.nih.gov/pubmed/25451075/)\] \[[PMC7113785](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113785/)\]
- April 29
    - Wang Y, Zhang D, et int., and Wang C. [“Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.”](/search/?article=Wang20c) _The Lancet_, 2020. [doi.org/10.1016/S0140-6736(20)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9). \[[PubMed32423584](https://www.ncbi.nlm.nih.gov/pubmed/32423584/)\] \[[PMC7190303](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190303/)\]
- April 28
    - Hoffmann M, Schroeder S, et int., and Pöhlmann S. [“Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.”](/search/?article=Hoffmann20b) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.00754-20](https://doi.org/10.1128/aac.00754-20). \[[PubMed32312781](https://www.ncbi.nlm.nih.gov/pubmed/32312781/)\] \[[PMC7269515](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269515/)\]
    - Lei C, Qian K, et int., and Hu S. [“Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.”](/search/?article=Lei20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-16048-4](https://doi.org/10.1038/s41467-020-16048-4). \[[PubMed32332765](https://www.ncbi.nlm.nih.gov/pubmed/32332765/)\] \[[PMC7265355](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265355/)\]
    - Sui J, Li W, et int., and Marasco WA. [“Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants.”](/search/?article=Sui05) _Journal of Virology_, 2005. [doi.org/10.1128/jvi.79.10.5900-5906.2005](https://doi.org/10.1128/jvi.79.10.5900-5906.2005). \[[PubMed15857975](https://www.ncbi.nlm.nih.gov/pubmed/15857975/)\] \[[PMC1091676](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1091676/)\]
    - Yamamoto M, Kiso M, et int., and Inoue J. [“The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects.”](/search/?article=Yamamoto20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.22.054981](https://doi.org/10.1101/2020.04.22.054981).
    - Updated: Hoffmann M, Kleine-Weber H, et int., and Pöhlmann S. [“SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.”](/search/?article=Hoffmann20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.02.052](https://doi.org/10.1016/j.cell.2020.02.052). \[[PubMed32142651](https://www.ncbi.nlm.nih.gov/pubmed/32142651/)\] \[[PMC7102627](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627/)\]
- April 27
    - Weston S, Coleman CM, et int., and Frieman MB. [“Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo.”](/search/?article=Weston20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.25.008482](https://doi.org/10.1101/2020.03.25.008482).
- April 24
    - He Y, Li J, et int., and Jiang S. [“Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein.”](/search/?article=He06) _The Journal of Immunology_, 2006. [doi.org/10.4049/jimmunol.176.10.6085](https://doi.org/10.4049/jimmunol.176.10.6085). \[[PubMed16670317](https://www.ncbi.nlm.nih.gov/pubmed/16670317/)\]
    - Hoffmann M, Schroeder S, et int., and Pöhlmann S. [“Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.”](/search/?article=Hoffmann20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.00754-20](https://doi.org/10.1128/aac.00754-20). \[[PubMed32312781](https://www.ncbi.nlm.nih.gov/pubmed/32312781/)\] \[[PMC7269515](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269515/)\]
    - Li Y, Xie Z, et int., and Li L. [“An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI).”](/search/?article=Li20) _medRxiv_, 2020. [doi.org/10.1101/2020.03.19.20038984](https://doi.org/10.1101/2020.03.19.20038984).
    - Rockx B, Corti D, et int., and Baric R. [“Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge.”](/search/?article=Rockx08) _Journal of Virology_, 2008. [doi.org/10.1128/jvi.02377-07](https://doi.org/10.1128/jvi.02377-07). \[[PubMed18199635](https://www.ncbi.nlm.nih.gov/pubmed/18199635/)\] \[[PMC2268459](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268459/)\]
    - Tang X, Agnihothram SS, et int., and Marasco WA. [“Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.”](/search/?article=Tang14) _Proceedings of the National Academy of Sciences_, 2014. [doi.org/10.1073/pnas.1402074111](https://doi.org/10.1073/pnas.1402074111). \[[PubMed24778221](https://www.ncbi.nlm.nih.gov/pubmed/24778221/)\] \[[PMC4024880](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024880/)\]
    - Traggiai E, Becker S, et int., and Lanzavecchia A. [“An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.”](/search/?article=Traggiai04) _Nature Medicine_, 2004. [doi.org/10.1038/nm1080](https://doi.org/10.1038/nm1080). \[[PubMed15247913](https://www.ncbi.nlm.nih.gov/pubmed/15247913/)\] \[[PMC7095806](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095806/)\]
    - Yamamoto M, Matsuyama S, et int., and Matsuda Z. [“Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.”](/search/?article=Yamamoto16) _Antimicrobial Agents and Chemotherapy_, 2016. [doi.org/10.1128/aac.01043-16](https://doi.org/10.1128/aac.01043-16). \[[PubMed27550352](https://www.ncbi.nlm.nih.gov/pubmed/27550352/)\] \[[PMC5075056](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075056/)\]
    - ter Meulen J, Bakker AB, et int., and Osterhaus AD. [“Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.”](/search/?article=terMeulen04) _The Lancet_, 2004. [doi.org/10.1016/s0140-6736(04)16506-9](https://doi.org/10.1016/s0140-6736(04)16506-9). \[[PubMed15220038](https://www.ncbi.nlm.nih.gov/pubmed/15220038/)\] \[[PMC7112500](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112500/)\]
    - ter Meulen J, van den Brink EN, et int., and Goudsmit J. [“Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants.”](/search/?article=terMeulen06) _PLoS Medicine_, 2006. [doi.org/10.1371/journal.pmed.0030237](https://doi.org/10.1371/journal.pmed.0030237). \[[PubMed16796401](https://www.ncbi.nlm.nih.gov/pubmed/16796401/)\] \[[PMC1483912](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1483912/)\]
    - van Doremalen N, Falzarano D, et int., and Munster VJ. [“Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets.”](/search/?article=van%20Doremalen17) _Antiviral Research_, 2017. [doi.org/10.1016/j.antiviral.2017.03.025](https://doi.org/10.1016/j.antiviral.2017.03.025). \[[PubMed28389142](https://www.ncbi.nlm.nih.gov/pubmed/28389142/)\] \[[PMC6957253](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957253/)\]
- April 22
    - Chen Z, Bao L, et int., and Jin Q. [“Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.”](/search/?article=Chen17) _The Journal of Infectious Diseases_, 2017. [doi.org/10.1093/infdis/jix209](https://doi.org/10.1093/infdis/jix209). \[[PubMed28472421](https://www.ncbi.nlm.nih.gov/pubmed/28472421/)\] \[[PMC7107363](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107363/)\]
    - Corti D, Zhao J, et int., and Lanzavecchia A. [“Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.”](/search/?article=Corti15) _Proceedings of the National Academy of Sciences_, 2015. [doi.org/10.1073/pnas.1510199112](https://doi.org/10.1073/pnas.1510199112). \[[PubMed26216974](https://www.ncbi.nlm.nih.gov/pubmed/26216974/)\] \[[PMC4547275](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547275/)\]
    - Ma C, Sacco MD, et int., and Wang J. [“Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.”](/search/?article=Ma20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.20.051581](https://doi.org/10.1101/2020.04.20.051581). \[[PubMed32511378](https://www.ncbi.nlm.nih.gov/pubmed/32511378/)\] \[[PMC7263507](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263507/)\]
    - de Wit E, Feldmann F, et int., and Feldmann H. [“Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.”](/search/?article=deWit19) _Antiviral Research_, 2019. [doi.org/10.1016/j.antiviral.2019.01.016](https://doi.org/10.1016/j.antiviral.2019.01.016). \[[PubMed30684561](https://www.ncbi.nlm.nih.gov/pubmed/30684561/)\] \[[PMC7113761](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113761/)\]
- April 21
    - Magagnoli J, Narendran S, et int., and Ambati J. [“Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19.”](/search/?article=Magagnoli20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.16.20065920](https://doi.org/10.1101/2020.04.16.20065920). \[[PubMed32511622](https://www.ncbi.nlm.nih.gov/pubmed/32511622/)\] \[[PMC7276049](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276049/)\]
    - Ohashi H, Watashi K, et int., and Wakita T. [“Multidrug treatment with nelfinavir and cepharanthine against COVID-19.”](/search/?article=Ohashi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.14.039925](https://doi.org/10.1101/2020.04.14.039925).
    - Zhu Z, Chakraborti S, et int., and Dimitrov DS. [“Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.”](/search/?article=Zhu07) _Proceedings of the National Academy of Sciences_, 2007. [doi.org/10.1073/pnas.0701000104](https://doi.org/10.1073/pnas.0701000104). \[[PubMed17620608](https://www.ncbi.nlm.nih.gov/pubmed/17620608/)\] \[[PMC1924550](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924550/)\]
- April 19
    - Zhang L, Lin D, et int., and Hilgenfeld R. [“Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.”](/search/?article=Zhang20c) _Science_, 2020. [doi.org/10.1126/science.abb3405](https://doi.org/10.1126/science.abb3405). \[[PubMed32198291](https://www.ncbi.nlm.nih.gov/pubmed/32198291/)\] \[[PMC7164518](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164518/)\]
    - Gassen NC, Papies J, et int., and Müller MA. [“Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics.”](/search/?article=Gassen20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.15.997254](https://doi.org/10.1101/2020.04.15.997254).
    - Rothan HA, Stone S, et int., and Kumar M. [“The FDA- approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.”](/search/?article=Rothan20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.14.041228](https://doi.org/10.1101/2020.04.14.041228).
    - Williamson BN, Feldmann F, et int., and Wit Ed. [“Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.”](/search/?article=Williamson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.15.043166](https://doi.org/10.1101/2020.04.15.043166). \[[PubMed32511319](https://www.ncbi.nlm.nih.gov/pubmed/32511319/)\] \[[PMC7239049](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239049/)\]
- April 17
    - Tang W, Cao Z, et int., and Xie Q. [“Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial.”](/search/?article=Tang20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.10.20060558](https://doi.org/10.1101/2020.04.10.20060558).
- April 16
    - Chen L, Gui C, et int., and Jiang H. [“Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro.”](/search/?article=Chen05) _Journal of Virology_, 2005. [doi.org/10.1128/jvi.79.11.7095-7103.2005](https://doi.org/10.1128/jvi.79.11.7095-7103.2005). \[[PubMed15890949](https://www.ncbi.nlm.nih.gov/pubmed/15890949/)\] \[[PMC1112131](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1112131/)\]
- April 15
    - Mahevas M, Tran V, et int., and Costedoat N. [“No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial.”](/search/?article=Mahevas20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.10.20060699](https://doi.org/10.1101/2020.04.10.20060699).
    - Zhu Z, Lu Z, et int., and Xue Y. [“Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.”](/search/?article=Zhu20b) _Journal of Infection_, 2020. [doi.org/10.1016/j.jinf.2020.03.060](https://doi.org/10.1016/j.jinf.2020.03.060). \[[PubMed32283143](https://www.ncbi.nlm.nih.gov/pubmed/32283143/)\] \[[PMC7195393](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195393/)\]
- April 14
    - Han Y, Chang G, et int., and Chen X. [“Papain-Like Protease 2 (PLP2) from Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV):  Expression, Purification, Characterization, and Inhibition†.”](/search/?article=Han05) _Biochemistry_, 2005. [doi.org/10.1021/bi0504761](https://doi.org/10.1021/bi0504761). \[[PubMed16042412](https://www.ncbi.nlm.nih.gov/pubmed/16042412/)\]
    - Jin Z, Du X, et int., and Yang H. [“Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.”](/search/?article=Jin20) _Nature_, 2020. [doi.org/10.1038/s41586-020-2223-y](https://doi.org/10.1038/s41586-020-2223-y). \[[PubMed32272481](https://www.ncbi.nlm.nih.gov/pubmed/32272481/)\]
    - SAIJO M, MORIKAWA S, et int., and KURANE I. [“Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.”](/search/?article=Saijo05) _Antiviral Research_, 2005. [doi.org/10.1016/j.antiviral.2005.01.003](https://doi.org/10.1016/j.antiviral.2005.01.003). \[[PubMed15911031](https://www.ncbi.nlm.nih.gov/pubmed/15911031/)\] \[[PMC7114120](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114120/)\]
    - Zhang B, Liu S, et int., and Zhang S. [“Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.”](/search/?article=Zhang20b) _Chest_, 2020. [doi.org/10.1016/j.chest.2020.03.039](https://doi.org/10.1016/j.chest.2020.03.039). \[[PubMed32243945](https://www.ncbi.nlm.nih.gov/pubmed/32243945/)\] \[[PMC7195335](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195335/)\]
- April 11
    - Bukreyeva N, Mantlo EK, et int., and Zeldis J. [“The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro.”](/search/?article=Bukreyeva20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.07.028589](https://doi.org/10.1101/2020.04.07.028589).
    - Grein J, Ohmagari N, et int., and Flanigan T. [“Compassionate Use of Remdesivir for Patients with Severe Covid-19.”](/search/?article=Grein20) New England Journal of Medicine, 2020. [doi.org/10.1056/nejmoa2007016](https://doi.org/10.1056/nejmoa2007016). \[[PubMed32275812](https://www.ncbi.nlm.nih.gov/pubmed/32275812/)\] \[[PMC7169476](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169476/)\]
    - Jeon S, Ko M, et int., and Kim S. [“Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.”](/search/?article=Jeon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.20.999730](https://doi.org/10.1101/2020.03.20.999730).
    - Yamamoto N, Matsuyama S, et int., and Yamamoto N. [“Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.”](/search/?article=Yamamoto20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.06.026476](https://doi.org/10.1101/2020.04.06.026476).
    - Borba MGS, Val FdA, et int., and Lacerda MVG. [“Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).”](/search/?article=Borba20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.07.20056424](https://doi.org/10.1101/2020.04.07.20056424).
    - Matsuyama S, Kawase M, et int., and Fukushi S. [“The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15.”](/search/?article=Matsuyama20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.11.987016](https://doi.org/10.1101/2020.03.11.987016).
    - Zhou Q, Wei X, et int., and Fish EN. [“Interferon-a2b treatment for COVID-19.”](/search/?article=Zhou20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.06.20042580](https://doi.org/10.1101/2020.04.06.20042580).
    - Updated: Grein J, Ohmagari N, et int., and Flanigan T. [“Compassionate Use of Remdesivir for Patients with Severe Covid-19.”](/search/?article=Grein20) New England Journal of Medicine, 2020. [doi.org/10.1056/nejmoa2007016](https://doi.org/10.1056/nejmoa2007016). \[[PubMed32275812](https://www.ncbi.nlm.nih.gov/pubmed/32275812/)\] \[[PMC7169476](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169476/)\]
    - Updated: Jeon S, Ko M, et int., and Kim S. [“Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.”](/search/?article=Jeon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.20.999730](https://doi.org/10.1101/2020.03.20.999730).
    - Updated: Yamamoto N, Matsuyama S, et int., and Yamamoto N. [“Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.”](/search/?article=Yamamoto20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.06.026476](https://doi.org/10.1101/2020.04.06.026476).
- April 09
    - Bojkova D, McGreig JE, et int., and Cinatl J. [“SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles.”](/search/?article=Bojkova20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.03.024257](https://doi.org/10.1101/2020.04.03.024257).
    - Cao W, Liu X, et int., and Li T. [“High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.”](/search/?article=Cao20b) _Open Forum Infectious Diseases_, 2020. [doi.org/10.1093/ofid/ofaa102](https://doi.org/10.1093/ofid/ofaa102). \[[PubMed32258207](https://www.ncbi.nlm.nih.gov/pubmed/32258207/)\] \[[PMC7111600](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111600/)\]
    - Choy K, Wong AY, et int., and Yen H. [“Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.”](/search/?article=Choy20) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104786](https://doi.org/10.1016/j.antiviral.2020.104786). \[[PubMed32251767](https://www.ncbi.nlm.nih.gov/pubmed/32251767/)\] \[[PMC7127386](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127386/)\]
    - De Meyer S, Bojkova D, et int., and Ciesek S. [“Lack of Antiviral Activity of Darunavir against SARS-CoV-2.”](/search/?article=Meyer20) _medRxiv_, 2020. [doi.org/10.1101/2020.04.03.20052548](https://doi.org/10.1101/2020.04.03.20052548).
    - Milewska A, Chi Y, et int., and Pyrc K. [“HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV.”](/search/?article=Milewska20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.29.014183](https://doi.org/10.1101/2020.03.29.014183).
    - Touret F, Gilles M, et int., and Coutard B. [“In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.”](/search/?article=Touret20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.03.023846](https://doi.org/10.1101/2020.04.03.023846).
    - Updated: Bojkova D, McGreig JE, et int., and Cinatl J. [“SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles.”](/search/?article=Bojkova20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.03.024257](https://doi.org/10.1101/2020.04.03.024257).
- April 08
    - Amici C, Di Caro A, et int., and Santoro MG. [“Indomethacin has a potent antiviral activity against SARS coronavirus.”](/search/?article=Amici06) _Antiviral therapy_, 2006. \[[PubMed17302372](https://www.ncbi.nlm.nih.gov/pubmed/17302372/)\]
    - Chou C, Chien C, et int., and Chen X. [“Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.”](/search/?article=Chou08) _Biochemical Pharmacology_, 2008. [doi.org/10.1016/j.bcp.2008.01.005](https://doi.org/10.1016/j.bcp.2008.01.005). \[[PubMed18313035](https://www.ncbi.nlm.nih.gov/pubmed/18313035/)\] \[[PMC7092826](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092826/)\]
    - Fintelman-Rodrigues N, Sacramento CQ, et int., and Souza TML. [“Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.”](/search/?article=Fintelman-Rodrigues20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.04.020925](https://doi.org/10.1101/2020.04.04.020925).
    - Mantlo E, Bukreyeva N, et int., and Huang C. [“Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection.”](/search/?article=Mantlo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.02.022764](https://doi.org/10.1101/2020.04.02.022764). \[[PubMed32511327](https://www.ncbi.nlm.nih.gov/pubmed/32511327/)\] \[[PMC7239057](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239057/)\]
    - Xu T, Gao X, et int., and Zhou Z. [“Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo.”](/search/?article=Xu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.01.017624](https://doi.org/10.1101/2020.04.01.017624).
- April 07
    - Kao RY, Tsui WH, et int., and Yuen K. [“Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics.”](/search/?article=Kao04) _Chemistry & Biology_, 2004. [doi.org/10.1016/j.chembiol.2004.07.013](https://doi.org/10.1016/j.chembiol.2004.07.013). \[[PubMed15380189](https://www.ncbi.nlm.nih.gov/pubmed/15380189/)\] \[[PMC7128553](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128553/)\]
    - Molina J, Delaugerre C, et int., and de Castro N. [“No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.”](/search/?article=Molina20) _Médecine et Maladies Infectieuses_, 2020. [doi.org/10.1016/j.medmal.2020.03.006](https://doi.org/10.1016/j.medmal.2020.03.006). \[[PubMed32240719](https://www.ncbi.nlm.nih.gov/pubmed/32240719/)\] \[[PMC7195369](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195369/)\]
    - Shen C, Wang Z, et int., and Liu L. [“Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.”](/search/?article=Shen20) _JAMA_, 2020. [doi.org/10.1001/jama.2020.4783](https://doi.org/10.1001/jama.2020.4783). \[[PubMed32219428](https://www.ncbi.nlm.nih.gov/pubmed/32219428/)\] \[[PMC7101507](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101507/)\]
    - Yang G, Tan Z, et int., and He S. [“Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension.”](/search/?article=Yang20) _medRxiv_, 2020. [doi.org/10.1101/2020.03.31.20038935](https://doi.org/10.1101/2020.03.31.20038935).
    - Updated: Coughlin MM, Babcook J, and Prabhakar BS. [“Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.”](/search/?article=Coughlin09) _Virology_, 2009. [doi.org/10.1016/j.virol.2009.07.028](https://doi.org/10.1016/j.virol.2009.07.028). \[[PubMed19748648](https://www.ncbi.nlm.nih.gov/pubmed/19748648/)\] \[[PMC7111986](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111986/)\]
    - Updated: Shen C, Wang Z, et int., and Liu L. [“Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.”](/search/?article=Shen20) _JAMA_, 2020. [doi.org/10.1001/jama.2020.4783](https://doi.org/10.1001/jama.2020.4783). \[[PubMed32219428](https://www.ncbi.nlm.nih.gov/pubmed/32219428/)\] \[[PMC7101507](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101507/)\]
- April 05
    - Chen F, Chan K, et int., and Lee T. [“In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.”](/search/?article=Chen04) _Journal of Clinical Virology_, 2004. [doi.org/10.1016/j.jcv.2004.03.003](https://doi.org/10.1016/j.jcv.2004.03.003). \[[PubMed15288617](https://www.ncbi.nlm.nih.gov/pubmed/15288617/)\] \[[PMC7128415](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128415/)\]
    - Coughlin MM, Babcook J, and Prabhakar BS. [“Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.”](/search/?article=Coughlin09) _Virology_, 2009. [doi.org/10.1016/j.virol.2009.07.028](https://doi.org/10.1016/j.virol.2009.07.028). \[[PubMed19748648](https://www.ncbi.nlm.nih.gov/pubmed/19748648/)\] \[[PMC7111986](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111986/)\]
    - Liu Q, Xia S, et int., and Jiang S. [“Testing of Middle East Respiratory Syndrome Coronavirus Replication Inhibitors for the Ability To Block Viral Entry.”](/search/?article=Liu15) _Antimicrobial Agents and Chemotherapy_, 2014. [doi.org/10.1128/aac.03977-14](https://doi.org/10.1128/aac.03977-14). \[[PubMed25331705](https://www.ncbi.nlm.nih.gov/pubmed/25331705/)\] \[[PMC4291393](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291393/)\]
    - Millet JK, and Whittaker GR. [“Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein.”](/search/?article=Millet14) _Proceedings of the National Academy of Sciences_, 2014. [doi.org/10.1073/pnas.1407087111](https://doi.org/10.1073/pnas.1407087111). \[[PubMed25288733](https://www.ncbi.nlm.nih.gov/pubmed/25288733/)\] \[[PMC4210292](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210292/)\]
    - Ohnuma K, Haagmans BL, et int., and Morimoto C. [“Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody.”](/search/?article=Ohnuma13) _Journal of Virology_, 2013. [doi.org/10.1128/jvi.02448-13](https://doi.org/10.1128/jvi.02448-13). \[[PubMed24067970](https://www.ncbi.nlm.nih.gov/pubmed/24067970/)\] \[[PMC3838260](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838260/)\]
    - Updated: Caly L, Druce JD, et int., and Wagstaff KM. [“The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.”](/search/?article=Caly20) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104787](https://doi.org/10.1016/j.antiviral.2020.104787). \[[PubMed32251768](https://www.ncbi.nlm.nih.gov/pubmed/32251768/)\] \[[PMC7129059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/)\]
- April 04
    - Caly L, Druce JD, et int., and Wagstaff KM. [“The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.”](/search/?article=Caly20) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104787](https://doi.org/10.1016/j.antiviral.2020.104787). \[[PubMed32251768](https://www.ncbi.nlm.nih.gov/pubmed/32251768/)\] \[[PMC7129059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/)\]
    - Clementi N, Criscuolo E, et int., and Mancini N. [“Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro.”](/search/?article=Clementi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.29.014407](https://doi.org/10.1101/2020.03.29.014407).
    - Updated: Dahl H, Linde A, and Strannegård Ö. [“In vitro inhibition of SARS virus replication by human interferons.”](/search/?article=Dahl04) _Scandinavian Journal of Infectious Diseases_, 2004. [doi.org/10.1080/00365540410021144](https://doi.org/10.1080/00365540410021144). \[[PubMed15764169](https://www.ncbi.nlm.nih.gov/pubmed/15764169/)\]
- April 03
    - Dahl H, Linde A, and Strannegård Ö. [“In vitro inhibition of SARS virus replication by human interferons.”](/search/?article=Dahl04) _Scandinavian Journal of Infectious Diseases_, 2004. [doi.org/10.1080/00365540410021144](https://doi.org/10.1080/00365540410021144). \[[PubMed15764169](https://www.ncbi.nlm.nih.gov/pubmed/15764169/)\]
    - Updated: Zhu Y, Yu D, et int., and He Y. [“Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity.”](/search/?article=Zhu20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.26.009233](https://doi.org/10.1101/2020.03.26.009233).
    - Updated: Dahl H, Linde A, and Strannegård Ö. [“In vitro inhibition of SARS virus replication by human interferons.”](/search/?article=Dahl04) _Scandinavian Journal of Infectious Diseases_, 2004. [doi.org/10.1080/00365540410021144](https://doi.org/10.1080/00365540410021144). \[[PubMed15764169](https://www.ncbi.nlm.nih.gov/pubmed/15764169/)\]
- April 02
    - Updated: Smits SL, de Lang A, et int., and Haagmans BL. [“Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates.”](/search/?article=Smits10) _PLoS Pathogens_, 2010. [doi.org/10.1371/journal.ppat.1000756](https://doi.org/10.1371/journal.ppat.1000756). \[[PubMed20140198](https://www.ncbi.nlm.nih.gov/pubmed/20140198/)\] \[[PMC2816697](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816697/)\]
### March 2020
- March 31
    - Chen Z, Hu J, et int., and Zhang Z. [“Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.”](/search/?article=Chen20c) _medRxiv_, 2020. [doi.org/10.1101/2020.03.22.20040758](https://doi.org/10.1101/2020.03.22.20040758).
    - Dai W, Zhang B, et int., and Liu H. [“Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease.”](/search/?article=Dai20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.25.996348](https://doi.org/10.1101/2020.03.25.996348).
    - Ekins S, and Madrid PB. [“Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses.”](/search/?article=Ekins20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.00440-20](https://doi.org/10.1128/aac.00440-20). \[[PubMed32205350](https://www.ncbi.nlm.nih.gov/pubmed/32205350/)\] \[[PMC7179581](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179581/)\]
    - Wrapp D, De Vlieger D, et int., and McLellan JS. [“Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies.”](/search/?article=Wrapp20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.26.010165](https://doi.org/10.1101/2020.03.26.010165).
    - Zhang L, Lin D, et int., and Hilgenfeld R. [“α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.”](/search/?article=Zhang20) _Journal of Medicinal Chemistry_, 2020. [doi.org/10.1021/acs.jmedchem.9b01828](https://doi.org/10.1021/acs.jmedchem.9b01828). \[[PubMed32045235](https://www.ncbi.nlm.nih.gov/pubmed/32045235/)\] \[[PMC7098070](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098070/)\]
    - Zhou Y, Vedantham P, et int., and Simmons G. [“Protease inhibitors targeting coronavirus and filovirus entry.”](/search/?article=Zhou15) _Antiviral Research_, 2015. [doi.org/10.1016/j.antiviral.2015.01.011](https://doi.org/10.1016/j.antiviral.2015.01.011). \[[PubMed25666761](https://www.ncbi.nlm.nih.gov/pubmed/25666761/)\] \[[PMC4774534](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774534/)\]
    - Zhu Y, Yu D, et int., and He Y. [“Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity.”](/search/?article=Zhu20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.26.009233](https://doi.org/10.1101/2020.03.26.009233).
    - Chen C, Zhang Y, et int., and Wang X. [“Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.”](/search/?article=Chen20) _medRxiv_, 2020. [doi.org/10.1101/2020.03.17.20037432](https://doi.org/10.1101/2020.03.17.20037432).
    - Channappanavar R, Fehr AR, et int., and Perlman S. [“IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.”](/search/?article=Channappanavar19) _Journal of Clinical Investigation_, 2019. [doi.org/10.1172/jci126363](https://doi.org/10.1172/jci126363). \[[PubMed31355779](https://www.ncbi.nlm.nih.gov/pubmed/31355779/)\] \[[PMC6715373](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715373/)\]
    - Chen J, Liu D, et int., and Lu H. [“[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].”](/search/?article=Chen20d) _Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences_, 2020. [doi.org/10.3785/j.issn.1008-9292.2020.03.03](https://doi.org/10.3785/j.issn.1008-9292.2020.03.03). \[[PubMed32391667](https://www.ncbi.nlm.nih.gov/pubmed/32391667/)\]
    - Kumaki Y, Ennis J, et int., and Barnard DL. [“Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model.”](/search/?article=Kumaki11) _Antiviral Research_, 2010. [doi.org/10.1016/j.antiviral.2010.11.007](https://doi.org/10.1016/j.antiviral.2010.11.007). \[[PubMed21093489](https://www.ncbi.nlm.nih.gov/pubmed/21093489/)\] \[[PMC3018546](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018546/)\]
    - Kumaki Y, Salazar AM, et int., and Barnard DL. [“Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model.”](/search/?article=Kumaki17) _Antiviral Research_, 2016. [doi.org/10.1016/j.antiviral.2016.12.007](https://doi.org/10.1016/j.antiviral.2016.12.007). \[[PubMed27956136](https://www.ncbi.nlm.nih.gov/pubmed/27956136/)\] \[[PMC7113886](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113886/)\]
    - Pascal KE, Coleman CM, et int., and Kyratsous CA. [“Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.”](/search/?article=Pascal15) _Proceedings of the National Academy of Sciences_, 2015. [doi.org/10.1073/pnas.1510830112](https://doi.org/10.1073/pnas.1510830112). \[[PubMed26124093](https://www.ncbi.nlm.nih.gov/pubmed/26124093/)\] \[[PMC4507189](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507189/)\]
    - Pascal KE, Coleman CM, et int., and Kyratsous CA. [“Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.”](/search/?article=Smits10) _Proceedings of the National Academy of Sciences_, 2015. [doi.org/10.1073/pnas.1510830112](https://doi.org/10.1073/pnas.1510830112). \[[PubMed26124093](https://www.ncbi.nlm.nih.gov/pubmed/26124093/)\] \[[PMC4507189](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507189/)\]
    - Soo Y, Cheng Y, et int., and Sung J. [“Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.”](/search/?article=Soo04) _Clinical Microbiology and Infection_, 2004. [doi.org/10.1111/j.1469-0691.2004.00956.x](https://doi.org/10.1111/j.1469-0691.2004.00956.x). \[[PubMed15214887](https://www.ncbi.nlm.nih.gov/pubmed/15214887/)\] \[[PMC7129386](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129386/)\]
    - Kim Y, Lovell S, et int., and Chang K. [“Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses.”](/search/?article=Kim12) _Journal of Virology_, 2012. [doi.org/10.1128/jvi.01348-12](https://doi.org/10.1128/jvi.01348-12). \[[PubMed22915796](https://www.ncbi.nlm.nih.gov/pubmed/22915796/)\] \[[PMC3486288](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486288/)\]
    - Kindrachuk J, Ork B, et int., and Jahrling PB. [“Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis.”](/search/?article=Kindrachuk15) _Antimicrobial Agents and Chemotherapy_, 2014. [doi.org/10.1128/aac.03659-14](https://doi.org/10.1128/aac.03659-14). \[[PubMed25487801](https://www.ncbi.nlm.nih.gov/pubmed/25487801/)\] \[[PMC4335870](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335870/)\]
    - Yang H, Xie W, et int., and Rao Z. [“Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases.”](/search/?article=Yang05) _PLoS Biology_, 2005. [doi.org/10.1371/journal.pbio.0030324](https://doi.org/10.1371/journal.pbio.0030324). \[[PubMed16128623](https://www.ncbi.nlm.nih.gov/pubmed/16128623/)\] \[[PMC1197287](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1197287/)\]
    - Updated: Xu XL, Han MF, et int., and Wei HM.  [“Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2.”](/search/?article=Xu20b) _chinaxiv_, 2020. [doi.org/10.12074/202003.00026](https://doi.org/10.12074/202003.00026).
- March 30
    - Bian H, Zheng Z, et int., and Zhu P. [“Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial.”](/search/?article=Bian20) _medRxiv_, 2020. [doi.org/10.1101/2020.03.21.20040691](https://doi.org/10.1101/2020.03.21.20040691).
    - Cheng Y, Wong R, et int., and Cheng G. [“Use of convalescent plasma therapy in SARS patients in Hong Kong.”](/search/?article=Cheng05) _European Journal of Clinical Microbiology & Infectious Diseases_, 2004. [doi.org/10.1007/s10096-004-1271-9](https://doi.org/10.1007/s10096-004-1271-9). \[[PubMed15616839](https://www.ncbi.nlm.nih.gov/pubmed/15616839/)\] \[[PMC7088355](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088355/)\]
    - Du L, Zhao G, et int., and Zhou Y. [“A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein.”](/search/?article=Du14) _Journal of Virology_, 2014. [doi.org/10.1128/jvi.00433-14](https://doi.org/10.1128/jvi.00433-14). \[[PubMed24719424](https://www.ncbi.nlm.nih.gov/pubmed/24719424/)\] \[[PMC4054355](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054355/)\]
    - Han DP, Penn-Nicholson A, and Cho MW. [“Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.”](/search/?article=Han06) _Virology_, 2006. [doi.org/10.1016/j.virol.2006.01.029](https://doi.org/10.1016/j.virol.2006.01.029). \[[PubMed16510163](https://www.ncbi.nlm.nih.gov/pubmed/16510163/)\] \[[PMC7111894](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111894/)\]
    - Liu Y, Huang F, et int., and Jiang C. [“Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients.”](/search/?article=Liu20b) _medRxiv_, 2020. [doi.org/10.1101/2020.03.20.20039586](https://doi.org/10.1101/2020.03.20.20039586).
    - Wilson L, Gage P, and Ewart G. [“Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication.”](/search/?article=Wilson06) _Virology_, 2006. [doi.org/10.1016/j.virol.2006.05.028](https://doi.org/10.1016/j.virol.2006.05.028). \[[PubMed16815524](https://www.ncbi.nlm.nih.gov/pubmed/16815524/)\] \[[PMC7111787](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111787/)\]
    - Ying T, Du L, et int., and Dimitrov DS. [“Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies.”](/search/?article=Ying14) _Journal of Virology_, 2014. [doi.org/10.1128/jvi.00912-14](https://doi.org/10.1128/jvi.00912-14). \[[PubMed24789777](https://www.ncbi.nlm.nih.gov/pubmed/24789777/)\] \[[PMC4097770](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097770/)\]
    - Yuan K, Yi L, et int., and Deng H. [“Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.”](/search/?article=Yuan04) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.05.046](https://doi.org/10.1016/j.bbrc.2004.05.046). \[[PubMed15184046](https://www.ncbi.nlm.nih.gov/pubmed/15184046/)\] \[[PMC7111000](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111000/)\]
    - Chen C, Zhang Y, et int., and Wang X. [“Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.”](/search/?article=chen20) medRxiv, 2020. [doi.org/10.1101/2020.03.17.20037432](https://doi.org/10.1101/2020.03.17.20037432).
- March 29
    - Cheng K, Cheng S, et int., and Chou C. [“Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus.”](/search/?article=Cheng15) _Antiviral Research_, 2014. [doi.org/10.1016/j.antiviral.2014.12.011](https://doi.org/10.1016/j.antiviral.2014.12.011). \[[PubMed25542975](https://www.ncbi.nlm.nih.gov/pubmed/25542975/)\] \[[PMC7113672](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113672/)\]
    - Greenough T, Babcock G, et int., and Ambrosino D. [“Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice.”](/search/?article=Greenough05) _The Journal of Infectious Diseases_, 2005. [doi.org/10.1086/427242](https://doi.org/10.1086/427242). \[[PubMed15655773](https://www.ncbi.nlm.nih.gov/pubmed/15655773/)\] \[[PMC7110081](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110081/)\]
    - HO T, WU S, et int., and HSIANG C. [“Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction.”](/search/?article=Ho07) _Antiviral Research_, 2006. [doi.org/10.1016/j.antiviral.2006.04.014](https://doi.org/10.1016/j.antiviral.2006.04.014). \[[PubMed16730806](https://www.ncbi.nlm.nih.gov/pubmed/16730806/)\] \[[PMC7114332](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114332/)\]
    - Li H, Kuok DI, et int., and Nicholls JM. [“Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model.”](/search/?article=Li18) _Antiviral Research_, 2018. [doi.org/10.1016/j.antiviral.2018.05.007](https://doi.org/10.1016/j.antiviral.2018.05.007). \[[PubMed29772254](https://www.ncbi.nlm.nih.gov/pubmed/29772254/)\] \[[PMC7113667](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113667/)\]
    - Lokugamage KG, Hage A, et int., and Menachery VD. [“Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.”](/search/?article=Lokugamage20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.07.982264](https://doi.org/10.1101/2020.03.07.982264). \[[PubMed32511335](https://www.ncbi.nlm.nih.gov/pubmed/32511335/)\] \[[PMC7239075](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239075/)\]
    - Updated: Morgenstern B, Michaelis M, et int., and Cinatl J. [“Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.”](/search/?article=Morgenstern05) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.11.128](https://doi.org/10.1016/j.bbrc.2004.11.128). \[[PubMed15607755](https://www.ncbi.nlm.nih.gov/pubmed/15607755/)\] \[[PMC7092851](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092851/)\]
    - Updated: Sheahan TP, Sims AC, et int., and Baric RS. [“An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus.”](/search/?article=Sheahan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.19.997890](https://doi.org/10.1101/2020.03.19.997890).
- March 28
    - Adedeji AO, Singh K, et int., and Sarafianos SG. [“Severe Acute Respiratory Syndrome Coronavirus Replication Inhibitor That Interferes with the Nucleic Acid Unwinding of the Viral Helicase.”](/search/?article=Adedeji12) _Antimicrobial Agents and Chemotherapy_, 2012. [doi.org/10.1128/aac.00957-12](https://doi.org/10.1128/aac.00957-12). \[[PubMed22733076](https://www.ncbi.nlm.nih.gov/pubmed/22733076/)\] \[[PMC3421890](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421890/)\]
    - Adedeji AO, Severson W, et int., and Sarafianos SG. [“Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms.”](/search/?article=Adedeji13) _Journal of Virology_, 2013. [doi.org/10.1128/jvi.00998-13](https://doi.org/10.1128/jvi.00998-13). \[[PubMed23678171](https://www.ncbi.nlm.nih.gov/pubmed/23678171/)\] \[[PMC3700180](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700180/)\]
    - Adedeji AO, Singh K, et int., and Sarafianos SG. [“Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses.”](/search/?article=Adedeji14) _Antimicrobial Agents and Chemotherapy_, 2014. [doi.org/10.1128/aac.02994-14](https://doi.org/10.1128/aac.02994-14). \[[PubMed24841268](https://www.ncbi.nlm.nih.gov/pubmed/24841268/)\] \[[PMC4136041](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136041/)\]
    - Agostini ML, Andres EL, et int., and Denison MR. [“Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.”](/search/?article=Agostini18) _mBio_, 2018. [doi.org/10.1128/mbio.00221-18](https://doi.org/10.1128/mbio.00221-18). \[[PubMed29511076](https://www.ncbi.nlm.nih.gov/pubmed/29511076/)\] \[[PMC5844999](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844999/)\]
    - Agostini ML, Pruijssers AJ, et int., and Denison MR. [“Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.”](/search/?article=Agostini19) _Journal of Virology_, 2019. [doi.org/10.1128/jvi.01348-19](https://doi.org/10.1128/jvi.01348-19). \[[PubMed31578288](https://www.ncbi.nlm.nih.gov/pubmed/31578288/)\] \[[PMC6880162](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880162/)\]
    - Al-Tawfiq JA, Momattin H, et int., and Memish ZA. [“Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.”](/search/?article=AlTawfiq14) _International Journal of Infectious Diseases_, 2014. [doi.org/10.1016/j.ijid.2013.12.003](https://doi.org/10.1016/j.ijid.2013.12.003). \[[PubMed24406736](https://www.ncbi.nlm.nih.gov/pubmed/24406736/)\] \[[PMC7110882](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110882/)\]
    - Arabi YM, Shalhoub S, et int., and Fowler R. [“Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.”](/search/?article=Arabi19) _Clinical Infectious Diseases_, 2019. [doi.org/10.1093/cid/ciz544](https://doi.org/10.1093/cid/ciz544). \[[PubMed31925415](https://www.ncbi.nlm.nih.gov/pubmed/31925415/)\] \[[PMC7108209](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108209/)\]
    - Barnard DL, Hubbard VD, et int., and Sidwell RW. [“Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N4-Hydroxycytidine.”](/search/?article=Barnard04) _Antiviral Chemistry and Chemotherapy_, 2004. [doi.org/10.1177/095632020401500102](https://doi.org/10.1177/095632020401500102). \[[PubMed15074711](https://www.ncbi.nlm.nih.gov/pubmed/15074711/)\]
    - Barnard DL, Day CW, et int., and Sidwell RW. [“Evaluation of Immunomodulators, Interferons and Knownin VitroSARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice.”](/search/?article=Barnard06) _Antiviral Chemistry and Chemotherapy_, 2006. [doi.org/10.1177/095632020601700505](https://doi.org/10.1177/095632020601700505). \[[PubMed17176632](https://www.ncbi.nlm.nih.gov/pubmed/17176632/)\]
    - Barton C, Kouokam JC, et int., and Palmer KE. [“Activity of and Effect of Subcutaneous Treatment with the Broad-Spectrum Antiviral Lectin Griffithsin in Two Laboratory Rodent Models.”](/search/?article=Barton14) _Antimicrobial Agents and Chemotherapy_, 2013. [doi.org/10.1128/aac.01407-13](https://doi.org/10.1128/aac.01407-13). \[[PubMed24145548](https://www.ncbi.nlm.nih.gov/pubmed/24145548/)\] \[[PMC3910741](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910741/)\]
    - Booth CM. [“Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area.”](/search/?article=Booth03) _JAMA_, 2003. [doi.org/10.1001/jama.289.21.joc30885](https://doi.org/10.1001/jama.289.21.joc30885). \[[PubMed12734147](https://www.ncbi.nlm.nih.gov/pubmed/12734147/)\]
    - Brown AJ, Won JJ, et int., and Sheahan TP. [“Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.”](/search/?article=Brown19) _Antiviral Research_, 2019. [doi.org/10.1016/j.antiviral.2019.104541](https://doi.org/10.1016/j.antiviral.2019.104541). \[[PubMed31233808](https://www.ncbi.nlm.nih.gov/pubmed/31233808/)\] \[[PMC6699884](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699884/)\]
    - Cao B, Wang Y, et int., and Wang C. [“A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19.”](/search/?article=Cao20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2001282](https://doi.org/10.1056/nejmoa2001282). \[[PubMed32187464](https://www.ncbi.nlm.nih.gov/pubmed/32187464/)\] \[[PMC7121492](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121492/)\]
    - Carbajo-Lozoya J, Ma-Lauer Y, et int., and von Brunn A. [“Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir.”](/search/?article=Carbajo-Lozoya14) _Virus Research_, 2014. [doi.org/10.1016/j.virusres.2014.02.010](https://doi.org/10.1016/j.virusres.2014.02.010). \[[PubMed24566223](https://www.ncbi.nlm.nih.gov/pubmed/24566223/)\] \[[PMC7114444](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114444/)\]
    - Chan KS, Lai ST, et int., and Yuen KY. [“Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.”](/search/?article=Chan03) _Hong Kong medical journal = Xianggang yi xue za zhi_, 2003. \[[PubMed14660806](https://www.ncbi.nlm.nih.gov/pubmed/14660806/)\]
    - Chan JF, Chan K, et int., and Yuen K. [“Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.”](/search/?article=Chan13) _Journal of Infection_, 2013. [doi.org/10.1016/j.jinf.2013.09.029](https://doi.org/10.1016/j.jinf.2013.09.029). \[[PubMed24096239](https://www.ncbi.nlm.nih.gov/pubmed/24096239/)\] \[[PMC7112612](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112612/)\]
    - Chan JF, Yao Y, et int., and Yuen K. [“Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.”](/search/?article=Chan15) _The Journal of Infectious Diseases_, 2015. [doi.org/10.1093/infdis/jiv392](https://doi.org/10.1093/infdis/jiv392). \[[PubMed26198719](https://www.ncbi.nlm.nih.gov/pubmed/26198719/)\] \[[PMC7107395](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107395/)\]
    - Channappanavar R, Lu L, et int., and Jiang S. [“Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection.”](/search/?article=Channappanavar15) _The Journal of Infectious Diseases_, 2015. [doi.org/10.1093/infdis/jiv325](https://doi.org/10.1093/infdis/jiv325). \[[PubMed26164863](https://www.ncbi.nlm.nih.gov/pubmed/26164863/)\] \[[PMC4655857](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655857/)\]
    - Chen H, Zhang Z, et int., and WU JJ. [“First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients.”](/search/?article=Chen20b) _medRxiv_, 2020. [doi.org/10.1101/2020.03.22.20034041](https://doi.org/10.1101/2020.03.22.20034041).
    - Chu CM. [“Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.”](/search/?article=Chu04) _Thorax_, 2004. [doi.org/10.1136/thorax.2003.012658](https://doi.org/10.1136/thorax.2003.012658). \[[PubMed14985565](https://www.ncbi.nlm.nih.gov/pubmed/14985565/)\] \[[PMC1746980](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746980/)\]
    - Cinatl J, Morgenstern B, et int., and Doerr H. [“Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.”](/search/?article=Cinatl03) _The Lancet_, 2003. [doi.org/10.1016/s0140-6736(03)13615-x](https://doi.org/10.1016/s0140-6736(03)13615-x). \[[PubMed12814717](https://www.ncbi.nlm.nih.gov/pubmed/12814717/)\] \[[PMC7112442](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112442/)\]
    - Cinatl J, Morgenstern B, et int., and Doerr H. [“Treatment of SARS with human interferons.”](/search/?article=Cinatl03b) _The Lancet_, 2003. [doi.org/10.1016/s0140-6736(03)13973-6](https://doi.org/10.1016/s0140-6736(03)13973-6). \[[PubMed12892961](https://www.ncbi.nlm.nih.gov/pubmed/12892961/)\] \[[PMC7112413](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112413/)\]
    - Coleman CM, Sisk JM, et int., and Frieman MB. [“Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.”](/search/?article=Coleman16) _Journal of Virology_, 2016. [doi.org/10.1128/jvi.01429-16](https://doi.org/10.1128/jvi.01429-16). \[[PubMed27466418](https://www.ncbi.nlm.nih.gov/pubmed/27466418/)\] \[[PMC5021412](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021412/)\]
    - Cong Y, Hart BJ, et int., and Holbrook MR. [“MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells.”](/search/?article=Cong18) _PLoS ONE_, 2018. [doi.org/10.1371/journal.pone.0194868](https://doi.org/10.1371/journal.pone.0194868). \[[PubMed29566060](https://www.ncbi.nlm.nih.gov/pubmed/29566060/)\] \[[PMC5864050](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864050/)\]
    - Deng L, Li C, et int., and Xia J. [“Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.”](/search/?article=Deng20) _Journal of Infection_, 2020. [doi.org/10.1016/j.jinf.2020.03.002](https://doi.org/10.1016/j.jinf.2020.03.002). \[[PubMed32171872](https://www.ncbi.nlm.nih.gov/pubmed/32171872/)\] \[[PMC7156152](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156152/)\]
    - Duan K, Liu B, et int., and Yang X. [“The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study.”](/search/?article=Duan20) _medRxiv_, 2020. [doi.org/10.1101/2020.03.16.20036145](https://doi.org/10.1101/2020.03.16.20036145).
    - Dyall J, Coleman CM, et int., and Frieman MB. [“Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection.”](/search/?article=Dyall14) _Antimicrobial Agents and Chemotherapy_, 2014. [doi.org/10.1128/aac.03036-14](https://doi.org/10.1128/aac.03036-14). \[[PubMed24841273](https://www.ncbi.nlm.nih.gov/pubmed/24841273/)\] \[[PMC4136000](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/)\]
    - Falzarano D, de Wit E, et int., and Feldmann H. [“Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques.”](/search/?article=Falzarano13) _Nature Medicine_, 2013. [doi.org/10.1038/nm.3362](https://doi.org/10.1038/nm.3362). \[[PubMed24013700](https://www.ncbi.nlm.nih.gov/pubmed/24013700/)\] \[[PMC4093902](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093902/)\]
    - Falzarano D, de Wit E, et int., and Feldmann H. [“Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.”](/search/?article=Falzarano13b) _Scientific Reports_, 2013. [doi.org/10.1038/srep01686](https://doi.org/10.1038/srep01686). \[[PubMed23594967](https://www.ncbi.nlm.nih.gov/pubmed/23594967/)\] \[[PMC3629412](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629412/)\]
    - Galasiti Kankanamalage AC, Kim Y, et int., and Groutas WC. [“Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.”](/search/?article=Galasiti18) _European Journal of Medicinal Chemistry_, 2018. [doi.org/10.1016/j.ejmech.2018.03.004](https://doi.org/10.1016/j.ejmech.2018.03.004). \[[PubMed29544147](https://www.ncbi.nlm.nih.gov/pubmed/29544147/)\] \[[PMC5891363](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/)\]
    - Gao J, Tian Z, and Yang X. [“Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.”](/search/?article=Gao20) _BioScience Trends_, 2020. [doi.org/10.5582/bst.2020.01047](https://doi.org/10.5582/bst.2020.01047). \[[PubMed32074550](https://www.ncbi.nlm.nih.gov/pubmed/32074550/)\]
    - Gautret P, Lagier J, et int., and Raoult D. [“Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.”](/search/?article=Gautret20) _International Journal of Antimicrobial Agents_, 2020. [doi.org/10.1016/j.ijantimicag.2020.105949](https://doi.org/10.1016/j.ijantimicag.2020.105949). \[[PubMed32205204](https://www.ncbi.nlm.nih.gov/pubmed/32205204/)\] \[[PMC7102549](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/)\]
    - Gordon CJ, Tchesnokov EP, et int., and Götte M. [“The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.”](/search/?article=Gordon20) _Journal of Biological Chemistry_, 2020. [doi.org/10.1074/jbc.ac120.013056](https://doi.org/10.1074/jbc.ac120.013056). \[[PubMed32094225](https://www.ncbi.nlm.nih.gov/pubmed/32094225/)\] \[[PMC7152756](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152756/)\]
    - Haagmans BL, Kuiken T, et int., and Osterhaus ADME. [“Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques.”](/search/?article=Haagmans04) _Nature Medicine_, 2004. [doi.org/10.1038/nm1001](https://doi.org/10.1038/nm1001). \[[PubMed14981511](https://www.ncbi.nlm.nih.gov/pubmed/14981511/)\] \[[PMC7095986](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095986/)\]
    - Hart BJ, Dyall J, et int., and Hensley L. [“Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays.”](/search/?article=Hart14) _Journal of General Virology_, 2013. [doi.org/10.1099/vir.0.061911-0](https://doi.org/10.1099/vir.0.061911-0). \[[PubMed24323636](https://www.ncbi.nlm.nih.gov/pubmed/24323636/)\] \[[PMC3929173](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929173/)\]
    - He R, Adonov A, et int., and Li X. [“Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.”](/search/?article=He04) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.06.076](https://doi.org/10.1016/j.bbrc.2004.06.076). \[[PubMed15249217](https://www.ncbi.nlm.nih.gov/pubmed/15249217/)\] \[[PMC7111066](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111066/)\]
    - Hensley LE, Fritz EA, et int., and Geisbert TW. [“Interferon-β 1a and SARS Coronavirus Replication.”](/search/?article=Hensley04) _Emerging Infectious Diseases_, 2004. [doi.org/10.3201/eid1002.030482](https://doi.org/10.3201/eid1002.030482). \[[PubMed15030704](https://www.ncbi.nlm.nih.gov/pubmed/15030704/)\] \[[PMC3322919](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322919/)\]
    - Hoever G, Baltina L, et int., and Cinatl J. [“Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS−Coronavirus.”](/search/?article=Hoever05) _Journal of Medicinal Chemistry_, 2005. [doi.org/10.1021/jm0493008](https://doi.org/10.1021/jm0493008). \[[PubMed15715493](https://www.ncbi.nlm.nih.gov/pubmed/15715493/)\]
    - Hoffmann M, Kleine-Weber H, et int., and Pöhlmann S. [“SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.”](/search/?article=Hoffman20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.02.052](https://doi.org/10.1016/j.cell.2020.02.052). \[[PubMed32142651](https://www.ncbi.nlm.nih.gov/pubmed/32142651/)\] \[[PMC7102627](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627/)\]
    - Hofmann H, Geier M, et int., and Pöhlmann S. [“Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor.”](/search/?article=Hofmann04) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.05.114](https://doi.org/10.1016/j.bbrc.2004.05.114). \[[PubMed15194496](https://www.ncbi.nlm.nih.gov/pubmed/15194496/)\] \[[PMC7111153](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111153/)\]
    - Holshue ML, DeBolt C, et int., and Pillai SK. [“First Case of 2019 Novel Coronavirus in the United States.”](/search/?article=Holshue20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2001191](https://doi.org/10.1056/nejmoa2001191). \[[PubMed32004427](https://www.ncbi.nlm.nih.gov/pubmed/32004427/)\] \[[PMC7092802](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092802/)\]
    - Kadam RU, and Wilson IA. [“Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.”](/search/?article=Kadam17) _Proceedings of the National Academy of Sciences_, 2016. [doi.org/10.1073/pnas.1617020114](https://doi.org/10.1073/pnas.1617020114). \[[PubMed28003465](https://www.ncbi.nlm.nih.gov/pubmed/28003465/)\] \[[PMC5240704](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240704/)\]
    - Karypidou K, Ribone SR, et int., and Dehaen W. [“Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.”](/search/?article=Karypidou18) _Bioorganic & Medicinal Chemistry Letters_, 2018. [doi.org/10.1016/j.bmcl.2018.09.019](https://doi.org/10.1016/j.bmcl.2018.09.019). \[[PubMed30286952](https://www.ncbi.nlm.nih.gov/pubmed/30286952/)\] \[[PMC7127349](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127349/)\]
    - Keyaerts E, Vijgen L, et int., and Ranst MV. [“In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.”](/search/?article=Keyaerts04) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.08.085](https://doi.org/10.1016/j.bbrc.2004.08.085). \[[PubMed15351731](https://www.ncbi.nlm.nih.gov/pubmed/15351731/)\] \[[PMC7092815](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092815/)\]
    - Keyaerts E, Li S, et int., and Maes P. [“Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice.”](/search/?article=Keyaerts09) _Antimicrobial Agents and Chemotherapy_, 2009. [doi.org/10.1128/aac.01509-08](https://doi.org/10.1128/aac.01509-08). \[[PubMed19506054](https://www.ncbi.nlm.nih.gov/pubmed/19506054/)\] \[[PMC2715625](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715625/)\]
    - Kim MK, Yu M, et int., and Chong Y. [“2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV).”](/search/?article=Kim11) _European Journal of Medicinal Chemistry_, 2011. [doi.org/10.1016/j.ejmech.2011.09.005](https://doi.org/10.1016/j.ejmech.2011.09.005). \[[PubMed21925774](https://www.ncbi.nlm.nih.gov/pubmed/21925774/)\] \[[PMC7115508](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115508/)\]
    - Kim UJ, Won E, et int., and Jang H. [“Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report.”](/search/?article=Kim16) _Antiviral therapy_, 2015. [doi.org/10.3851/imp3002](https://doi.org/10.3851/imp3002). \[[PubMed26492219](https://www.ncbi.nlm.nih.gov/pubmed/26492219/)\]
    - Kim Y, Liu H, et int., and Pedersen NC. [“Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.”](/search/?article=Kim16b) _PLoS Pathogens_, 2016. [doi.org/10.1371/journal.ppat.1005531](https://doi.org/10.1371/journal.ppat.1005531). \[[PubMed27027316](https://www.ncbi.nlm.nih.gov/pubmed/27027316/)\] \[[PMC4814111](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814111/)\]
    - Kim JY, Ko J, et int., and Chin BS. [“Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea.”](/search/?article=Kim20) _Journal of Korean Medical Science_, 2020. [doi.org/10.3346/jkms.2020.35.e86](https://doi.org/10.3346/jkms.2020.35.e86). \[[PubMed32080991](https://www.ncbi.nlm.nih.gov/pubmed/32080991/)\] \[[PMC7036338](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036338/)\]
    - Ko M, Chang SY, et int., and Windisch MP. [“Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19.”](/search/?article=Ko20) _bioRxiv_, 2020. [doi.org/10.1101/2020.02.25.965582](https://doi.org/10.1101/2020.02.25.965582).
    - Konno H, Onuma T, et int., and Akaji K. [“Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor.”](/search/?article=Konno17) _Bioorganic & Medicinal Chemistry Letters_, 2017. [doi.org/10.1016/j.bmcl.2017.04.056](https://doi.org/10.1016/j.bmcl.2017.04.056). \[[PubMed28454669](https://www.ncbi.nlm.nih.gov/pubmed/28454669/)\] \[[PMC7127027](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127027/)\]
    - Kono M, Tatsumi K, et int., and Shirasawa H. [“Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK.”](/search/?article=Kono08) _Antiviral Research_, 2007. [doi.org/10.1016/j.antiviral.2007.10.011](https://doi.org/10.1016/j.antiviral.2007.10.011). \[[PubMed18055026](https://www.ncbi.nlm.nih.gov/pubmed/18055026/)\] \[[PMC7114149](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114149/)\]
    - Kujawski SA, Wong KK, et int., and Zhang J. [“First 12 patients with coronavirus disease 2019 (COVID-19) in the United States.”](/search/?article=Kujawski20) _medRxiv_, 2020. [doi.org/10.1101/2020.03.09.20032896](https://doi.org/10.1101/2020.03.09.20032896).
    - Kumar V, Tan K, et int., and Liang P. [“Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.”](/search/?article=Kumar16) _Bioorganic & Medicinal Chemistry_, 2016. [doi.org/10.1016/j.bmc.2016.05.013](https://doi.org/10.1016/j.bmc.2016.05.013). \[[PubMed27240464](https://www.ncbi.nlm.nih.gov/pubmed/27240464/)\] \[[PMC7079562](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079562/)\]
    - Kumar V, Shin JS, et int., and Liang P. [“Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL Pro inhibitors.”](/search/?article=Kumar17) _Antiviral Research_, 2017. [doi.org/10.1016/j.antiviral.2017.02.007](https://doi.org/10.1016/j.antiviral.2017.02.007). \[[PubMed28216367](https://www.ncbi.nlm.nih.gov/pubmed/28216367/)\] \[[PMC7113684](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113684/)\]
    - Lee J, Cho J, et int., and Jeong Y. [“A Novel Chemical Compound for Inhibition of SARS Coronavirus Helicase.”](/search/?article=Lee17) _Journal of Microbiology and Biotechnology_, 2017. [doi.org/10.4014/jmb.1707.07073](https://doi.org/10.4014/jmb.1707.07073). \[[PubMed28910865](https://www.ncbi.nlm.nih.gov/pubmed/28910865/)\]
    - Lee H, Ren J, et int., and Johnson ME. [“Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.”](/search/?article=Lee19) _Bioorganic & Medicinal Chemistry_, 2019. [doi.org/10.1016/j.bmc.2019.03.050](https://doi.org/10.1016/j.bmc.2019.03.050). \[[PubMed30940566](https://www.ncbi.nlm.nih.gov/pubmed/30940566/)\] \[[PMC6638567](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638567/)\]
    - Leong H, Ang B, et int., and Leo Y. [“Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003.”](/search/?article=Leong04) _Tropical Medicine and International Health_, 2004. [doi.org/10.1111/j.1365-3156.2004.01281.x](https://doi.org/10.1111/j.1365-3156.2004.01281.x). \[[PubMed15303999](https://www.ncbi.nlm.nih.gov/pubmed/15303999/)\] \[[PMC7169743](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169743/)\]
    - Li L, Fu F, et int., and Liu P. [“IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha.”](/search/?article=Li17) _Antiviral Research_, 2017. [doi.org/10.1016/j.antiviral.2017.01.012](https://doi.org/10.1016/j.antiviral.2017.01.012). \[[PubMed28109912](https://www.ncbi.nlm.nih.gov/pubmed/28109912/)\] \[[PMC7113730](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113730/)\]
    - Lin S, Ho C, et int., and Lin C. [“Effective inhibition of MERS-CoV infection by resveratrol.”](/search/?article=Lin17) _BMC Infectious Diseases_, 2017. [doi.org/10.1186/s12879-017-2253-8](https://doi.org/10.1186/s12879-017-2253-8). \[[PubMed28193191](https://www.ncbi.nlm.nih.gov/pubmed/28193191/)\] \[[PMC5307780](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307780/)\]
    - Lin M, Moses DC, et int., and Chou C. [“Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes.”](/search/?article=Lin18) _Antiviral Research_, 2017. [doi.org/10.1016/j.antiviral.2017.12.015](https://doi.org/10.1016/j.antiviral.2017.12.015). \[[PubMed29289665](https://www.ncbi.nlm.nih.gov/pubmed/29289665/)\] \[[PMC7113793](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113793/)\]
    - Liu S, Xiao G, et int., and Jiang S. [“Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.”](/search/?article=Liu04) _The Lancet_, 2004. [doi.org/10.1016/s0140-6736(04)15788-7](https://doi.org/10.1016/s0140-6736(04)15788-7). \[[PubMed15043961](https://www.ncbi.nlm.nih.gov/pubmed/15043961/)\] \[[PMC7140173](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140173/)\]
    - Liu Y, Huang V, et int., and Chow L. [“Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.”](/search/?article=Liu05) _Biochemical and Biophysical Research Communications_, 2005. [doi.org/10.1016/j.bbrc.2005.05.095](https://doi.org/10.1016/j.bbrc.2005.05.095). \[[PubMed15950190](https://www.ncbi.nlm.nih.gov/pubmed/15950190/)\] \[[PMC7092914](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092914/)\]
    - Liu J, Cao R, et int., and Wang M. [“Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.”](/search/?article=Liu20) _Cell Discovery_, 2020. [doi.org/10.1038/s41421-020-0156-0](https://doi.org/10.1038/s41421-020-0156-0). \[[PubMed32194981](https://www.ncbi.nlm.nih.gov/pubmed/32194981/)\] \[[PMC7078228](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078228/)\]
    - Lo MK, Jordan R, et int., and Spiropoulou CF. [“GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.”](/search/?article=Lo17) _Scientific Reports_, 2017. [doi.org/10.1038/srep43395](https://doi.org/10.1038/srep43395). \[[PubMed28262699](https://www.ncbi.nlm.nih.gov/pubmed/28262699/)\] \[[PMC5338263](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338263/)\]
    - Lo MK, Feldmann F, et int., and de Wit E. [“Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge.”](/search/?article=Lo19) _Science Translational Medicine_, 2019. [doi.org/10.1126/scitranslmed.aau9242](https://doi.org/10.1126/scitranslmed.aau9242). \[[PubMed31142680](https://www.ncbi.nlm.nih.gov/pubmed/31142680/)\] \[[PMC6732787](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732787/)\]
    - Loutfy MR, Blatt LM, et int., and Fish EN. [“Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome.”](/search/?article=Loutfy03) _JAMA_, 2003. [doi.org/10.1001/jama.290.24.3222](https://doi.org/10.1001/jama.290.24.3222). \[[PubMed14693875](https://www.ncbi.nlm.nih.gov/pubmed/14693875/)\]
    - Lu L, Liu Q, et int., and Jiang S. [“Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.”](/search/?article=Lu14) _Nature Communications_, 2014. [doi.org/10.1038/ncomms4067](https://doi.org/10.1038/ncomms4067). \[[PubMed24473083](https://www.ncbi.nlm.nih.gov/pubmed/24473083/)\] \[[PMC7091805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091805/)\]
    - Lundin A, Dijkman R, et int., and Trybala E. [“Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus.”](/search/?article=Lundin14) _PLoS Pathogens_, 2014. [doi.org/10.1371/journal.ppat.1004166](https://doi.org/10.1371/journal.ppat.1004166). \[[PubMed24874215](https://www.ncbi.nlm.nih.gov/pubmed/24874215/)\] \[[PMC4038610](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038610/)\]
    - Millet JK, Séron K, et int., and Belouzard S. [“Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.”](/search/?article=Millet16) _Antiviral Research_, 2016. [doi.org/10.1016/j.antiviral.2016.07.011](https://doi.org/10.1016/j.antiviral.2016.07.011). \[[PubMed27424494](https://www.ncbi.nlm.nih.gov/pubmed/27424494/)\] \[[PMC7113895](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113895/)\]
    - Morgenstern B, Michaelis M, et int., and Cinatl J. [“Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.”](/search/?article=Morgenstern05) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.11.128](https://doi.org/10.1016/j.bbrc.2004.11.128). \[[PubMed15607755](https://www.ncbi.nlm.nih.gov/pubmed/15607755/)\] \[[PMC7092851](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092851/)\]
    - Murphy B, Perron M, et int., and Pedersen N. [“The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies.”](/search/?article=Murphy18) _Veterinary Microbiology_, 2018. [doi.org/10.1016/j.vetmic.2018.04.026](https://doi.org/10.1016/j.vetmic.2018.04.026). \[[PubMed29778200](https://www.ncbi.nlm.nih.gov/pubmed/29778200/)\] \[[PMC7117434](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117434/)\]
    - Nukoolkarn V, Lee VS, et int., and Hannongbua S. [“Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors.”](/search/?article=Nukoolkarn08) _Journal of Theoretical Biology_, 2008. [doi.org/10.1016/j.jtbi.2008.07.030](https://doi.org/10.1016/j.jtbi.2008.07.030). \[[PubMed18706430](https://www.ncbi.nlm.nih.gov/pubmed/18706430/)\] \[[PMC7094092](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094092/)\]
    - O'Keefe BR, Giomarelli B, et int., and McCray PB. [“Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae.”](/search/?article=OKeefe10) _Journal of Virology_, 2009. [doi.org/10.1128/jvi.02322-09](https://doi.org/10.1128/jvi.02322-09). \[[PubMed20032190](https://www.ncbi.nlm.nih.gov/pubmed/20032190/)\] \[[PMC2820936](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820936/)\]
    - Omrani AS, Saad MM, et int., and Albarrak AM. [“Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.”](/search/?article=Omrani14) _The Lancet Infectious Diseases_, 2014. [doi.org/10.1016/s1473-3099(14)70920-x](https://doi.org/10.1016/s1473-3099(14)70920-x). \[[PubMed25278221](https://www.ncbi.nlm.nih.gov/pubmed/25278221/)\] \[[PMC7106357](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106357/)\]
    - Park S, Lee J, et int., and Shi H. [“Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.”](/search/?article=Park19) _Journal of Hospital Infection_, 2018. [doi.org/10.1016/j.jhin.2018.09.005](https://doi.org/10.1016/j.jhin.2018.09.005). \[[PubMed30240813](https://www.ncbi.nlm.nih.gov/pubmed/30240813/)\] \[[PMC7114948](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114948/)\]
    - Pécheur E, Borisevich V, et int., and Polyak SJ. [“The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.”](/search/?article=Pecheur16) _Journal of Virology_, 2016. [doi.org/10.1128/jvi.02077-15](https://doi.org/10.1128/jvi.02077-15). \[[PubMed26739045](https://www.ncbi.nlm.nih.gov/pubmed/26739045/)\] \[[PMC4810626](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810626/)\]
    - Peters HL, Jochmans D, et int., and Seley-Radtke KL. [“Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.”](/search/?article=Peters15) _Bioorganic & Medicinal Chemistry Letters_, 2015. [doi.org/10.1016/j.bmcl.2015.05.039](https://doi.org/10.1016/j.bmcl.2015.05.039). \[[PubMed26048809](https://www.ncbi.nlm.nih.gov/pubmed/26048809/)\] \[[PMC4466200](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466200/)\]
    - Pyrc K, Bosch BJ, et int., and van der Hoek L. [“Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle.”](/search/?article=Pyrc06) _Antimicrobial Agents and Chemotherapy_, 2006. [doi.org/10.1128/aac.01598-05](https://doi.org/10.1128/aac.01598-05). \[[PubMed16723558](https://www.ncbi.nlm.nih.gov/pubmed/16723558/)\] \[[PMC1479111](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1479111/)\]
    - Ratia K, Pegan S, et int., and Mesecar AD. [“A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.”](/search/?article=Ratia08) _Proceedings of the National Academy of Sciences_, 2008. [doi.org/10.1073/pnas.0805240105](https://doi.org/10.1073/pnas.0805240105). \[[PubMed18852458](https://www.ncbi.nlm.nih.gov/pubmed/18852458/)\] \[[PMC2571001](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571001/)\]
    - Rossignol J. [“Nitazoxanide: A first-in-class broad-spectrum antiviral agent.”](/search/?article=Rossignol14) _Antiviral Research_, 2014. [doi.org/10.1016/j.antiviral.2014.07.014](https://doi.org/10.1016/j.antiviral.2014.07.014). \[[PubMed25108173](https://www.ncbi.nlm.nih.gov/pubmed/25108173/)\] \[[PMC7113776](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113776/)\]
    - Sainz B, Mossel EC, et int., and Garry RF. [“Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).”](/search/?article=Sainz04) _Virology_, 2004. [doi.org/10.1016/j.virol.2004.08.011](https://doi.org/10.1016/j.virol.2004.08.011). \[[PubMed15476870](https://www.ncbi.nlm.nih.gov/pubmed/15476870/)\] \[[PMC7111895](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111895/)\]
    - Scagnolari C, Vicenzi E, et int., and Antonelli G. [“Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.”](/search/?article=Scagnolari04) _Antiviral therapy_, 2004. \[[PubMed15651759](https://www.ncbi.nlm.nih.gov/pubmed/15651759/)\]
    - Schneider M, Ackermann K, et int., and Gilch S. [“Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain.”](/search/?article=Schneider12) _Journal of Virology_, 2012. [doi.org/10.1128/jvi.01001-12](https://doi.org/10.1128/jvi.01001-12). \[[PubMed22787216](https://www.ncbi.nlm.nih.gov/pubmed/22787216/)\] \[[PMC3446591](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446591/)\]
    - Shalhoub S, Farahat F, et int., and Mushtaq A. [“IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.”](/search/?article=Shalhoub15) _Journal of Antimicrobial Chemotherapy_, 2015. [doi.org/10.1093/jac/dkv085](https://doi.org/10.1093/jac/dkv085). \[[PubMed25900158](https://www.ncbi.nlm.nih.gov/pubmed/25900158/)\] \[[PMC7202429](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202429/)\]
    - Sheahan TP, Sims AC, et int., and Baric RS. [“Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.”](/search/?article=Sheahan17) _Science Translational Medicine_, 2017. [doi.org/10.1126/scitranslmed.aal3653](https://doi.org/10.1126/scitranslmed.aal3653). \[[PubMed28659436](https://www.ncbi.nlm.nih.gov/pubmed/28659436/)\] \[[PMC5567817](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567817/)\]
    - Sheahan TP, Sims AC, et int., and Baric RS. [“Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.”](/search/?article=Sheahan20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-019-13940-6](https://doi.org/10.1038/s41467-019-13940-6). \[[PubMed31924756](https://www.ncbi.nlm.nih.gov/pubmed/31924756/)\] \[[PMC6954302](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954302/)\]
    - Sheahan TP, Sims AC, et int., and Baric RS. [“An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus.”](/search/?article=Sheahan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.19.997890](https://doi.org/10.1101/2020.03.19.997890).
    - Shen L, Yang Y, et int., and Tan W. [“Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene.”](/search/?article=Shen16) _Antimicrobial Agents and Chemotherapy_, 2016. [doi.org/10.1128/aac.00814-16](https://doi.org/10.1128/aac.00814-16). \[[PubMed27381385](https://www.ncbi.nlm.nih.gov/pubmed/27381385/)\] \[[PMC4997878](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997878/)\]
    - Shen L, Niu J, et int., and Tan W. [“High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.”](/search/?article=Shen19) _Journal of Virology_, 2019. [doi.org/10.1128/jvi.00023-19](https://doi.org/10.1128/jvi.00023-19). \[[PubMed30918074](https://www.ncbi.nlm.nih.gov/pubmed/30918074/)\] \[[PMC6613765](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613765/)\]
    - Shie J, Fang J, et int., and Wong C. [“Discovery of Potent Anilide Inhibitors against the Severe Acute Respiratory Syndrome 3CL Protease.”](/search/?article=Shie05) _Journal of Medicinal Chemistry_, 2005. [doi.org/10.1021/jm050184y](https://doi.org/10.1021/jm050184y). \[[PubMed15974598](https://www.ncbi.nlm.nih.gov/pubmed/15974598/)\]
    - Shin J, Jung E, et int., and Go Y. [“Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.”](/search/?article=Shin18) _Viruses_, 2018. [doi.org/10.3390/v10060283](https://doi.org/10.3390/v10060283). \[[PubMed29795047](https://www.ncbi.nlm.nih.gov/pubmed/29795047/)\] \[[PMC6024778](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024778/)\]
    - Siegel D, Hui HC, et int., and Mackman RL. [“Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.”](/search/?article=Siegel17) _Journal of Medicinal Chemistry_, 2017. [doi.org/10.1021/acs.jmedchem.6b01594](https://doi.org/10.1021/acs.jmedchem.6b01594). \[[PubMed28124907](https://www.ncbi.nlm.nih.gov/pubmed/28124907/)\] \[[PMC7202039](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202039/)\]
    - Simmons G, Gosalia DN, et int., and Bates P. [“Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.”](/search/?article=Simmons05) _Proceedings of the National Academy of Sciences_, 2005. [doi.org/10.1073/pnas.0505577102](https://doi.org/10.1073/pnas.0505577102). \[[PubMed16081529](https://www.ncbi.nlm.nih.gov/pubmed/16081529/)\] \[[PMC1188015](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188015/)\]
    - St. John SE, Tomar S, et int., and Mesecar AD. [“Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4—The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS).”](/search/?article=StJohn15) _Bioorganic & Medicinal Chemistry_, 2015. [doi.org/10.1016/j.bmc.2015.06.039](https://doi.org/10.1016/j.bmc.2015.06.039). \[[PubMed26190463](https://www.ncbi.nlm.nih.gov/pubmed/26190463/)\] \[[PMC5433438](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433438/)\]
    - Ströher U, DiCaro A, et int., and Feldmann H. [“Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferon‐α.”](/search/?article=Stroher04) _The Journal of Infectious Diseases_, 2004. [doi.org/10.1086/382597](https://doi.org/10.1086/382597). \[[PubMed15031783](https://www.ncbi.nlm.nih.gov/pubmed/15031783/)\] \[[PMC7109643](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109643/)\]
    - Struck A, Axmann M, et int., and Meyer B. [“A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2.”](/search/?article=Struck12) _Antiviral Research_, 2012. [doi.org/10.1016/j.antiviral.2011.12.012](https://doi.org/10.1016/j.antiviral.2011.12.012). \[[PubMed22265858](https://www.ncbi.nlm.nih.gov/pubmed/22265858/)\] \[[PMC7114193](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114193/)\]
    - Sui J, Li W, et int., and Marasco WA. [“Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.”](/search/?article=Sui04) _Proceedings of the National Academy of Sciences_, 2004. [doi.org/10.1073/pnas.0307140101](https://doi.org/10.1073/pnas.0307140101). \[[PubMed14983044](https://www.ncbi.nlm.nih.gov/pubmed/14983044/)\] \[[PMC356985](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC356985/)\]
    - Sun Y, Zhang H, et int., and Gong R. [“Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.”](/search/?article=Sun17) _Viruses_, 2017. [doi.org/10.3390/v9090255](https://doi.org/10.3390/v9090255). \[[PubMed28906430](https://www.ncbi.nlm.nih.gov/pubmed/28906430/)\] \[[PMC5618021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618021/)\]
    - Tanner JA, Zheng B, et int., and Huang J. [“The Adamantane-Derived Bananins Are Potent Inhibitors of the Helicase Activities and Replication of SARS Coronavirus.”](/search/?article=Tanner05) _Chemistry & Biology_, 2005. [doi.org/10.1016/j.chembiol.2005.01.006](https://doi.org/10.1016/j.chembiol.2005.01.006). \[[PubMed15797214](https://www.ncbi.nlm.nih.gov/pubmed/15797214/)\] \[[PMC7110988](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110988/)\]
    - Tian X, Li C, et int., and Ying T. [“Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.”](/search/?article=Tian20) _Emerging Microbes & Infections_, 2020. [doi.org/10.1080/22221751.2020.1729069](https://doi.org/10.1080/22221751.2020.1729069). \[[PubMed32065055](https://www.ncbi.nlm.nih.gov/pubmed/32065055/)\] \[[PMC7048180](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048180/)\]
    - Vincent MJ, Bergeron E, et int., and Nichol ST. [“Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.”](/search/?article=Vincent05) _Virology Journal_, 2005. [doi.org/10.1186/1743-422x-2-69](https://doi.org/10.1186/1743-422x-2-69). \[[PubMed16115318](https://www.ncbi.nlm.nih.gov/pubmed/16115318/)\] \[[PMC1232869](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)\]
    - Wang L, Bao B, et int., and Wang J. [“Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.”](/search/?article=Wang17) _European Journal of Medicinal Chemistry_, 2017. [doi.org/10.1016/j.ejmech.2017.05.045](https://doi.org/10.1016/j.ejmech.2017.05.045). \[[PubMed28624700](https://www.ncbi.nlm.nih.gov/pubmed/28624700/)\] \[[PMC7115414](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115414/)\]
    - Wang C, Zhao L, et int., and Liu K. [“De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.”](/search/?article=Wang18) _Journal of Medicinal Chemistry_, 2018. [doi.org/10.1021/acs.jmedchem.8b00890](https://doi.org/10.1021/acs.jmedchem.8b00890). \[[PubMed30192544](https://www.ncbi.nlm.nih.gov/pubmed/30192544/)\] \[[PMC7075651](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075651/)\]
    - Wang C, Hua C, et int., and Jiang S. [“Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.”](/search/?article=Wang19) _Viruses_, 2019. [doi.org/10.3390/v11010031](https://doi.org/10.3390/v11010031). \[[PubMed30621343](https://www.ncbi.nlm.nih.gov/pubmed/30621343/)\] \[[PMC6356712](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356712/)\]
    - Wang L, Xu J, et int., and Ying T. [“Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV.”](/search/?article=Wang19b) _Antibodies_, 2019. [doi.org/10.3390/antib8040053](https://doi.org/10.3390/antib8040053). \[[PubMed31690009](https://www.ncbi.nlm.nih.gov/pubmed/31690009/)\] \[[PMC6963733](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963733/)\]
    - Wang M, Cao R, et int., and Xiao G. [“Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.”](/search/?article=Wang20) _Cell Research_, 2020. [doi.org/10.1038/s41422-020-0282-0](https://doi.org/10.1038/s41422-020-0282-0). \[[PubMed32020029](https://www.ncbi.nlm.nih.gov/pubmed/32020029/)\] \[[PMC7054408](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054408/)\]
    - Wang C, Li W, et int., and Bosch B. [“A human monoclonal antibody blocking SARS-CoV-2 infection.”](/search/?article=Wang20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.11.987958](https://doi.org/10.1101/2020.03.11.987958).
    - Warren TK, Wells J, et int., and Bavari S. [“Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.”](/search/?article=Warren14) _Nature_, 2014. [doi.org/10.1038/nature13027](https://doi.org/10.1038/nature13027). \[[PubMed24590073](https://www.ncbi.nlm.nih.gov/pubmed/24590073/)\] \[[PMC7095208](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095208/)\]
    - Warren TK, Jordan R, et int., and Bavari S. [“Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.”](/search/?article=Warren16) _Nature_, 2016. [doi.org/10.1038/nature17180](https://doi.org/10.1038/nature17180). \[[PubMed26934220](https://www.ncbi.nlm.nih.gov/pubmed/26934220/)\] \[[PMC5551389](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551389/)\]
    - Wen C, Kuo Y, et int., and Yang N. [“Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus.”](/search/?article=Wen07) _Journal of Medicinal Chemistry_, 2007. [doi.org/10.1021/jm070295s](https://doi.org/10.1021/jm070295s). \[[PubMed17663539](https://www.ncbi.nlm.nih.gov/pubmed/17663539/)\]
    - Wu C, Jan J, et int., and Hsu JTA. [“Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide.”](/search/?article=Wu04) _Antimicrobial Agents and Chemotherapy_, 2004. [doi.org/10.1128/aac.48.7.2693-2696.2004](https://doi.org/10.1128/aac.48.7.2693-2696.2004). \[[PubMed15215127](https://www.ncbi.nlm.nih.gov/pubmed/15215127/)\] \[[PMC434198](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC434198/)\]
    - Wu C, Jan J, et int., and Wong C. [“Small molecules targeting severe acute respiratory syndrome human coronavirus.”](/search/?article=Wu04b) _Proceedings of the National Academy of Sciences_, 2004. [doi.org/10.1073/pnas.0403596101](https://doi.org/10.1073/pnas.0403596101). \[[PubMed15226499](https://www.ncbi.nlm.nih.gov/pubmed/15226499/)\] \[[PMC454157](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC454157/)\]
    - Wu R, Zhou K, et int., and Wang J. [“Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives.”](/search/?article=Wu19) _European Journal of Medicinal Chemistry_, 2019. [doi.org/10.1016/j.ejmech.2019.02.002](https://doi.org/10.1016/j.ejmech.2019.02.002). \[[PubMed30784880](https://www.ncbi.nlm.nih.gov/pubmed/30784880/)\] \[[PMC7111276](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111276/)\]
    - Xia S, Lan Q, et int., and Lu L. [“Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4.”](/search/?article=Xia19) _Viruses_, 2019. [doi.org/10.3390/v11010056](https://doi.org/10.3390/v11010056). \[[PubMed30646495](https://www.ncbi.nlm.nih.gov/pubmed/30646495/)\] \[[PMC6357153](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357153/)\]
    - Xia S, Yan L, et int., and Lu L. [“A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.”](/search/?article=Xia19b) _Science Advances_, 2019. [doi.org/10.1126/sciadv.aav4580](https://doi.org/10.1126/sciadv.aav4580). \[[PubMed30989115](https://www.ncbi.nlm.nih.gov/pubmed/30989115/)\] \[[PMC6457931](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457931/)\]
    - Xia S, Liu M, et int., and Lu L. [“Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.”](/search/?article=Xia20) _bioRxiv_, 2020. [doi.org/10.1101/2020.03.09.983247](https://doi.org/10.1101/2020.03.09.983247).
    - Xu XL, Han MF, et int., and Wei HM.  [“Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2.”](/search/?article=Xu20b) _chinaxiv_, 2020. [doi.org/10.12074/202003.00026](https://doi.org/10.12074/202003.00026).
    - Yamamoto N, Yang R, et int., and Yamamoto N. [“HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.”](/search/?article=Yamamoto04) _Biochemical and Biophysical Research Communications_, 2004. [doi.org/10.1016/j.bbrc.2004.04.083](https://doi.org/10.1016/j.bbrc.2004.04.083). \[[PubMed15144898](https://www.ncbi.nlm.nih.gov/pubmed/15144898/)\] \[[PMC7111005](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111005/)\]
    - Yao X, Ye F, et int., and Liu D. [“In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).”](/search/?article=Yao20) _Clinical Infectious Diseases_, 2020. [doi.org/10.1093/cid/ciaa237](https://doi.org/10.1093/cid/ciaa237). \[[PubMed32150618](https://www.ncbi.nlm.nih.gov/pubmed/32150618/)\] \[[PMC7108130](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108130/)\]
    - Yoon J, Kim G, et int., and Jeong LS. [“Design, Synthesis, and Anti-RNA Virus Activity of 6′-Fluorinated-Aristeromycin Analogues.”](/search/?article=Yoon19) _Journal of Medicinal Chemistry_, 2019. [doi.org/10.1021/acs.jmedchem.9b00781](https://doi.org/10.1021/acs.jmedchem.9b00781). \[[PubMed31244113](https://www.ncbi.nlm.nih.gov/pubmed/31244113/)\] \[[PMC7075649](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075649/)\]
    - Young BE, Ong SWX, et int., and Lye DC. [“Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.”](/search/?article=Young20) _JAMA_, 2020. [doi.org/10.1001/jama.2020.3204](https://doi.org/10.1001/jama.2020.3204). \[[PubMed32125362](https://www.ncbi.nlm.nih.gov/pubmed/32125362/)\] \[[PMC7054855](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054855/)\]
    - Zaher NH, Mostafa MI, and Altaher AY. [“Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.”](/search/?article=Zaher20) _Acta Pharmaceutica_, 2020. [doi.org/10.2478/acph-2020-0024](https://doi.org/10.2478/acph-2020-0024). \[[PubMed31955138](https://www.ncbi.nlm.nih.gov/pubmed/31955138/)\]
    - Zhao Z. [“Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China.”](/search/?article=Zhao03) _Journal of Medical Microbiology_, 2003. [doi.org/10.1099/jmm.0.05320-0](https://doi.org/10.1099/jmm.0.05320-0). \[[PubMed12867568](https://www.ncbi.nlm.nih.gov/pubmed/12867568/)\]
    - Zhao H, Zhou J, et int., and Zheng B. [“A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses.”](/search/?article=Zhao16) _Scientific Reports_, 2016. [doi.org/10.1038/srep22008](https://doi.org/10.1038/srep22008). \[[PubMed26911565](https://www.ncbi.nlm.nih.gov/pubmed/26911565/)\] \[[PMC4766503](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766503/)\]
    - Zhao P, Wang B, et int., and Huang Y. [“Identification of a peptide derived from the heptad repeat 2 region of the porcine epidemic diarrhea virus (PEDV) spike glycoprotein that is capable of suppressing PEDV entry and inducing neutralizing antibodies.”](/search/?article=Zhao18) _Antiviral Research_, 2017. [doi.org/10.1016/j.antiviral.2017.11.021](https://doi.org/10.1016/j.antiviral.2017.11.021). \[[PubMed29203391](https://www.ncbi.nlm.nih.gov/pubmed/29203391/)\] \[[PMC7113693](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113693/)\]
    - Zheng B, He M, et int., and Kung H. [“Potent Inhibition of SARS-Associated Coronavirus (SCoV) Infection and Replication by Type I Interferons (IFN-α/β) but Not by Type II Interferon (IFN-γ).”](/search/?article=Zheng04) _Journal of Interferon & Cytokine Research_, 2004. [doi.org/10.1089/1079990041535610](https://doi.org/10.1089/1079990041535610). \[[PubMed15296649](https://www.ncbi.nlm.nih.gov/pubmed/15296649/)\]
    - Zheng B, Guan Y, et int., and Huang J. [“Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.”](/search/?article=Zheng05) _Antiviral therapy_, 2005. \[[PubMed15918330](https://www.ncbi.nlm.nih.gov/pubmed/15918330/)\]
    - de Wilde AH, Zevenhoven-Dobbe JC, et int., and van Hemert MJ. [“Cyclosporin A inhibits the replication of diverse coronaviruses.”](/search/?article=deWilde11) _Journal of General Virology_, 2011. [doi.org/10.1099/vir.0.034983-0](https://doi.org/10.1099/vir.0.034983-0). \[[PubMed21752960](https://www.ncbi.nlm.nih.gov/pubmed/21752960/)\] \[[PMC3352363](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352363/)\]
    - de Wilde AH, Raj VS, et int., and van den Hoogen BG. [“MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.”](/search/?article=deWilde13) _Journal of General Virology_, 2013. [doi.org/10.1099/vir.0.052910-0](https://doi.org/10.1099/vir.0.052910-0). \[[PubMed23620378](https://www.ncbi.nlm.nih.gov/pubmed/23620378/)\] \[[PMC3749523](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749523/)\]
    - de Wilde AH, Jochmans D, et int., and Snijder EJ. [“Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture.”](/search/?article=deWilde14) _Antimicrobial Agents and Chemotherapy_, 2014. [doi.org/10.1128/aac.03011-14](https://doi.org/10.1128/aac.03011-14). \[[PubMed24841269](https://www.ncbi.nlm.nih.gov/pubmed/24841269/)\] \[[PMC4136071](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/)\]
    - de Wilde AH, Falzarano D, et int., and Snijder EJ. [“Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.”](/search/?article=deWilde17) _Virus Research_, 2016. [doi.org/10.1016/j.virusres.2016.11.011](https://doi.org/10.1016/j.virusres.2016.11.011). \[[PubMed27840112](https://www.ncbi.nlm.nih.gov/pubmed/27840112/)\] \[[PMC7114565](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114565/)\]
    - de Wit E, Feldmann F, et int., and Feldmann H. [“Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.”](/search/?article=deWit20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.1922083117](https://doi.org/10.1073/pnas.1922083117). \[[PubMed32054787](https://www.ncbi.nlm.nih.gov/pubmed/32054787/)\] \[[PMC7104368](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104368/)\]
## Preprints => Peer-Reviewed Publications
### September 2020
- September 28
    - Zhu W, Xu M, et int., and Zheng W. [“Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.”](/search/?article=Zhu20d) _ACS Pharmacology & Translational Science_, 2020. [doi.org/10.1021/acsptsci.0c00108](https://doi.org/10.1021/acsptsci.0c00108).
- September 19
    - Lokugamage KG, Hage A, et int., and Menachery VD. [“Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.”](/search/?article=Lokugamage20) _Journal of Virology_, 2020. [doi.org/10.1128/jvi.01410-20](https://doi.org/10.1128/jvi.01410-20). \[[PubMed32938761](https://www.ncbi.nlm.nih.gov/pubmed/32938761/)\]
- September 17
    - Liu STH, Lin H, et int., and Bouvier NM. [“Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study.”](/search/?article=Liu20d) _Nature Medicine_, 2020. [doi.org/10.1038/s41591-020-1088-9](https://doi.org/10.1038/s41591-020-1088-9). \[[PubMed32934372](https://www.ncbi.nlm.nih.gov/pubmed/32934372/)\]
- September 09
    - Hanke L, Vidakovics Perez L, et int., and McInerney GM. [“An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.”](/search/?article=Hanke20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18174-5](https://doi.org/10.1038/s41467-020-18174-5). \[[PubMed32887876](https://www.ncbi.nlm.nih.gov/pubmed/32887876/)\] \[[PMC7473855](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473855/)\]
- September 01
    - Klemm T, Ebert G, et int., and Komander D. [“Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2.”](/search/?article=Klemm20) _The EMBO Journal_, 2020. [doi.org/10.15252/embj.2020106275](https://doi.org/10.15252/embj.2020106275). \[[PubMed32845033](https://www.ncbi.nlm.nih.gov/pubmed/32845033/)\] \[[PMC7461020](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461020/)\]
    - Vuong W, Khan MB, et int., and Lemieux MJ. [“Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.”](/search/?article=Vuong20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18096-2](https://doi.org/10.1038/s41467-020-18096-2). \[[PubMed32855413](https://www.ncbi.nlm.nih.gov/pubmed/32855413/)\] \[[PMC7453019](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453019/)\]
### August 2020
- August 24
    - Liu L, Wang P, et int., and Ho DD. [“Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.”](/search/?article=Liu20e) _Nature_, 2020. [doi.org/10.1038/s41586-020-2571-7](https://doi.org/10.1038/s41586-020-2571-7). \[[PubMed32698192](https://www.ncbi.nlm.nih.gov/pubmed/32698192/)\]
    - Weston S, Coleman CM, et int., and Frieman MB. [“Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo.”](/search/?article=Weston20) _Journal of Virology_, 2020. [doi.org/10.1128/JVI.01218-20](https://doi.org/10.1128/JVI.01218-20). \[[PubMed32817221](https://www.ncbi.nlm.nih.gov/pubmed/32817221/)\]
- August 17
    - Fintelman-Rodrigues N, Sacramento CQ, et int., and Souza TML. [“Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.”](/search/?article=Fintelman-Rodrigues20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.00825-20](https://doi.org/10.1128/aac.00825-20). \[[PubMed32759267](https://www.ncbi.nlm.nih.gov/pubmed/32759267/)\]
    - Ko M, Jeon S, et int., and Kim S. [“Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells.”](/search/?article=Ko20b) _Journal of Medical Virology_, 2020. [doi.org/10.1002/jmv.26397](https://doi.org/10.1002/jmv.26397). \[[PubMed32767684](https://www.ncbi.nlm.nih.gov/pubmed/32767684/)\] \[[PMC7436731](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436731/)\]
    - Wan J, Xing S, et int., and Lan F. [“Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.”](/search/?article=Lan20b) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.107918](https://doi.org/10.1016/j.celrep.2020.107918). \[[PubMed32668215](https://www.ncbi.nlm.nih.gov/pubmed/32668215/)\] \[[PMC7332464](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332464/)\]
    - Seydoux E, Homad LJ, et int., and Stamatatos L. [“Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.”](/search/?article=Seydoux20) _Immunity_, 2020. [doi.org/10.1016/j.immuni.2020.06.001](https://doi.org/10.1016/j.immuni.2020.06.001). \[[PubMed32561270](https://www.ncbi.nlm.nih.gov/pubmed/32561270/)\] \[[PMC7276322](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276322/)\]
    - Tang W, Cao Z, et int., and Xie Q. [“Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.”](/search/?article=Tang20) _BMJ_, 2020. [doi.org/10.1136/bmj.m1849](https://doi.org/10.1136/bmj.m1849). \[[PubMed32409561](https://www.ncbi.nlm.nih.gov/pubmed/32409561/)\] \[[PMC7221473](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221473/)\]
    - Yang G, Tan Z, et int., and He S. [“Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension.”](/search/?article=Yang20) _Hypertension_, 2020. [doi.org/10.1161/hypertensionaha.120.15143](https://doi.org/10.1161/hypertensionaha.120.15143). \[[PubMed32348166](https://www.ncbi.nlm.nih.gov/pubmed/32348166/)\]
    - Zheng F, Zhou Y, et int., and Gong G. [“SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.”](/search/?article=Zheng20) _International Journal of Infectious Diseases_, 2020. [doi.org/10.1016/j.ijid.2020.07.053](https://doi.org/10.1016/j.ijid.2020.07.053). \[[PubMed32758689](https://www.ncbi.nlm.nih.gov/pubmed/32758689/)\] \[[PMC7397938](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397938/)\]
    - Zost SJ, Gilchuk P, et int., and Crowe JE. [“Potently neutralizing and protective human antibodies against SARS-CoV-2.”](/search/?article=Zost20b) _Nature_, 2020. [doi.org/10.1038/s41586-020-2548-6](https://doi.org/10.1038/s41586-020-2548-6). \[[PubMed32668443](https://www.ncbi.nlm.nih.gov/pubmed/32668443/)\]
- August 14
    - Clementi N, Criscuolo E, et int., and Mancini N. [“Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro.”](/search/?article=Clementi20) _Frontiers in Microbiology_, 2020. [doi.org/10.3389/fmicb.2020.01704](https://doi.org/10.3389/fmicb.2020.01704). \[[PubMed32754147](https://www.ncbi.nlm.nih.gov/pubmed/32754147/)\] \[[PMC7365881](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365881/)\]
    - Dai W, Zhang B, et int., and Liu H. [“Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.”](/search/?article=Dai20) _Science_, 2020. [doi.org/10.1126/science.abb4489](https://doi.org/10.1126/science.abb4489). \[[PubMed32321856](https://www.ncbi.nlm.nih.gov/pubmed/32321856/)\] \[[PMC7179937](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179937/)\]
    - Huang M, Li M, et int., and Shan H. [“Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.”](/search/?article=Huang20) _National Science Review_, 2020. [doi.org/10.1093/nsr/nwaa113](https://doi.org/10.1093/nsr/nwaa113).
    - Magagnoli J, Narendran S, et int., and Ambati J. [“Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.”](/search/?article=Magagnoli20) _Med_, 2020. [doi.org/10.1016/j.medj.2020.06.001](https://doi.org/10.1016/j.medj.2020.06.001). \[[PubMed32838355](https://www.ncbi.nlm.nih.gov/pubmed/32838355/)\] \[[PMC7274588](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274588/)\]
    - Pizzorno A, Padey B, et int., and Rosa-Calatrava M. [“Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.”](/search/?article=Pizzorno20) _Cell Reports Medicine_, 2020. [doi.org/10.1016/j.xcrm.2020.100059](https://doi.org/10.1016/j.xcrm.2020.100059). \[[PubMed32835306](https://www.ncbi.nlm.nih.gov/pubmed/32835306/)\] \[[PMC7373044](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373044/)\]
    - Touret F, Gilles M, et int., and Coutard B. [“In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.”](/search/?article=Touret20) _Scientific Reports_, 2020. [doi.org/10.1038/s41598-020-70143-6](https://doi.org/10.1038/s41598-020-70143-6). \[[PubMed32753646](https://www.ncbi.nlm.nih.gov/pubmed/32753646/)\] \[[PMC7403393](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403393/)\]
    - Xiong R, Zhang L, et int., and Xu K. [“Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.”](/search/?article=Xiong20b) _Protein & Cell_, 2020. [doi.org/10.1007/s13238-020-00768-w](https://doi.org/10.1007/s13238-020-00768-w). \[[PubMed32754890](https://www.ncbi.nlm.nih.gov/pubmed/32754890/)\] \[[PMC7402641](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402641/)\]
- August 10
    - Li Y, Xie Z, et int., and Li L. [“Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.”](/search/?article=Li20) _Med_, 2020. [doi.org/10.1016/j.medj.2020.04.001](https://doi.org/10.1016/j.medj.2020.04.001). \[[PubMed32838353](https://www.ncbi.nlm.nih.gov/pubmed/32838353/)\] \[[PMC7235585](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235585/)\]
- August 05
    - Davoudi-Monfared E, Rahmani H, et int., and Yekaninejad MS. [“A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.”](/search/?article=Davoudi-Monfared20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01061-20](https://doi.org/10.1128/aac.01061-20). \[[PubMed32661006](https://www.ncbi.nlm.nih.gov/pubmed/32661006/)\] \[[PMC7449227](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449227/)\]
    - Pinto D, Park Y, et int., and Corti D. [“Structural and functional analysis of a potent sarbecovirus neutralizing antibody.”](/search/?article=Pinto20) _bioRxiv_, 2020. [doi.org/10.1101/2020.04.07.023903](https://doi.org/10.1101/2020.04.07.023903). \[[PubMed32511354](https://www.ncbi.nlm.nih.gov/pubmed/32511354/)\] \[[PMC7255795](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255795/)\]
    - Rogers TF, Zhao F, et int., and Burton DR. [“Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.”](/search/?article=Rogers20) _Science_, 2020. [doi.org/10.1126/science.abc7520](https://doi.org/10.1126/science.abc7520). \[[PubMed32540903](https://www.ncbi.nlm.nih.gov/pubmed/32540903/)\] \[[PMC7299280](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299280/)\]
- August 03
    - Mantlo E, Bukreyeva N, et int., and Huang C. [“Antiviral activities of type I interferons to SARS-CoV-2 infection.”](/search/?article=Mantlo20) _Antiviral Research_, 2020. [doi.org/10.1016/j.antiviral.2020.104811](https://doi.org/10.1016/j.antiviral.2020.104811). \[[PubMed32360182](https://www.ncbi.nlm.nih.gov/pubmed/32360182/)\] \[[PMC7188648](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188648/)\]
    - Zhou Q, Chen V, et int., and Fish EN. [“Interferon-α2b Treatment for COVID-19.”](/search/?article=Zhou20) _Frontiers in Immunology_, 2020. [doi.org/10.3389/fimmu.2020.01061](https://doi.org/10.3389/fimmu.2020.01061). \[[PubMed32574262](https://www.ncbi.nlm.nih.gov/pubmed/32574262/)\] \[[PMC7242746](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242746/)\]
### July 2020
- July 27
    - Riva L, Yuan S, et int., and Chanda SK. [“Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.”](/search/?article=Riva20) _Nature_, 2020. [doi.org/10.1038/s41586-020-2577-1](https://doi.org/10.1038/s41586-020-2577-1). \[[PubMed32707573](https://www.ncbi.nlm.nih.gov/pubmed/32707573/)\]
- July 22
    - Borba MGS, Val FFA, et int., and CloroCovid-19 Team . [“Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.”](/search/?article=Borba20) _JAMA Netw Open_, 2020. \[[PubMed32339248](https://www.ncbi.nlm.nih.gov/pubmed/32339248/)\]
    - Freedberg DE, Conigliaro J, et int., and Landry DW. [“Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.”](/search/?article=Freedberg20) _Gastroenterology_, 2020. [doi.org/10.1053/j.gastro.2020.05.053](https://doi.org/10.1053/j.gastro.2020.05.053). \[[PubMed32446698](https://www.ncbi.nlm.nih.gov/pubmed/32446698/)\] \[[PMC7242191](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242191/)\]
    - Jeon S, Ko M, et int., and Kim S. [“Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.”](/search/?article=Jeon20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.00819-20](https://doi.org/10.1128/aac.00819-20). \[[PubMed32366720](https://www.ncbi.nlm.nih.gov/pubmed/32366720/)\] \[[PMC7318052](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318052/)\]
    - Mahévas M, Tran V, et int., and Costedoat-Chalumeau N. [“Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.”](/search/?article=Mahevas20) _BMJ_, 2020. [doi.org/10.1136/bmj.m1844](https://doi.org/10.1136/bmj.m1844). \[[PubMed32409486](https://www.ncbi.nlm.nih.gov/pubmed/32409486/)\] \[[PMC7221472](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221472/)\]
    - Salazar E, Perez KK, et int., and Musser JM. [“Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.”](/search/?article=Salazar20) _The American Journal of Pathology_, 2020. [doi.org/10.1016/j.ajpath.2020.05.014](https://doi.org/10.1016/j.ajpath.2020.05.014). \[[PubMed32473109](https://www.ncbi.nlm.nih.gov/pubmed/32473109/)\] \[[PMC7251400](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251400/)\]
    - Sheahan TP, Sims AC, et int., and Baric RS. [“An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.”](/search/?article=Sheahan20b) _Science Translational Medicine_, 2020. [doi.org/10.1126/scitranslmed.abb5883](https://doi.org/10.1126/scitranslmed.abb5883). \[[PubMed32253226](https://www.ncbi.nlm.nih.gov/pubmed/32253226/)\] \[[PMC7164393](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164393/)\]
    - Wu Y, Wang F, et int., and Liu L. [“A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.”](/search/?article=Wu20) _Science_, 2020. [doi.org/10.1126/science.abc2241](https://doi.org/10.1126/science.abc2241). \[[PubMed32404477](https://www.ncbi.nlm.nih.gov/pubmed/32404477/)\] \[[PMC7223722](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223722/)\]
    - Yamamoto M, Kiso M, et int., and Inoue J. [“The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.”](/search/?article=Yamamoto20b) _Viruses_, 2020. [doi.org/10.3390/v12060629](https://doi.org/10.3390/v12060629). \[[PubMed32532094](https://www.ncbi.nlm.nih.gov/pubmed/32532094/)\] \[[PMC7354595](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354595/)\]
- July 20
    - Pruijssers AJ, George AS, et int., and Sheahan TP. [“Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.”](/search/?article=Pruijssers20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.107940](https://doi.org/10.1016/j.celrep.2020.107940). \[[PubMed32668216](https://www.ncbi.nlm.nih.gov/pubmed/32668216/)\] \[[PMC7340027](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340027/)\]
- July 13
    - Duan K, Liu B, et int., and Yang X. [“Effectiveness of convalescent plasma therapy in severe COVID-19 patients.”](/search/?article=Duan20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2004168117](https://doi.org/10.1073/pnas.2004168117). \[[PubMed32253318](https://www.ncbi.nlm.nih.gov/pubmed/32253318/)\] \[[PMC7196837](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196837/)\]
    - Joyner MJ, Wright RS, et int., and Casadevall A. [“Early safety indicators of COVID-19 convalescent plasma in 5000 patients.”](/search/?article=Joyner20) _Journal of Clinical Investigation_, 2020. [doi.org/10.1172/jci140200](https://doi.org/10.1172/jci140200). \[[PubMed32525844](https://www.ncbi.nlm.nih.gov/pubmed/32525844/)\] \[[PMC7456238](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456238/)\]
    - Kujawski SA, Wong KK, et int., and The COVID-19 Investigation Team . [“Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States.”](/search/?article=Kujawski20) _Nature Medicine_, 2020. [doi.org/10.1038/s41591-020-0877-5](https://doi.org/10.1038/s41591-020-0877-5). \[[PubMed32327757](https://www.ncbi.nlm.nih.gov/pubmed/32327757/)\]
    - Ma C, Sacco MD, et int., and Wang J. [“Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.”](/search/?article=Ma20) _Cell Research_, 2020. [doi.org/10.1038/s41422-020-0356-z](https://doi.org/10.1038/s41422-020-0356-z). \[[PubMed32541865](https://www.ncbi.nlm.nih.gov/pubmed/32541865/)\] \[[PMC7294525](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294525/)\]
    - De Meyer S, Bojkova D, et int., and Ciesek S. [“Lack of antiviral activity of darunavir against SARS-CoV-2.”](/search/?article=Meyer20) _International Journal of Infectious Diseases_, 2020. [doi.org/10.1016/j.ijid.2020.05.085](https://doi.org/10.1016/j.ijid.2020.05.085). \[[PubMed32479865](https://www.ncbi.nlm.nih.gov/pubmed/32479865/)\] \[[PMC7258847](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258847/)\]
    - Rothan HA, Stone S, et int., and Kumar M. [“The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.”](/search/?article=Rothan20) _Virology_, 2020. [doi.org/10.1016/j.virol.2020.05.002](https://doi.org/10.1016/j.virol.2020.05.002). \[[PubMed32442105](https://www.ncbi.nlm.nih.gov/pubmed/32442105/)\] \[[PMC7236683](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236683/)\]
    - Wang C, Li W, et int., and Bosch B. [“A human monoclonal antibody blocking SARS-CoV-2 infection.”](/search/?article=Wang20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-16256-y](https://doi.org/10.1038/s41467-020-16256-y). \[[PubMed32366817](https://www.ncbi.nlm.nih.gov/pubmed/32366817/)\] \[[PMC7198537](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198537/)\]
    - Wrapp D, De Vlieger D, et int., and McLellan JS. [“Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.”](/search/?article=Wrapp20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.04.031](https://doi.org/10.1016/j.cell.2020.04.031). \[[PubMed32375025](https://www.ncbi.nlm.nih.gov/pubmed/32375025/)\] \[[PMC7199733](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199733/)\]
    - Xia S, Liu M, et int., and Lu L. [“Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.”](/search/?article=Xia20) _Cell Research_, 2020. [doi.org/10.1038/s41422-020-0305-x](https://doi.org/10.1038/s41422-020-0305-x). \[[PubMed32231345](https://www.ncbi.nlm.nih.gov/pubmed/32231345/)\] \[[PMC7104723](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104723/)\]
    - Zhu Y, Yu D, et int., and He Y. [“Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.”](/search/?article=Zhu20) _Journal of Virology_, 2020. [doi.org/10.1128/jvi.00635-20](https://doi.org/10.1128/jvi.00635-20). \[[PubMed32376627](https://www.ncbi.nlm.nih.gov/pubmed/32376627/)\] \[[PMC7343218](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343218/)\]
- July 05
    - Brouwer PJM, Caniels TG, et int., and van Gils MJ. [“Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.”](/search/?article=Brouwer20) _Science_, 2020. [doi.org/10.1126/science.abc5902](https://doi.org/10.1126/science.abc5902). \[[PubMed32540902](https://www.ncbi.nlm.nih.gov/pubmed/32540902/)\] \[[PMC7299281](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299281/)\]
### June 2020
- June 18
    - Williamson BN, Feldmann F, et int., and de Wit E. [“Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.”](/search/?article=Williamson20) _Nature_, 2020. [doi.org/10.1038/s41586-020-2423-5](https://doi.org/10.1038/s41586-020-2423-5). \[[PubMed32516797](https://www.ncbi.nlm.nih.gov/pubmed/32516797/)\] \[[PMC7486271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486271/)\]
- June 15
    - Ju B, Zhang Q, et int., and Zhang L. [“Human neutralizing antibodies elicited by SARS-CoV-2 infection.”](/search/?article=Ju20) _Nature_, 2020. [doi.org/10.1038/s41586-020-2380-z](https://doi.org/10.1038/s41586-020-2380-z). \[[PubMed32454513](https://www.ncbi.nlm.nih.gov/pubmed/32454513/)\]
<!-- end of study -->

<!-- start of clinical trials -->

## Clinical Trials
### October 2020
- October 01
    - [9 clinical trials were added.](/clinical-trials/?fromDate=2020-10-01)
    - EUCTR2020-002728-35-HU
    - EUCTR2020-003470-47-NL
    - ISRCTN53038326
    - NCT04565197
    - NCT04567173
    - NCT04567810
    - NCT04569188
    - NCT04573153
    - NCT04573855
### September 2020
- September 24
    - [10 clinical trials were added.](/clinical-trials/?fromDate=2020-09-24)
    - NCT04554992
    - NCT04555148
    - NCT04558021
    - NCT04558463
    - NCT04558476
    - NCT04560231
    - NCT04561063
    - NCT04561076
    - NCT04561219
    - NCT04563208
- September 17
    - [14 clinical trials were added.](/clinical-trials/?fromDate=2020-09-17)
    - EUCTR2020-001608-40-DE
    - EUCTR2020-002503-19-GB
    - ISRCTN31062548
    - NCT04546581
    - NCT04547127
    - NCT04547140
    - NCT04547660
    - NCT04548557
    - NCT04550325
    - NCT04551755
    - NCT04551768
    - NCT04551898
    - NCT04552379
    - NCT04552483
- September 10
    - [18 clinical trials were added.](/clinical-trials/?fromDate=2020-09-10)
    - CTRI/2020/08/027225
    - CTRI/2020/08/027282
    - CTRI/2020/08/027345
    - CTRI/2020/08/027394
    - CTRI/2020/09/027535
    - EUCTR2020-002869-34-BE
    - IRCT20180922041089N4
    - IRCT20200509047364N2
    - NCT04539795
    - NCT04540926
    - NCT04541485
    - NCT04542330
    - NCT04542434
    - NCT04542694
    - NCT04542941
    - NCT04542967
    - NCT04545060
    - NCT04545541
- September 03
    - [14 clinical trials were added.](/clinical-trials/?fromDate=2020-09-03)
    - NCT04532294
    - NCT04532372
    - NCT04532931
    - NCT04533048
    - NCT04533347
    - NCT04534673
    - NCT04534725
    - NCT04534803
    - NCT04535063
    - NCT04535167
    - NCT04535869
    - NCT04537663
    - NCT04539262
    - NCT04539275
### August 2020
- August 27
    - [18 clinical trials were added.](/clinical-trials/?fromDate=2020-08-27)
    - NCT04523831
    - NCT04524052
    - NCT04524507
    - NCT04524663
    - NCT04525079
    - NCT04527133
    - NCT04527211
    - NCT04528368
    - NCT04528888
    - NCT04528927
    - NCT04529499
    - NCT04529525
    - NCT04530370
    - NCT04530422
    - NCT04530474
    - NCT04530578
    - NCT04530617
    - NCT04531748
- August 26
    - [1 clinical trials were added.](/clinical-trials/?fromDate=2020-08-26)
    - ChiCTR2000030262
- August 20
    - [38 clinical trials were added.](/clinical-trials/?fromDate=2020-08-20)
    - ACTRN12620000816954
    - CTRI/2020/07/026668
    - CTRI/2020/08/027162
    - EUCTR2020-000936-23-PT
    - EUCTR2020-002038-33-FI
    - EUCTR2020-002283-32-IT
    - EUCTR2020-002458-25-IT
    - IRCT20151227025726N20
    - IRCT20190602043787N3
    - IRCT20190624043993N2
    - IRCT20200404046937N4
    - IRCT20200414047076N1
    - IRCT20200426047206N3
    - IRCT20200503047281N1
    - IRCT20200506047323N3
    - IRCT20200511047399N1
    - IRCT20200718048129N1
    - NCT04513158
    - NCT04514302
    - NCT04516564
    - NCT04516811
    - NCT04516915
    - NCT04516954
    - NCT04518410
    - NCT04519125
    - NCT04519437
    - NCT04521036
    - NCT04521296
    - NCT04521309
    - NCT04521322
    - NCT04521400
    - NCT04523090
    - NCT04523246
    - PACTR202007653923168
    - PACTR202007700757139
    - PACTR202008855701534
    - PER-031-20
    - PER-034-20
- August 18
    - [1 clinical trials were added.](/clinical-trials/?fromDate=2020-08-18)
    - NCT04379271
- August 13
    - [6 clinical trials were added.](/clinical-trials/?fromDate=2020-08-13)
    - EUCTR2020-002574-27-FR
    - ISRCTN13035264
    - ISRCTN15913068
    - JPRN-jRCT2071200023
    - NCT04507256
    - NCT04510233
- August 06
    - [21 clinical trials were added.](/clinical-trials/?fromDate=2020-08-06)
    - ChiCTR2000030058
    - EUCTR2020-002503-19-NL
    - ISRCTN10207947
    - ISRCTN67000769
    - NCT04496245
    - NCT04497324
    - NCT04497519
    - NCT04497649
    - NCT04497987
    - NCT04498325
    - NCT04498377
    - NCT04498936
    - NCT04499677
    - NCT04500067
    - NCT04501783
    - NCT04501796
    - NCT04501952
    - NCT04501965
    - NCT04501978
    - NCT04502342
    - NCT04502472
- August 02
    - [2 clinical trials were added.](/clinical-trials/?fromDate=2020-08-02)
    - ChiCTR2000029544
    - ChiCTR2000029853
### July 2020
- July 30
    - [19 clinical trials were added.](/clinical-trials/?fromDate=2020-07-30)
    - CTRI/2020/06/026001
    - EUCTR2020-001890-56-ES
    - EUCTR2020-001971-33-ES
    - EUCTR2020-002449-41-ES
    - EUCTR2020-002668-29-GB
    - IRCT20150107020592N26
    - IRCT20160118026097N3
    - ISRCTN14241621
    - NCT04487444
    - NCT04487574
    - NCT04488081
    - NCT04491994
    - NCT04492475
    - NCT04492891
    - NCT04494399
    - NCT04494984
    - NCT04495101
    - NL8477
    - NL8726
- July 23
    - [17 clinical trials were added.](/clinical-trials/?fromDate=2020-07-23)
    - EUCTR2020-002106-68-GB
    - NCT04476888
    - NCT04477083
    - NCT04479163
    - NCT04479631
    - NCT04479644
    - NCT04480138
    - NCT04480333
    - NCT04480424
    - NCT04480632
    - NCT04482686
    - NCT04483375
    - NCT04483960
    - NCT04483973
    - NCT04484025
    - NCT04485130
    - NCT04486313
- July 16
    - [31 clinical trials were added.](/clinical-trials/?fromDate=2020-07-16)
    - CTRI/2020/06/026087
    - CTRI/2020/06/026123
    - CTRI/2020/06/026220
    - CTRI/2020/06/026222
    - CTRI/2020/06/026232
    - EUCTR2020-002456-21-NL
    - IRCT20111224008507N3
    - IRCT20150107020592N27
    - IRCT20150107020592N30
    - IRCT20200416047099N2
    - IRCT20200504047298N1
    - IRCT20200513047426N1
    - IRCT20200624047908N1
    - JPRN-jRCTs041200025
    - NCT04464460
    - NCT04468009
    - NCT04468087
    - NCT04468958
    - NCT04469179
    - NCT04469491
    - NCT04470544
    - NCT04472572
    - NCT04472585
    - NCT04473053
    - NCT04474340
    - NCT04475120
    - NCT04475302
    - PACTR202006537901307
    - PACTR202006760881890
    - PER-013-20
    - PER-016-20
- July 09
    - [35 clinical trials were added.](/clinical-trials/?fromDate=2020-07-09)
    - CTRI/2020/04/024706
    - CTRI/2020/05/025209
    - CTRI/2020/05/025224
    - CTRI/2020/05/025242
    - CTRI/2020/05/025299
    - CTRI/2020/05/025328
    - CTRI/2020/05/025346
    - CTRI/2020/06/025575
    - CTRI/2020/06/025704
    - CTRI/2020/06/025760
    - CTRI/2020/06/025799
    - CTRI/2020/06/025803
    - CTRI/2020/06/025849
    - CTRI/2020/06/025854
    - CTRI/2020/06/025957
    - DRKS00022203
    - EUCTR2020-001549-38-DE
    - EUCTR2020-001803-17-GB
    - EUCTR2020-002110-41-GB
    - NCT04457726
    - NCT04458363
    - NCT04458948
    - NCT04459286
    - NCT04459702
    - NCT04460443
    - NCT04461353
    - NCT04461379
    - NCT04462848
    - NCT04463264
    - NCT04464395
    - NCT04464408
    - NCT04465695
    - NCT04466241
    - NCT04466540
    - NCT04467151
- July 02
    - [19 clinical trials were added.](/clinical-trials/?fromDate=2020-07-02)
    - EUCTR2020-001172-15-DE
    - EUCTR2020-001501-24-IT
    - EUCTR2020-001528-32-IT
    - EUCTR2020-001558-23-IT
    - EUCTR2020-001987-28-IT
    - NCT04449588
    - NCT04451239
    - NCT04452318
    - NCT04452565
    - NCT04452643
    - NCT04452799
    - NCT04452812
    - NCT04453384
    - NCT04454398
    - NCT04455815
    - NCT04455958
    - NCT04456153
    - NCT04456413
    - NL8633
### June 2020
- June 25
    - [23 clinical trials were added.](/clinical-trials/?fromDate=2020-06-25)
    - EUCTR2020-000982-18-SE
    - EUCTR2020-002233-15-DE
    - NCT04441047
    - NCT04441398
    - NCT04441424
    - NCT04441918
    - NCT04442048
    - NCT04442178
    - NCT04442191
    - NCT04442230
    - NCT04442958
    - NCT04443270
    - NCT04443725
    - NCT04445207
    - NCT04445311
    - NCT04445467
    - NCT04446104
    - NCT04446377
    - NCT04446429
    - NCT04447235
    - NCT04447534
    - NCT04448119
    - NCT04449380
- June 18
    - [42 clinical trials were added.](/clinical-trials/?fromDate=2020-06-18)
    - EUCTR2020-001904-41-GB
    - EUCTR2020-001928-34-SE
    - EUCTR2020-002091-12-BG
    - EUCTR2020-002111-22-PL
    - IRCT20140428017469N1
    - IRCT20150107020592N22
    - IRCT20151227025726N15
    - IRCT20151227025726N18
    - IRCT20161206031256N3
    - IRCT20200411047019N1
    - IRCT20200412047042N1
    - IRCT20200422047168N2
    - IRCT20200428047228N2
    - IRCT20200501047259N1
    - IRCT20200502047268N1
    - IRCT20200511047396N1
    - IRCT20200517047485N1
    - IRCT20200523047550N1
    - IRCT20200525047562N1
    - KCT0005105
    - NCT04431453
    - NCT04431466
    - NCT04432103
    - NCT04432272
    - NCT04432324
    - NCT04433910
    - NCT04434131
    - NCT04434248
    - NCT04435015
    - NCT04435314
    - NCT04435522
    - NCT04435587
    - NCT04435795
    - NCT04435808
    - NCT04436458
    - NCT04437693
    - NCT04438057
    - NCT04438694
    - NCT04438837
    - NCT04438850
    - NCT04439071
    - PACTR202005622389003
- June 11
    - [27 clinical trials were added.](/clinical-trials/?fromDate=2020-06-11)
    - NCT04418128
    - NCT04418518
    - NCT04418531
    - NCT04420247
    - NCT04421404
    - NCT04421534
    - NCT04421664
    - NCT04422561
    - NCT04422678
    - NCT04423861
    - NCT04425460
    - NCT04425629
    - NCT04425707
    - NCT04425772
    - NCT04425837
    - NCT04425915
    - NCT04426201
    - NCT04426695
    - NCT04427501
    - NCT04427865
    - NCT04428008
    - NCT04428021
    - NCT04428268
    - NCT04429529
    - NCT04429711
    - NCT04429854
    - NCT04429867
- June 04
    - [22 clinical trials were added.](/clinical-trials/?fromDate=2020-06-04)
    - EUCTR2020-001512-26-DE
    - EUCTR2020-001573-78-FR
    - EUCTR2020-001605-23-ES
    - EUCTR2020-001671-32-ES
    - EUCTR2020-002287-31-ES
    - EUCTR2020-002448-21-GR
    - ISRCTN40302986
    - ISRCTN99916292
    - NCT04409262
    - NCT04409483
    - NCT04410354
    - NCT04410562
    - NCT04411433
    - NCT04411602
    - NCT04411628
    - NCT04411667
    - NCT04412486
    - NCT04412785
    - NCT04414241
    - NCT04414267
    - NCT04415086
    - NCT04417335
### May 2020
- May 28
    - [27 clinical trials were added.](/clinical-trials/?fromDate=2020-05-28)
    - EUCTR2020-001366-11-IE
    - EUCTR2020-001704-42-ES
    - NCT04400929
    - NCT04401579
    - NCT04402203
    - NCT04403100
    - NCT04403269
    - NCT04403477
    - NCT04403555
    - NCT04405271
    - NCT04405310
    - NCT04405570
    - NCT04405739
    - NCT04405843
    - NCT04405921
    - NCT04405999
    - NCT04406064
    - NCT04406194
    - NCT04406246
    - NCT04407000
    - NCT04407130
    - NCT04407208
    - NCT04407507
    - NCT04407689
    - NCT04408040
    - NCT04408183
    - NCT04408456
- May 21
    - [57 clinical trials were added.](/clinical-trials/?fromDate=2020-05-21)
    - ACTRN12620000566932
    - CTRI/2020/04/024729
    - CTRI/2020/04/024749
    - CTRI/2020/04/024775
    - CTRI/2020/04/024804
    - CTRI/2020/04/024806
    - CTRI/2020/04/024833
    - CTRI/2020/04/024858
    - CTRI/2020/04/024904
    - CTRI/2020/04/024915
    - CTRI/2020/04/024948
    - CTRI/2020/04/024949
    - CTRI/2020/05/025013
    - CTRI/2020/05/025022
    - CTRI/2020/05/025067
    - CTRI/2020/05/025068
    - CTRI/2020/05/025114
    - ISRCTN88057279
    - JPRN-jRCTs031200026
    - KCT0005003
    - NCT04389359
    - NCT04389385
    - NCT04389710
    - NCT04389944
    - NCT04390022
    - NCT04390061
    - NCT04390178
    - NCT04390503
    - NCT04390594
    - NCT04391101
    - NCT04391127
    - NCT04392128
    - NCT04392219
    - NCT04392232
    - NCT04392414
    - NCT04392427
    - NCT04392531
    - NCT04392713
    - NCT04392973
    - NCT04393311
    - NCT04393727
    - NCT04394416
    - NCT04394442
    - NCT04395170
    - NCT04396067
    - NCT04396106
    - NCT04397328
    - NCT04397523
    - NCT04397757
    - NCT04399356
    - NCT04399746
    - NCT04400019
    - NCT04400058
    - NCT04400682
    - NL8609
    - PACTR202004893013257
    - TCTR20200514001
- May 14
    - [47 clinical trials were added.](/clinical-trials/?fromDate=2020-05-14)
    - ACTRN12620000557932
    - EUCTR2020-001474-29-ES
    - EUCTR2020-001632-10-DE
    - EUCTR2020-001635-27-FR
    - EUCTR2020-001696-32-ES
    - EUCTR2020-001697-30-ES
    - EUCTR2020-001740-26-GB
    - EUCTR2020-001768-27-FR
    - EUCTR2020-001783-28-HU
    - EUCTR2020-001784-88-FI
    - EUCTR2020-001953-36-ES
    - EUCTR2020-001994-66-ES
    - EUCTR2020-002123-11-ES
    - NCT04380935
    - NCT04381364
    - NCT04381377
    - NCT04381858
    - NCT04381884
    - NCT04381936
    - NCT04381962
    - NCT04381988
    - NCT04382066
    - NCT04382625
    - NCT04382846
    - NCT04382950
    - NCT04383535
    - NCT04383548
    - NCT04383717
    - NCT04384380
    - NCT04384458
    - NCT04384497
    - NCT04384549
    - NCT04384588
    - NCT04385043
    - NCT04385095
    - NCT04385186
    - NCT04385199
    - NCT04385264
    - NCT04385836
    - NCT04385849
    - NCT04386070
    - NCT04387240
    - NCT04387409
    - NCT04387760
    - NCT04388410
    - NCT04388527
    - NCT04388709
- May 07
    - [39 clinical trials were added.](/clinical-trials/?fromDate=2020-05-07)
    - NCT04370782
    - NCT04371107
    - NCT04371406
    - NCT04371523
    - NCT04371926
    - NCT04372017
    - NCT04372082
    - NCT04372368
    - NCT04372628
    - NCT04372979
    - NCT04373044
    - NCT04373291
    - NCT04373460
    - NCT04373733
    - NCT04373824
    - NCT04374019
    - NCT04374279
    - NCT04374487
    - NCT04374526
    - NCT04374539
    - NCT04374552
    - NCT04374565
    - NCT04374903
    - NCT04374942
    - NCT04375046
    - NCT04375098
    - NCT04376034
    - NCT04376788
    - NCT04376814
    - NCT04377568
    - NCT04377646
    - NCT04377672
    - NCT04377711
    - NCT04379336
    - NCT04379479
    - NCT04379492
    - NCT04379518
    - RPCEC00000307
    - RPCEC00000308
### April 2020
- April 30
    - [39 clinical trials were added.](/clinical-trials/?fromDate=2020-04-30)
    - ACTRN12620000501943
    - NCT03648372
    - NCT04358406
    - NCT04358549
    - NCT04358783
    - NCT04359095
    - NCT04359316
    - NCT04359537
    - NCT04359615
    - NCT04359680
    - NCT04359810
    - NCT04359953
    - NCT04360122
    - NCT04360356
    - NCT04360486
    - NCT04360759
    - NCT04361253
    - NCT04361318
    - NCT04361461
    - NCT04362176
    - NCT04362332
    - NCT04363060
    - NCT04363203
    - NCT04363450
    - NCT04363827
    - NCT04363866
    - NCT04364022
    - NCT04364737
    - NCT04364815
    - NCT04365101
    - NCT04365231
    - NCT04365439
    - NCT04365582
    - NCT04366245
    - NCT04366739
    - NCT04369365
    - NCT04369742
    - NCT04370015
    - NCT04370262
- April 23
    - [40 clinical trials were added.](/clinical-trials/?fromDate=2020-04-23)
    - ACTRN12620000473965
    - CTRI/2020/03/024402
    - CTRI/2020/04/024479
    - IRCT20200310046736N1
    - ISRCTN14326006
    - JPRN-JapicCTI-205238
    - JPRN-jRCT2031190264
    - JPRN-jRCTs031190269
    - NCT04252885
    - NCT04352400
    - NCT04352751
    - NCT04352933
    - NCT04352946
    - NCT04353037
    - NCT04353206
    - NCT04353271
    - NCT04353284
    - NCT04354259
    - NCT04354389
    - NCT04354428
    - NCT04354441
    - NCT04354597
    - NCT04354805
    - NCT04354831
    - NCT04354870
    - NCT04355026
    - NCT04355052
    - NCT04355767
    - NCT04355897
    - NCT04356482
    - NCT04356495
    - NCT04356534
    - NCT04356677
    - NCT04357106
    - NCT04357444
    - NCT04357613
    - NCT04358068
    - NCT04358081
    - PACTR202004801273802
    - TCTR20200404004
- April 17
    - [69 clinical trials were added.](/clinical-trials/?fromDate=2020-04-17)
    - ACTRN12620000457943
    - ChiCTR2000029757
    - ChiCTR2000030391
    - EUCTR2020-001188-96-FR
    - EUCTR2020-001194-69-ES
    - EUCTR2020-001250-21-FR
    - EUCTR2020-001310-38-DE
    - EUCTR2020-001333-13-FR
    - EUCTR2020-001421-31-ES
    - EUCTR2020-001565-37-ES
    - EUCTR2020-001606-33-ES
    - NCT02845843
    - NCT03891420
    - NCT04342650
    - NCT04343092
    - NCT04343248
    - NCT04343261
    - NCT04343677
    - NCT04343755
    - NCT04343768
    - NCT04343976
    - NCT04344379
    - NCT04344444
    - NCT04344457
    - NCT04344535
    - NCT04344600
    - NCT04344951
    - NCT04345276
    - NCT04345289
    - NCT04345406
    - NCT04345419
    - NCT04345523
    - NCT04345653
    - NCT04345679
    - NCT04345692
    - NCT04345861
    - NCT04345991
    - NCT04346147
    - NCT04346329
    - NCT04346446
    - NCT04346589
    - NCT04346628
    - NCT04346667
    - NCT04347031
    - NCT04347174
    - NCT04347512
    - NCT04347681
    - NCT04347889
    - NCT04347915
    - NCT04347980
    - NCT04348409
    - NCT04348474
    - NCT04348656
    - NCT04349228
    - NCT04349241
    - NCT04349371
    - NCT04349592
    - NCT04350281
    - NCT04350450
    - NCT04350580
    - NCT04350671
    - NCT04350684
    - NCT04351191
    - NCT04351295
    - NCT04351347
    - NCT04351516
    - NCT04351620
    - NCT04351724
    - NCT04351919
- April 10
    - [29 clinical trials were added.](/clinical-trials/?fromDate=2020-04-10)
    - ACTRN12620000445976
    - ACTRN12620000447954
    - EUCTR2020-001236-10-NL
    - EUCTR2020-001270-29-GB
    - EUCTR2020-001271-33-FR
    - EUCTR2020-001281-11-FR
    - EUCTR2020-001345-38-GR
    - ISRCTN50189673
    - NCT04336332
    - NCT04336748
    - NCT04336904
    - NCT04338360
    - NCT04338698
    - NCT04338906
    - NCT04339426
    - NCT04339816
    - NCT04340050
    - NCT04340349
    - NCT04340544
    - NCT04341441
    - NCT04341493
    - NCT04341727
    - NCT04341870
    - NCT04342156
    - NCT04342169
    - NCT04342182
    - NCT04342221
    - NL8490
    - NL8491
- April 06
    - [19 clinical trials were added.](/clinical-trials/?fromDate=2020-04-06)
    - NCT04331600
    - NCT04331834
    - NCT04331899
    - NCT04332094
    - NCT04332380
    - NCT04332835
    - NCT04332991
    - NCT04333225
    - NCT04333355
    - NCT04333654
    - NCT04334382
    - NCT04334460
    - NCT04334512
    - NCT04334928
    - NCT04334967
    - NCT04335084
    - NCT04335136
    - NCT04335552
    - IRCT202003117046797N4
- April 01
    - [83 clinical trials were added.](/clinical-trials/?fromDate=2020-04-01)
    - ACTRN12620000417987
    - ChiCTR2000029496
    - ChiCTR2000029559
    - ChiCTR2000029609
    - ChiCTR2000029868
    - ChiCTR2000030046
    - ChiCTR2000030254
    - EUCTR2020-000890-25-FR
    - EUCTR2020-000919-69-NL
    - EUCTR2020-000982-18-NO
    - EUCTR2020-001010-38-NO
    - EUCTR2020-001023-14-GB
    - EUCTR2020-001224-33-DE
    - EUCTR2020-001243-15-BE
    - IRCT20100228003449N27
    - IRCT20100228003449N28
    - IRCT20100228003449N29
    - IRCT20100228003449N30
    - IRCT20151227025726N12
    - IRCT20200128046294N2
    - ISRCTN86534580
    - JPRN-jRCTs031190226
    - JPRN-jRCTs031190227
    - JPRN-jRCTs041190120
    - NCT04252274
    - NCT04252664
    - NCT04254874
    - NCT04255017
    - NCT04257656
    - NCT04261270
    - NCT04261517
    - NCT04264858
    - NCT04275245
    - NCT04276688
    - NCT04280705
    - NCT04291729
    - NCT04292340
    - NCT04292730
    - NCT04292899
    - NCT04293887
    - NCT04295551
    - NCT04302766
    - NCT04303299
    - NCT04303507
    - NCT04304053
    - NCT04307693
    - NCT04308668
    - NCT04310228
    - NCT04315896
    - NCT04315948
    - NCT04318015
    - NCT04318444
    - NCT04320238
    - NCT04321096
    - NCT04321174
    - NCT04321278
    - NCT04321421
    - NCT04321616
    - NCT04322123
    - NCT04322344
    - NCT04322396
    - NCT04323527
    - NCT04323631
    - NCT04323761
    - NCT04323800
    - NCT04324463
    - NCT04325893
    - NCT04326725
    - NCT04327206
    - NCT04327349
    - NCT04328012
    - NCT04328272
    - NCT04328285
    - NCT04328467
    - NCT04328493
    - NCT04329572
    - NCT04329611
    - NCT04329832
    - NCT04329923
    - NCT04330144
    - NCT04330495
    - NCT04330586
    - NCT04330690
